symbol	chrom	hgvsp	consequence	evidence_id	variant_name	clinical_significance	pubmed_html_link	cancer_type	evidence_type	evidence_level	disease_ontology_id	codon	exon	therapeutic_context	variant_name_2	name	hgvsc	genomic_change	ensembl_transcript_id	start	end
ERRFI1	1	E384X	stop_gained	EID1724	E384*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24550739' target='_blank'>Borad et al., 2014, PLoS Genet.</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	NA	NA	Erlotinib	E384X	EID1724:ERRFI1:p.E384	c.1150G>T	1_8073509_C_A	ENST00000377482	8073503	8073515
MTOR	1	M2327I	missense_variant	EID1544	M2327I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	AZD8055	M2327I	EID1544:MTOR:p.M2327	c.6981G>T	1_11177096_C_A	ENST00000361445	11177090	11177102
MTOR	1	M2327I	missense_variant	EID1545	M2327I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Rapamycin (Sirolimus), RapaLink-1	M2327I	EID1545:MTOR:p.M2327	c.6981G>T	1_11177096_C_A	ENST00000361445	11177090	11177102
MTOR	1	S2215Y	missense_variant	EID1319	S2215Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24631838' target='_blank'>Grabiner et al., 2014, Cancer Discov</a>	Endometrial Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:2870	NA	NA	Rapamycin (Sirolimus)	S2215Y	EID1319:MTOR:p.S2215	c.6644C>A	1_11184573_G_T	ENST00000361445	11184567	11184579
MTOR	1	P2213S	missense_variant	EID722	P2213S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26490311' target='_blank'>Kong et al., 2016, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	LY294002, AZD5363	P2213S	EID722:MTOR:p.P2213	c.6637C>T	1_11184580_G_A	ENST00000361445	11184574	11184586
MTOR	1	F2108L	missense_variant	EID1110	F2108L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25295501' target='_blank'>Wagle et al., 2014, N. Engl. J. Med.</a>	Thyroid Carcinoma	Predictive	C: Case study	DOID:3963	NA	NA	Everolimus	F2108L	EID1110:MTOR:p.F2108	c.6324C>A	1_11187094_G_T	ENST00000361445	11187088	11187100
MTOR	1	F2108L	missense_variant	EID1543	F2108L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Rapamycin (Sirolimus)	F2108L	EID1543:MTOR:p.F2108	c.6324C>A	1_11187094_G_T	ENST00000361445	11187088	11187100
MTOR	1	A2034V	missense_variant	EID1547	A2034V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Rapamycin (Sirolimus)	A2034V	EID1547:MTOR:p.A2034	c.6101C>T	1_11187796_G_A	ENST00000361445	11187790	11187802
MTOR	1	A2034V	missense_variant	EID1548	A2034V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	RapaLink-1, AZD8055	A2034V	EID1548:MTOR:p.A2034	c.6101C>T	1_11187796_G_A	ENST00000361445	11187790	11187802
MTOR	1	H1968Y	missense_variant	EID713	H1968Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26490311' target='_blank'>Kong et al., 2016, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	AZD5363, LY294002	H1968Y	EID713:MTOR:p.H1968	c.5902C>T	1_11188519_G_A	ENST00000361445	11188513	11188525
MTOR	1	E1799K	missense_variant	EID1321	E1799K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24631838' target='_blank'>Grabiner et al., 2014, Cancer Discov</a>	Clear Cell Renal Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:4467	NA	NA	Rapamycin (Sirolimus)	E1799K	EID1321:MTOR:p.E1799	c.5395G>A	1_11190804_C_T	ENST00000361445	11190798	11190810
MTOR	1	C1483Y	missense_variant	EID1320	C1483Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24631838' target='_blank'>Grabiner et al., 2014, Cancer Discov</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	NA	NA	Rapamycin (Sirolimus)	C1483Y	EID1320:MTOR:p.C1483	c.4448G>A	1_11217230_C_T	ENST00000361445	11217224	11217236
CSF3R	1	T618I	missense_variant	EID6380	T618I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24081659' target='_blank'>Fleischman et al., 2013, Blood</a>	Chronic Neutrophilic Leukemia	Predictive	D: Preclinical evidence	NA	NA	NA	Ruxolitinib	T618I	EID6380:CSF3R:p.T618	c.1853_1854delinsTT, c.1853_1854delinsTA, c.1853C>T	1_36933433_GG_AA, 1_36933433_GG_TA, 1_36933434_G_A	ENST00000373103	36933427	36933440
CSF3R	1	T618I	missense_variant	EID6381	T618I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25180155' target='_blank'>Dao et al., 2014, Leuk Res Rep</a>	Chronic Neutrophilic Leukemia	Predictive	C: Case study	NA	NA	NA	Ruxolitinib	T618I	EID6381:CSF3R:p.T618	c.1853_1854delinsTT, c.1853_1854delinsTA, c.1853C>T	1_36933433_GG_AA, 1_36933433_GG_TA, 1_36933434_G_A	ENST00000373103	36933427	36933440
JAK1	1	S703I	missense_variant	EID1900	S703I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26701727' target='_blank'>Yang et al., 2016, Oncotarget</a>	Hepatocellular Carcinoma	Predictive	D: Preclinical evidence	DOID:684	NA	NA	Ruxolitinib	S703I	EID1900:JAK1:p.S703	c.2108G>T	1_65311203_C_A	ENST00000342505	65311197	65311209
JAK1	1	Q503X	stop_gained	EID1567	Q503*	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27433843' target='_blank'>Zaretsky et al., 2016, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	NA	NA	Pembrolizumab	Q503X	EID1567:JAK1:p.Q503	c.1507C>T	1_65321333_G_A	ENST00000342505	65321327	65321339
NRAS	1	Q61L	missense_variant	EID22	Q61L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21576590' target='_blank'>Soon et al., 2011, Arch Dermatol</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Temozolomide	Q61L	EID22:NRAS:p.Q61	c.182A>T	1_115256529_T_A	ENST00000369535	115256523	115256535
NRAS	1	Q61R	missense_variant	EID23	Q61R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21576590' target='_blank'>Soon et al., 2011, Arch Dermatol</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Temozolomide	Q61R	EID23:NRAS:p.Q61	c.182A>G	1_115256529_T_C	ENST00000369535	115256523	115256535
NRAS	1	Q61K	missense_variant	EID1002	Q61K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26821351' target='_blank'>Kiessling et al., 2016, PLoS ONE</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	Everolimus, Binimetinib (MEK162)	Q61K	EID1002:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	115256524	115256536
NRAS	1	Q61K	missense_variant	EID1474	Q61K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22194965' target='_blank'>Atefi et al., 2011, PLoS ONE</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	Vemurafenib	Q61K	EID1474:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	115256524	115256536
NRAS	1	Q61K	missense_variant	EID1475	Q61K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22194965' target='_blank'>Atefi et al., 2011, PLoS ONE</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	Selumetinib (AZD6244)	Q61K	EID1475:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	115256524	115256536
NRAS	1	Q61K	missense_variant	EID2192	Q61K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Selumetinib (AZD6244), BEZ235	Q61K	EID2192:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	115256524	115256536
NRAS	1	Q61K	missense_variant	EID2907	Q61K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23515407' target='_blank'>Ohashi et al., 2013, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Trametinib, Selumetinib (AZD6244)	Q61K	EID2907:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	115256524	115256536
NRAS	1	NA	NA	EID1473	Q61	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18390968' target='_blank'>Adjei et al., 2008, J. Clin. Oncol.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	61	NA	Selumetinib (AZD6244)	Q61	EID1473:NRAS:p.Q61	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID1226	Q61	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23414587' target='_blank'>Ascierto et al., 2013, Lancet Oncol.</a>	Skin Melanoma	Predictive	B: Clinical evidence	DOID:8923	61	NA	Binimetinib (MEK162)	Q61	EID1226:NRAS:p.Q61	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID124	Q61	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	61	NA	Cetuximab	Q61	EID124:NRAS:p.Q61	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID36	Q61	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	61	NA	Cetuximab	Q61	EID36:NRAS:p.Q61	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID10	Q61	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23861977' target='_blank'>Tschandl et al., 2013, PLoS ONE</a>	Melanoma	Diagnostic	B: Clinical evidence	DOID:1909	61	NA	NA	Q61	EID10:NRAS:p.Q61	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID14	Q61	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23569304' target='_blank'>Trunzer et al., 2013, J. Clin. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	61	NA	Vemurafenib	Q61	EID14:NRAS:p.Q61	NA	NA	NA	115256527	115256530
NRAS	1	G13D	missense_variant	EID21	G13D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18375819' target='_blank'>Banerji et al., 2008, Mol. Cancer Ther.</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	17-AAG	G13D	EID21:NRAS:p.G13	c.38G>A	1_115258744_C_T	ENST00000369535	115258738	115258750
NRAS	1	G12D	missense_variant	EID3693	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25666295' target='_blank'>Kaczirek et al., 2015, Clin Colorectal Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab	G12D	EID3693:NRAS:p.G12	c.35G>A	1_115258747_C_T	ENST00000369535	115258741	115258753
NRAS	1	NA	NA	EID1516	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27276561' target='_blank'>Papaemmanuil et al., 2016, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	12	NA	NA	G12	EID1516:NRAS:p.G12	NA	NA	NA	115258743	115258748
NRAS	1	NA	NA	EID1516B	G13	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27276561' target='_blank'>Papaemmanuil et al., 2016, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	13	NA	NA	G13	EID1516B:NRAS:p.G13	NA	NA	NA	115258743	115258748
DDR2	1	L63V	missense_variant&splice_region_variant	EID271	L63V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Dasatinib	L63V	EID271:DDR2:p.L63	c.187C>G	1_162724415_C_G	ENST00000367922	162724409	162724421
DDR2	1	L239R	missense_variant	EID270	L239R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Dasatinib	L239R	EID270:DDR2:p.L239	c.716T>G	1_162729630_T_G	ENST00000367922	162729624	162729636
DDR2	1	G253C	missense_variant	EID266	G253C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Dasatinib	G253C	EID266:DDR2:p.G253	c.757G>T	1_162729671_G_T	ENST00000367922	162729665	162729677
DDR2	1	G505S	missense_variant	EID267	G505S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Dasatinib	G505S	EID267:DDR2:p.G505	c.1513G>A	1_162741822_G_A	ENST00000367922	162741816	162741828
DDR2	1	I638F	missense_variant	EID269	I638F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Dasatinib	I638F	EID269:DDR2:p.I638	c.1912A>T	1_162745497_A_T	ENST00000367922	162745491	162745503
DDR2	1	S768R	missense_variant	EID272	S768R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib, Dasatinib	S768R	EID272:DDR2:p.S768	c.2304T>A	1_162748390_T_A	ENST00000367922	162748384	162748396
DDR2	1	G774V	missense_variant	EID268	G774V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Dasatinib	G774V	EID268:DDR2:p.G774	c.2321G>T	1_162748407_G_T	ENST00000367922	162748401	162748413
AKT3	1	E17K	missense_variant&splice_region_variant	EID4521	E17K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	E17K	EID4521:AKT3:p.E17	c.49G>A	1_243859016_C_T	ENST00000366539	243859010	243859022
RET	10	C634W	missense_variant	EID75	C634W	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21422803' target='_blank'>Coxon et al., 2012, J. Endocrinol. Invest.</a>	Thyroid Medullary Carcinoma	Predictive	D: Preclinical evidence	DOID:3973	NA	NA	Motesanib	C634W	EID75:RET:p.C634	c.1902C>G	10_43609950_C_G	ENST00000355710	43609944	43609956
RET	10	M918T	missense_variant	EID1365	M918T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20368568' target='_blank'>Lam et al., 2010, J. Clin. Oncol.</a>	Thyroid Medullary Carcinoma	Predictive	B: Clinical evidence	DOID:3973	NA	NA	Sorafenib	M918T	EID1365:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	43617410	43617422
RET	10	M918T	missense_variant	EID74	M918T	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18073307' target='_blank'>Elisei et al., 2008, J. Clin. Endocrinol. Metab.</a>	Thyroid Medullary Carcinoma	Diagnostic	B: Clinical evidence	DOID:3973	NA	NA	NA	M918T	EID74:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	43617410	43617422
RET	10	M918T	missense_variant	EID76	M918T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21422803' target='_blank'>Coxon et al., 2012, J. Endocrinol. Invest.</a>	Thyroid Medullary Carcinoma	Predictive	D: Preclinical evidence	DOID:3973	NA	NA	Motesanib	M918T	EID76:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	43617410	43617422
RET	10	M918T	missense_variant	EID77	M918T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23056499' target='_blank'>Couto et al., 2012, PLoS ONE</a>	Thyroid Medullary Carcinoma	Predictive	D: Preclinical evidence	DOID:3973	NA	NA	AZD1480	M918T	EID77:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	43617410	43617422
RET	10	M918T	missense_variant	EID78	M918T	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9839497' target='_blank'>Egawa et al., 1998, Jpn. J. Clin. Oncol.</a>	Thyroid Medullary Carcinoma	Prognostic	B: Clinical evidence	DOID:3973	NA	NA	NA	M918T	EID78:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	43617410	43617422
PTEN	10	R233X	stop_gained	EID317	R233*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20085938' target='_blank'>Courtney et al., 2010, J. Clin. Oncol.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	MTOR Inhibitors	R233X	EID317:PTEN:p.R233	c.697C>T	10_89717672_C_T	ENST00000371953	89717666	89717678
PTEN	10	R233X	stop_gained	EID343	R233*	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22479427' target='_blank'>Carico et al., 2012, PLoS ONE</a>	Glioblastoma Multiforme	Prognostic	B: Clinical evidence	DOID:3068	NA	NA	NA	R233X	EID343:PTEN:p.R233	c.697C>T	10_89717672_C_T	ENST00000371953	89717666	89717678
PTEN	10	NA	NA	EID1534	V317FS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24504448' target='_blank'>Turajlic et al., 2014, Ann. Oncol.</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	317	NA	PD184352, MK-2206	V317	EID1534:PTEN:p.V317	NA	NA	NA	89720798	89720802
NT5C2	10	D407A	missense_variant	EID632	D407A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	NA	NA	6-thioguanine, 6-mercaptopurine	D407A	EID632:NT5C2:p.D407	c.1220A>C	10_104850745_T_G	ENST00000343289	104850739	104850751
NT5C2	10	D407A	missense_variant	EID635	D407A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	NA	NA	Arabinosylguanine, Nelarabine	D407A	EID635:NT5C2:p.D407	c.1220A>C	10_104850745_T_G	ENST00000343289	104850739	104850751
NT5C2	10	R367Q	missense_variant	EID630	R367Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	NA	NA	6-thioguanine, 6-mercaptopurine	R367Q	EID630:NT5C2:p.R367	c.1100G>A	10_104852955_C_T	ENST00000343289	104852949	104852961
NT5C2	10	R367Q	missense_variant	EID633	R367Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	NA	NA	Arabinosylguanine, Nelarabine	R367Q	EID633:NT5C2:p.R367	c.1100G>A	10_104852955_C_T	ENST00000343289	104852949	104852961
NT5C2	10	K359Q	missense_variant	EID631	K359Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	NA	NA	6-thioguanine, 6-mercaptopurine	K359Q	EID631:NT5C2:p.K359	c.1075A>C	10_104852980_T_G	ENST00000343289	104852974	104852986
NT5C2	10	K359Q	missense_variant	EID636	K359Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	NA	NA	Nelarabine, Arabinosylguanine	K359Q	EID636:NT5C2:p.K359	c.1075A>C	10_104852980_T_G	ENST00000343289	104852974	104852986
NT5C2	10	K359Q	missense_variant	EID667	K359Q	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	Acute Lymphocytic Leukemia	Prognostic	B: Clinical evidence	DOID:9952	NA	NA	NA	K359Q	EID667:NT5C2:p.K359	c.1075A>C	10_104852980_T_G	ENST00000343289	104852974	104852986
FGFR2	10	N550K	missense_variant	EID1322	N550K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18757403' target='_blank'>Byron et al., 2008, Cancer Res.</a>	Endometrial Cancer	Predictive	D: Preclinical evidence	DOID:1380	NA	NA	PD173074	N550K	EID1322:FGFR2:p.N550	c.1650T>A	10_123258034_A_T	ENST00000457416	123258028	123258040
HRAS	11	G13D	missense_variant	EID3851	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22256804' target='_blank'>Su et al., 2012, N. Engl. J. Med.</a>	Skin Squamous Cell Carcinoma	Predictive	C: Case study	DOID:3151	NA	NA	Vemurafenib	G13D	EID3851:HRAS:p.G13	c.38G>A	11_534285_C_T	ENST00000451590	534279	534291
HRAS	11	G13D	missense_variant	EID3852	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26561417' target='_blank'>Boidot et al., 2016, Int J Colorectal Dis</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	G13D	EID3852:HRAS:p.G13	c.38G>A	11_534285_C_T	ENST00000451590	534279	534291
HRAS	11	G13D	missense_variant	EID699	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26561417' target='_blank'>Boidot et al., 2016, Int J Colorectal Dis</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	EGFR Inhibitor	G13D	EID699:HRAS:p.G13	c.38G>A	11_534285_C_T	ENST00000451590	534279	534291
WT1	11	NA	NA	EID210	EXON 9 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18559874' target='_blank'>Paschka et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	9	NA	EXON 9 MUTATION	EID210:WT1:exon9	NA	NA	NA	32413517	32413610
WT1	11	NA	NA	EID203	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19221039' target='_blank'>Gaidzik et al., 2009, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	EID203:WT1:exon7	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID204	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18559874' target='_blank'>Paschka et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	EID204:WT1:exon7	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID205	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18591546' target='_blank'>Virappane et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	EID205:WT1:exon7	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID206	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18591546' target='_blank'>Virappane et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	EID206:WT1:exon7	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID201	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19536888' target='_blank'>Renneville et al., 2009, Cancer</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	EID201:WT1:exon7	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID202	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19536888' target='_blank'>Renneville et al., 2009, Cancer</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	EID202:WT1:exon7	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID139	EXON 7 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18591546' target='_blank'>Virappane et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	7	Cytarabine, Daunorubicin	EXON 7 MUTATION	EID139:WT1:exon7	NA	NA	NA	32417802	32417953
ATM	11	NA	NA	EID647	V2288FS*1	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26510020' target='_blank'>Mateo et al., 2015, N. Engl. J. Med.</a>	Prostate Cancer	Predictive	C: Case study	DOID:10283	2288	NA	Olaparib	V2288	EID647:ATM:p.V2288	NA	NA	NA	108196839	108196841
ATM	11	N2875H	missense_variant	EID648	N2875H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26510020' target='_blank'>Mateo et al., 2015, N. Engl. J. Med.</a>	Prostate Cancer	Predictive	C: Case study	DOID:10283	NA	NA	Olaparib	N2875H	EID648:ATM:p.N2875	c.8623A>C	11_108218044_A_C	ENST00000278616	108218038	108218050
KRAS	12	A146V	missense_variant	EID2209	A146V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Selumetinib (AZD6244), BEZ235 (NVP-BEZ235, Dactolisib)	A146V	EID2209:KRAS:p.A146	c.437C>T	12_25378561_G_A	ENST00000256078	25378555	25378567
KRAS	12	A146V	missense_variant	EID794	A146V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24836576' target='_blank'>Van Allen et al., 2014, Nat. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	LY2835219	A146V	EID794:KRAS:p.A146	c.437C>T	12_25378561_G_A	ENST00000256078	25378555	25378567
KRAS	12	A146P	missense_variant	EID2225	A146P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603018' target='_blank'>Loupakis et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab	A146P	EID2225:KRAS:p.A146	c.436G>C	12_25378562_C_G	ENST00000256078	25378556	25378568
KRAS	12	A146T	missense_variant	EID2206	A146T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	BEZ235, Selumetinib (AZD6244)	A146T	EID2206:KRAS:p.A146	c.436G>A	12_25378562_C_T	ENST00000256078	25378556	25378568
KRAS	12	A146T	missense_variant	EID2943	A146T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20570890' target='_blank'>Janakiraman et al., 2010, Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	A146T	EID2943:KRAS:p.A146	c.436G>A	12_25378562_C_T	ENST00000256078	25378556	25378568
KRAS	12	A146T	missense_variant	EID3858	A146T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25666295' target='_blank'>Kaczirek et al., 2015, Clin Colorectal Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	FOLFOX4, Cetuximab	A146T	EID3858:KRAS:p.A146	c.436G>A	12_25378562_C_T	ENST00000256078	25378556	25378568
KRAS	12	Q61H	missense_variant	EID3862	Q61H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22722830' target='_blank'>Misale et al., 2012, Nature</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Cetuximab	Q61H	EID3862:KRAS:p.Q61	c.183A>C	12_25380275_T_G	ENST00000256078	25380269	25380281
KRAS	12	NA	NA	EID489	Q61	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18528420' target='_blank'>Chng et al., 2008, Leukemia</a>	Multiple Myeloma	Prognostic	B: Clinical evidence	DOID:9538	61	NA	NA	Q61	EID489:KRAS:p.Q61	NA	NA	NA	25380274	25380277
KRAS	12	NA	NA	EID1208	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27037411' target='_blank'>Azuara et al., 2016, Mol. Cancer Ther.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	2	EGFR Inhibitor	EXON 2 MUTATION	EID1208:KRAS:exon2	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID1326	EXON 2 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25322874' target='_blank'>Hochster et al., 2015, Cancer Chemother. Pharmacol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	2	Selumetinib (AZD6244), Irinotecan	EXON 2 MUTATION	EID1326:KRAS:exon2	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID993	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18946061' target='_blank'>Karapetis et al., 2008, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	A: Validated	DOID:9256	NA	2	Cetuximab	EXON 2 MUTATION	EID993:KRAS:exon2	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID916	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23435671' target='_blank'>Boeck et al., 2013, J. Gastroenterol.</a>	Pancreatic Carcinoma	Predictive	B: Clinical evidence	DOID:4905	NA	2	Erlotinib	EXON 2 MUTATION	EID916:KRAS:exon2	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID917	EXON 2 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23435671' target='_blank'>Boeck et al., 2013, J. Gastroenterol.</a>	Pancreatic Carcinoma	Prognostic	B: Clinical evidence	DOID:4905	NA	2	NA	EXON 2 MUTATION	EID917:KRAS:exon2	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID1219	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21862683' target='_blank'>Kim et al., 2011, Mol. Cancer Ther.</a>	Pancreatic Cancer	Predictive	B: Clinical evidence	DOID:1793	NA	2	Erlotinib, Gemcitabine	EXON 2 MUTATION	EID1219:KRAS:exon2	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID250	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16618717' target='_blank'>Lièvre et al., 2006, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	2	Cetuximab	EXON 2 MUTATION	EID250:KRAS:exon2	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID87	EXON 2 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24559322' target='_blank'>Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	2	Regorafenib	EXON 2 MUTATION	EID87:KRAS:exon2	NA	NA	NA	25398207	25398329
KRAS	12	Q22X	stop_gained	EID1131	Q22*	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19661358' target='_blank'>Palmirotta et al., 2009, Anticancer Res.</a>	Colon Mucinous Adenocarcinoma	Predictive	C: Case study	DOID:3029	NA	NA	Panitumumab	Q22X	EID1131:KRAS:p.Q22	c.64C>T	12_25398255_G_A	ENST00000256078	25398249	25398261
KRAS	12	G13D	missense_variant	EID1180	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26371285' target='_blank'>Schirripa et al., 2015, Ann. Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab	G13D	EID1180:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID1181	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26812186' target='_blank'>Rowland et al., 2016, Eur. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab	G13D	EID1181:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID145	G13D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20978259' target='_blank'>De Roock et al., 2010, JAMA</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	G13D	EID145:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID2183	G13D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Selumetinib (AZD6244), BEZ235	G13D	EID2183:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID2231	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab	G13D	EID2231:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID306	G13D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20978259' target='_blank'>De Roock et al., 2010, JAMA</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab	G13D	EID306:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID3878	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22722830' target='_blank'>Misale et al., 2012, Nature</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	G13D	EID3878:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID3882	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25666295' target='_blank'>Kaczirek et al., 2015, Clin Colorectal Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab	G13D	EID3882:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID6320	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Cetuximab, Panitumumab	G13D	EID6320:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID6322	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab, Cetuximab	G13D	EID6322:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G13D	missense_variant	EID806	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26623049' target='_blank'>Osumi et al., 2015, Mol Clin Oncol</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab	G13D	EID806:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	25398275	25398287
KRAS	12	G12A	missense_variant	EID2004	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab	G12A	EID2004:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	25398278	25398290
KRAS	12	G12A	missense_variant	EID2008	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	B: Clinical evidence	DOID:1324	NA	NA	Gefitinib	G12A	EID2008:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	25398278	25398290
KRAS	12	G12A	missense_variant	EID2009	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19284554' target='_blank'>Greco et al., 2009, J. Exp. Clin. Cancer Res.</a>	Multiple Myeloma	Predictive	B: Clinical evidence	DOID:9538	NA	NA	Melphalan	G12A	EID2009:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	25398278	25398290
KRAS	12	G12A	missense_variant	EID2012	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11050000' target='_blank'>Rowley et al., 2000, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12A	EID2012:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	25398278	25398290
KRAS	12	G12A	missense_variant	EID2013	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12483530' target='_blank'>Rowley et al., 2002, Oncogene</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12A	EID2013:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	25398278	25398290
KRAS	12	G12A	missense_variant	EID2014	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16497971' target='_blank'>Hoang et al., 2006, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12A	EID2014:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	25398278	25398290
KRAS	12	G12A	missense_variant	EID251	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19794967' target='_blank'>Marchetti et al., 2009, Neoplasia</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	NA	Gefitinib, Erlotinib	G12A	EID251:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	25398278	25398290
KRAS	12	G12A	missense_variant	EID3710	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Regorafenib	G12A	EID3710:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	25398278	25398290
KRAS	12	G12A	missense_variant	EID6319	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Cetuximab, Panitumumab	G12A	EID6319:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID1215	G12D	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22948721' target='_blank'>Modest et al., 2012, Oncology</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	G12D	EID1215:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID1300	G12D	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27010960' target='_blank'>Bournet et al., 2016, Clin Transl Gastroenterol</a>	Pancreatic Cancer	Prognostic	B: Clinical evidence	DOID:1793	NA	NA	NA	G12D	EID1300:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID1311	G12D	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23565280' target='_blank'>Rachakonda et al., 2013, PLoS ONE</a>	Tumor Of Exocrine Pancreas	Prognostic	B: Clinical evidence	DOID:1795	NA	NA	NA	G12D	EID1311:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID1580	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26352686' target='_blank'>Tiacci et al., 2015, N. Engl. J. Med.</a>	Hairy Cell Leukemia	Predictive	C: Case study	DOID:285	NA	NA	Vemurafenib	G12D	EID1580:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID1732	G12D	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27010960' target='_blank'>Bournet et al., 2016, Clin Transl Gastroenterol</a>	Pancreatic Ductal Carcinoma	Prognostic	B: Clinical evidence	DOID:3587	NA	NA	NA	G12D	EID1732:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID1898	G12D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27959684' target='_blank'>Tran et al., 2016, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Adoptive T-cell Transfer	G12D	EID1898:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID2218	G12D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Selumetinib (AZD6244), BEZ235	G12D	EID2218:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID2236	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab	G12D	EID2236:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID2240	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	B: Clinical evidence	DOID:1324	NA	NA	Gefitinib	G12D	EID2240:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID2247	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19284554' target='_blank'>Greco et al., 2009, J. Exp. Clin. Cancer Res.</a>	Multiple Myeloma	Predictive	B: Clinical evidence	DOID:9538	NA	NA	Melphalan	G12D	EID2247:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID2250	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11050000' target='_blank'>Rowley et al., 2000, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12D	EID2250:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID2251	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12483530' target='_blank'>Rowley et al., 2002, Oncogene</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12D	EID2251:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID2252	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16497971' target='_blank'>Hoang et al., 2006, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12D	EID2252:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID228	G12D	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23014527' target='_blank'>Dogan et al., 2012, Clin. Cancer Res.</a>	Lung Cancer	Diagnostic	B: Clinical evidence	DOID:1324	NA	NA	NA	G12D	EID228:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID305	G12D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19029981' target='_blank'>Engelman et al., 2008, Nat. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	ARRY-142886, BEZ235 (NVP-BEZ235, Dactolisib)	G12D	EID305:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID3946	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Regorafenib	G12D	EID3946:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID3957	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	G12D	EID3957:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID3958	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22246397' target='_blank'>Sato et al., 2012, Oncol. Rep.</a>	Ovarian Cancer	Predictive	D: Preclinical evidence	DOID:2394	NA	NA	Cetuximab	G12D	EID3958:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID6316	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab, Cetuximab	G12D	EID6316:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12D	missense_variant	EID937	G12D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22025163' target='_blank'>Yap et al., 2011, J. Clin. Oncol.</a>	Pancreatic Carcinoma	Predictive	C: Case study	DOID:4905	NA	NA	MK-2206	G12D	EID937:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID1143	G12V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26125448' target='_blank'>Jänne et al., 2015, Br. J. Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Docetaxel, Selumetinib (AZD6244)	G12V	EID1143:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID136	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20978259' target='_blank'>De Roock et al., 2010, JAMA</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	G12V	EID136:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID1715	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25232318' target='_blank'>Palma et al., 2014, Case Rep Oncol</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Crizotinib	G12V	EID1715:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID2001	G12V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Selumetinib (AZD6244), BEZ235	G12V	EID2001:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID2232	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab	G12V	EID2232:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID2268	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	C: Case study	DOID:1324	NA	NA	Gefitinib	G12V	EID2268:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID3924	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Regorafenib	G12V	EID3924:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID6323	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab, Cetuximab	G12V	EID6323:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID795	G12V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20609353' target='_blank'>Puyol et al., 2010, Cancer Cell</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	PD0332991	G12V	EID795:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	G12V	missense_variant	EID987	G12V	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26372703' target='_blank'>Renaud et al., 2015, Br. J. Cancer</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	NA	NA	G12V	EID987:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	25398278	25398290
KRAS	12	NA	NA	EID6363	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Panitumumab, Cetuximab	G12	EID6363:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6363B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Panitumumab, Cetuximab	G13	EID6363B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID35	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15696205' target='_blank'>Pao et al., 2005, PLoS Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	12	NA	Erlotinib, Gefitinib	G12	EID35:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID35B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15696205' target='_blank'>Pao et al., 2005, PLoS Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	13	NA	Erlotinib, Gefitinib	G13	EID35B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6293	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Oxaliplatin	G12	EID6293:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6293B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Oxaliplatin	G13	EID6293B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6294	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Irinotecan	G12	EID6294:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6294B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Irinotecan	G13	EID6294B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6295	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Bevacizumab	G12	EID6295:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6295B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Bevacizumab	G13	EID6295B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6296	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Cetuximab	G12	EID6296:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6296B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Cetuximab	G13	EID6296B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6292	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	12	NA	NA	G12	EID6292:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6292B	G13	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	13	NA	NA	G13	EID6292B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID990	G12	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24915778' target='_blank'>Infante et al., 2014, Eur. J. Cancer</a>	Pancreatic Adenocarcinoma	Predictive	B: Clinical evidence	DOID:4074	12	NA	Trametinib	G12	EID990:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID990B	G13	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24915778' target='_blank'>Infante et al., 2014, Eur. J. Cancer</a>	Pancreatic Adenocarcinoma	Predictive	B: Clinical evidence	DOID:4074	13	NA	Trametinib	G13	EID990B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID194	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18202412' target='_blank'>Lièvre et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Prognostic	D: Preclinical evidence	DOID:9256	12	NA	NA	G12	EID194:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID194B	G13	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18202412' target='_blank'>Lièvre et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Prognostic	D: Preclinical evidence	DOID:9256	13	NA	NA	G13	EID194B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID134	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Cetuximab	G12	EID134:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID134B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Cetuximab	G13	EID134B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID135	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18202412' target='_blank'>Lièvre et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Cetuximab	G12	EID135:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID135B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18202412' target='_blank'>Lièvre et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	13	NA	Cetuximab	G13	EID135B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID622	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24915778' target='_blank'>Infante et al., 2014, Eur. J. Cancer</a>	Pancreatic Adenocarcinoma	Predictive	B: Clinical evidence	DOID:4074	12	NA	Trametinib, Gemcitabine	G12	EID622:KRAS:p.G12	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID622B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24915778' target='_blank'>Infante et al., 2014, Eur. J. Cancer</a>	Pancreatic Adenocarcinoma	Predictive	B: Clinical evidence	DOID:4074	13	NA	Trametinib, Gemcitabine	G13	EID622B:KRAS:p.G13	NA	NA	NA	25398279	25398285
KRAS	12	G12C	missense_variant	EID1142	G12C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26125448' target='_blank'>Jänne et al., 2015, Br. J. Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Docetaxel, Selumetinib (AZD6244)	G12C	EID1142:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID1173	G12C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26739882' target='_blank'>Patricelli et al., 2016, Cancer Discov</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	ARS-853, EGFR Inhibitor	G12C	EID1173:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID1216	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23313110' target='_blank'>Fiala et al., Cancer Genet</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Gefitinib, Erlotinib	G12C	EID1216:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID1217	G12C	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22247021' target='_blank'>Ihle et al., 2012, J. Natl. Cancer Inst.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	NA	NA	G12C	EID1217:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID2212	G12C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Selumetinib (AZD6244), BEZ235	G12C	EID2212:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID2253	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab	G12C	EID2253:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID2257	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	B: Clinical evidence	DOID:1324	NA	NA	Gefitinib	G12C	EID2257:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID2258	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19284554' target='_blank'>Greco et al., 2009, J. Exp. Clin. Cancer Res.</a>	Multiple Myeloma	Predictive	B: Clinical evidence	DOID:9538	NA	NA	Melphalan	G12C	EID2258:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID2261	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11050000' target='_blank'>Rowley et al., 2000, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12C	EID2261:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID2262	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12483530' target='_blank'>Rowley et al., 2002, Oncogene</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12C	EID2262:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID2263	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16497971' target='_blank'>Hoang et al., 2006, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12C	EID2263:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID227	G12C	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23014527' target='_blank'>Dogan et al., 2012, Clin. Cancer Res.</a>	Lung Cancer	Diagnostic	B: Clinical evidence	DOID:1324	NA	NA	NA	G12C	EID227:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12C	missense_variant	EID3973	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Regorafenib	G12C	EID3973:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	25398279	25398291
KRAS	12	G12R	missense_variant	EID1298	G12R	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22983505' target='_blank'>Ogura et al., 2013, J. Gastroenterol.</a>	Pancreatic Cancer	Prognostic	B: Clinical evidence	DOID:1793	NA	NA	NA	G12R	EID1298:KRAS:p.G12	c.34G>C	12_25398285_C_G	ENST00000256078	25398279	25398291
KRAS	12	G12R	missense_variant	EID2264	G12R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab	G12R	EID2264:KRAS:p.G12	c.34G>C	12_25398285_C_G	ENST00000256078	25398279	25398291
KRAS	12	G12R	missense_variant	EID3989	G12R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22722830' target='_blank'>Misale et al., 2012, Nature</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	G12R	EID3989:KRAS:p.G12	c.34G>C	12_25398285_C_G	ENST00000256078	25398279	25398291
KRAS	12	G12R	missense_variant	EID3991	G12R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Regorafenib	G12R	EID3991:KRAS:p.G12	c.34G>C	12_25398285_C_G	ENST00000256078	25398279	25398291
KRAS	12	G12S	missense_variant	EID2269	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab	G12S	EID2269:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	25398279	25398291
KRAS	12	G12S	missense_variant	EID2273	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	B: Clinical evidence	DOID:1324	NA	NA	Gefitinib	G12S	EID2273:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	25398279	25398291
KRAS	12	G12S	missense_variant	EID2274	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19284554' target='_blank'>Greco et al., 2009, J. Exp. Clin. Cancer Res.</a>	Multiple Myeloma	Predictive	B: Clinical evidence	DOID:9538	NA	NA	Melphalan	G12S	EID2274:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	25398279	25398291
KRAS	12	G12S	missense_variant	EID2277	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11050000' target='_blank'>Rowley et al., 2000, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12S	EID2277:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	25398279	25398291
KRAS	12	G12S	missense_variant	EID2278	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12483530' target='_blank'>Rowley et al., 2002, Oncogene</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12S	EID2278:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	25398279	25398291
KRAS	12	G12S	missense_variant	EID2279	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16497971' target='_blank'>Hoang et al., 2006, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	NA	NA	Melphalan	G12S	EID2279:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	25398279	25398291
KRAS	12	G12S	missense_variant	EID4012	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Regorafenib	G12S	EID4012:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	25398279	25398291
KRAS	12	G12S	missense_variant	EID6314	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Cetuximab, Panitumumab	G12S	EID6314:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	25398279	25398291
KRAS	12	G12S	missense_variant	EID6324	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab, Cetuximab	G12S	EID6324:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	25398279	25398291
KRAS	12	NA	NA	EID488	G13	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18528420' target='_blank'>Chng et al., 2008, Leukemia</a>	Multiple Myeloma	Prognostic	B: Clinical evidence	DOID:9538	13	NA	NA	G13	EID488:KRAS:p.G13	NA	NA	NA	25398280	25398282
KRAS	12	NA	NA	EID487	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18528420' target='_blank'>Chng et al., 2008, Leukemia</a>	Multiple Myeloma	Prognostic	B: Clinical evidence	DOID:9538	12	NA	NA	G12	EID487:KRAS:p.G12	NA	NA	NA	25398283	25398285
KRAS	12	NA	NA	EID377	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18528420' target='_blank'>Chng et al., 2008, Leukemia</a>	Multiple Myeloma	Prognostic	B: Clinical evidence	DOID:9538	12	NA	NA	G12	EID377:KRAS:p.G12	NA	NA	NA	25398283	25398285
KRAS	12	NA	NA	EID378	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15597105' target='_blank'>Mascaux et al., 2005, Br. J. Cancer</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	12	NA	NA	G12	EID378:KRAS:p.G12	NA	NA	NA	25398283	25398285
KRAS	12	NA	NA	EID215	G12	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18794081' target='_blank'>Riely et al., 2008, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Diagnostic	B: Clinical evidence	DOID:3908	12	NA	NA	G12	EID215:KRAS:p.G12	NA	NA	NA	25398283	25398285
KRAS	12	NA	NA	EID8	G12	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24571676' target='_blank'>Andrade et al., 2014, BMC Cancer</a>	Acute Leukemia	Diagnostic	B: Clinical evidence	DOID:12603	12	NA	NA	G12	EID8:KRAS:p.G12	NA	NA	NA	25398283	25398285
ERBB3	12	R103G	missense_variant	EID1747	R103G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27044931' target='_blank'>Choudhury et al., 2016, J. Clin. Oncol.</a>	Urothelial Carcinoma	Predictive	B: Clinical evidence	DOID:2671	NA	NA	Afatinib	R103G	EID1747:ERBB3:p.R103	c.307C>G	12_56478851_C_G	ENST00000267101	56478845	56478857
ERBB3	12	V104M	missense_variant	EID1746	V104M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27044931' target='_blank'>Choudhury et al., 2016, J. Clin. Oncol.</a>	Urothelial Carcinoma	Predictive	B: Clinical evidence	DOID:2671	NA	NA	Afatinib	V104M	EID1746:ERBB3:p.V104	c.310G>A	12_56478854_G_A	ENST00000267101	56478848	56478860
ERBB3	12	G284R	missense_variant	EID1748	G284R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27044931' target='_blank'>Choudhury et al., 2016, J. Clin. Oncol.</a>	Urothelial Carcinoma	Predictive	B: Clinical evidence	DOID:2671	NA	NA	Afatinib	G284R	EID1748:ERBB3:p.G284	c.850G>A	12_56481922_G_A	ENST00000267101	56481916	56481928
ERBB3	12	V855A	missense_variant	EID1845	V855A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26689995' target='_blank'>Umelo et al., 2016, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Pertuzumab, Afatinib	V855A	EID1845:ERBB3:p.V855	c.2564T>C	12_56491672_T_C	ENST00000267101	56491666	56491678
CDK4	12	R24C	missense_variant	EID1376	R24C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24495407' target='_blank'>Young et al., 2014, Pigment Cell Melanoma Res</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	Palbociclib (PD0332991)	R24C	EID1376:CDK4:p.R24	c.70C>T	12_58145431_G_A	ENST00000257904	58145425	58145437
POLE	12	S679F	missense_variant	EID5019	S459F	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28404093' target='_blank'>Domingo et al., 2016, Lancet Gastroenterol Hepatol</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	S459F	EID5019:POLE:p.S679	c.2035_2037delinsTTC, c.2035_2036delinsTT	12_133245078_ACT_GAA, 12_133245079_CT_AA	ENST00000320574	133245072	133245086
POLE	12	S459F	missense_variant	EID5019	S459F	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28404093' target='_blank'>Domingo et al., 2016, Lancet Gastroenterol Hepatol</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	S459F	EID5019:POLE:p.S459	c.1376_1377delinsTC, c.1376C>T	12_133249846_AG_GA, 12_133249847_G_A	ENST00000320574	133249840	133249853
POLE	12	V411L	missense_variant	EID5018	V411L	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28404093' target='_blank'>Domingo et al., 2016, Lancet Gastroenterol Hepatol</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	V411L	EID5018:POLE:p.V411	c.1231_1233delinsCTA, c.1231_1233delinsCTT, c.1231_1233delinsCTC, c.1231_1233delinsTTA, c.1231G>T, c.1231G>C	12_133250287_CAC_TAG, 12_133250287_CAC_AAG, 12_133250287_CAC_GAG, 12_133250287_CAC_TAA, 12_133250289_C_A, 12_133250289_C_G	ENST00000320574	133250281	133250295
POLE	12	P286R	missense_variant	EID5017	P286R	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28404093' target='_blank'>Domingo et al., 2016, Lancet Gastroenterol Hepatol</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	P286R	EID5017:POLE:p.P286	c.857_858delinsGG, c.857_858delinsGC, c.857_858delinsGA, c.856_858inv, c.856_858delinsAGA, c.857C>G	12_133253183_AG_CC, 12_133253183_AG_GC, 12_133253183_AG_TC, 12_133253183_AGG_CCT, 12_133253183_AGG_TCT, 12_133253184_G_C	ENST00000320574	133253177	133253191
FLT3	13	D835H	missense_variant	EID1557	D835H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23969938' target='_blank'>Baker et al., 2013, Clin. Cancer Res.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	Sorafenib	D835H	EID1557:FLT3:p.D835	c.2503_2505delinsCAC, c.2503G>C	13_28592640_ATC_GTG, 13_28592642_C_G	ENST00000241453	28592634	28592648
FLT3	13	D835Y	missense_variant	EID1557B	D835Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23969938' target='_blank'>Baker et al., 2013, Clin. Cancer Res.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	Sorafenib	D835Y	EID1557B:FLT3:p.D835	c.2503_2505delinsTAC, c.2503G>T	13_28592640_ATC_GTA, 13_28592642_C_A	ENST00000241453	28592634	28592648
FLT3	13	D835V	missense_variant	EID3007	D835V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15256420' target='_blank'>Clark et al., 2004, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	MLN518	D835V	EID3007:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	28592635	28592647
FLT3	13	D835V	missense_variant	EID3008	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15304385' target='_blank'>Yee et al., 2004, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	SU11248	D835V	EID3008:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	28592635	28592647
FLT3	13	D835V	missense_variant	EID3009	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15304385' target='_blank'>Yee et al., 2004, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	SU11248, Cytarabine	D835V	EID3009:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	28592635	28592647
FLT3	13	D835V	missense_variant	EID3010	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15304385' target='_blank'>Yee et al., 2004, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	SU11248, Daunorubicin	D835V	EID3010:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	28592635	28592647
FLT3	13	D835V	missense_variant	EID3012	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23497317' target='_blank'>Kampa-Schittenhelm et al., 2013, Mol. Cancer</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	Quizartinib	D835V	EID3012:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	28592635	28592647
FLT3	13	D835V	missense_variant	EID3034	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17330097' target='_blank'>Griessinger et al., 2007, Leukemia</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	AS602868, AG1296	D835V	EID3034:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	28592635	28592647
FLT3	13	D835V	missense_variant	EID4022	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15459012' target='_blank'>Fiedler et al., 2005, Blood</a>	Acute Myeloid Leukemia	Predictive	C: Case study	DOID:9119	NA	NA	Sunitinib	D835V	EID4022:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	28592635	28592647
FLT3	13	D835H	missense_variant	EID1556	D835H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23969938' target='_blank'>Baker et al., 2013, Clin. Cancer Res.</a>	Acute Myeloid Leukemia	Predictive	C: Case study	DOID:9119	NA	NA	Sorafenib	D835H	EID1556:FLT3:p.D835	c.2503G>C	13_28592642_C_G	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID1036	D835	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23430109' target='_blank'>Smith et al., 2013, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	Quizartinib (AC220), Ponatinib	D835	EID1036:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID1037	D835	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19318574' target='_blank'>von Bubnoff et al., 2009, Cancer Res.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	SU5614	D835	EID1037:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID1038	D835	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22504184' target='_blank'>Smith et al., 2012, Nature</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	NA	Quizartinib (AC220), Sorafenib	D835	EID1038:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID1039	D835	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22368270' target='_blank'>Man et al., 2012, Blood</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	NA	Sorafenib	D835	EID1039:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID1295	TKD MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20733134' target='_blank'>Fischer et al., 2010, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	NA	Midostaurin	TKD MUTATION	EID1295:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID171	TKD MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17965322' target='_blank'>Bacher et al., 2008, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	NA	NA	TKD MUTATION	EID171:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID214	TKD MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11290608' target='_blank'>Yamamoto et al., 2001, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	NA	NA	TKD MUTATION	EID214:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID247	TKD MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22368270' target='_blank'>Man et al., 2012, Blood</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	NA	Sorafenib	TKD MUTATION	EID247:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID248	TKD MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18230792' target='_blank'>Zhang et al., 2008, J. Natl. Cancer Inst.</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	NA	Sorafenib	TKD MUTATION	EID248:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
FLT3	13	D835Y	missense_variant	EID373	TKD MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17940205' target='_blank'>Whitman et al., 2008, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	NA	NA	TKD MUTATION	EID373:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	28592636	28592648
BRCA2	13	M1?	start_lost	EID2879	M1R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	M1R	EID2879:BRCA2:p.M1?	c.2T>G	13_32890599_T_G	ENST00000544455	32890593	32890605
BRCA2	13	M1?	start_lost	EID2880	M1I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	M1I	EID2880:BRCA2:p.M1?	c.3G>T	13_32890600_G_T	ENST00000544455	32890594	32890606
BRCA2	13	V159M	missense_variant&splice_region_variant	EID2881	V159M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	V159M	EID2881:BRCA2:p.V159	c.475G>A	13_32900287_G_A	ENST00000544455	32900281	32900293
BRCA2	13	.	splice_donor_variant	EID2882	V211L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	V211L	EID2882:BRCA2:c.631+1G>C	c.631+1G>C	13_32900751_G_C	ENST00000544455	32900745	32900757
BRCA2	13	.	splice_donor_variant	EID2883	V211I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	V211I	EID2883:BRCA2:c.631+1G>A	c.631+1G>A	13_32900751_G_A	ENST00000544455	32900745	32900757
BRCA2	13	R2336H	missense_variant&splice_region_variant	EID2885	R2336H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	R2336H	EID2885:BRCA2:p.R2336	c.7007G>A	13_32921033_G_A	ENST00000544455	32921027	32921039
BRCA2	13	R2336P	missense_variant&splice_region_variant	EID2884	R2336P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	R2336P	EID2884:BRCA2:p.R2336	c.7007G>C	13_32921033_G_C	ENST00000544455	32921027	32921039
RB1	13	M695fs	frameshift_variant	EID1630	M695FS*26	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27020857' target='_blank'>Herrera-Abreu et al., 2016, Cancer Res.</a>	Estrogen-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060075	NA	NA	Palbociclib (PD0332991)	M695fs*26	EID1630:RB1:p.M695	c.2083dup	13_49033946_A_AA	ENST00000267163	49033940	49033953
DICER1	14	E1813Q	missense_variant	EID5535	E1813Q	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26428316' target='_blank'>Conlon et al., 2015, Mod. Pathol.</a>	Malignant Sertoli-Leydig Cell Tumor	Diagnostic	B: Clinical evidence	DOID:0050618	NA	NA	NA	E1813Q	EID5535:DICER1:p.E1813	c.5437_5439delinsCAA, c.5437G>C	14_95557628_CTC_TTG, 14_95557630_C_G	ENST00000526495	95557622	95557636
DICER1	14	D1709N	missense_variant	EID5534	D1709N	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26428316' target='_blank'>Conlon et al., 2015, Mod. Pathol.</a>	Malignant Sertoli-Leydig Cell Tumor	Diagnostic	B: Clinical evidence	DOID:0050618	NA	NA	NA	D1709N	EID5534:DICER1:p.D1709	c.5125_5127delinsAAC, c.5125G>A	14_95560462_ATC_GTT, 14_95560464_C_T	ENST00000526495	95560456	95560470
DICER1	14	E1705K	missense_variant	EID5533	E1705K	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26428316' target='_blank'>Conlon et al., 2015, Mod. Pathol.</a>	Malignant Sertoli-Leydig Cell Tumor	Diagnostic	B: Clinical evidence	DOID:0050618	NA	NA	NA	E1705K	EID5533:DICER1:p.E1705	c.5113_5115delinsAAG, c.5113G>A	14_95560474_TTC_CTT, 14_95560476_C_T	ENST00000526495	95560468	95560482
AKT1	14	Q79K	missense_variant	EID439	Q79K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265152' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	Q79K	EID439:AKT1:p.Q79	c.235C>A	14_105243048_G_T	ENST00000554581	105243042	105243054
AKT1	14	Q79K	missense_variant	EID4498	Q79K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	Q79K	EID4498:AKT1:p.Q79	c.235C>A	14_105243048_G_T	ENST00000554581	105243042	105243054
AKT1	14	Q79K	missense_variant	EID6260	Q79K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Dabrafenib	Q79K	EID6260:AKT1:p.Q79	c.235C>A	14_105243048_G_T	ENST00000554581	105243042	105243054
AKT1	14	E17K	missense_variant&splice_region_variant	EID231	E17K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23888070' target='_blank'>Beaver et al., 2013, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	MK-2206	E17K	EID231:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	105246545	105246557
AKT1	14	E17K	missense_variant&splice_region_variant	EID3039	E17K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28489509' target='_blank'>Hyman et al., 2017, J. Clin. Oncol.</a>	Cancer	Predictive	B: Clinical evidence	DOID:162	NA	NA	AZD-5363	E17K	EID3039:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	105246545	105246557
AKT1	14	E17K	missense_variant&splice_region_variant	EID4029	E17K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	E17K	EID4029:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	105246545	105246557
AKT1	14	E17K	missense_variant&splice_region_variant	EID707	E17K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24735930' target='_blank'>Lassen et al., 2014, Mol. Cancer</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	GSK2141795	E17K	EID707:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	105246545	105246557
AKT1	14	E17K	missense_variant&splice_region_variant	EID709	E17K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26351323' target='_blank'>Davies et al., 2015, Mol. Cancer Ther.</a>	Breast Cancer	Predictive	C: Case study	DOID:1612	NA	NA	AZD5363	E17K	EID709:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	105246545	105246557
B2M	15	NA	NA	EID1569	S14FS	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27433843' target='_blank'>Zaretsky et al., 2016, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	14	NA	Pembrolizumab	S14	EID1569:B2M:p.S14	NA	NA	NA	45003785	45003789
MAP2K1	15	Q56P	missense_variant	EID13	Q56P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19915144' target='_blank'>Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Selumetinib (AZD6244)	Q56P	EID13:MAP2K1:p.Q56	c.167A>C	15_66727451_A_C	ENST00000307102	66727445	66727457
MAP2K1	15	K57N	missense_variant	EID2935	K57N	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25351745' target='_blank'>Arcila et al., 2015, Clin. Cancer Res.</a>	Lung Adenocarcinoma	Diagnostic	C: Case study	DOID:3910	NA	NA	NA	K57N	EID2935:MAP2K1:p.K57	c.171G>T	15_66727455_G_T	ENST00000307102	66727449	66727461
MAP2K1	15	K57N	missense_variant	EID2936	K57N	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18632602' target='_blank'>Marks et al., 2008, Cancer Res.</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	NA	NA	Selumetinib (AZD6244)	K57N	EID2936:MAP2K1:p.K57	c.171G>T	15_66727455_G_T	ENST00000307102	66727449	66727461
MAP2K1	15	C121S	missense_variant	EID1602	C121S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21383288' target='_blank'>Wagle et al., 2011, J. Clin. Oncol.</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Vemurafenib	C121S	EID1602:MAP2K1:p.C121	c.362G>C	15_66729154_G_C	ENST00000307102	66729148	66729160
MAP2K1	15	P124S	missense_variant	EID12	P124S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19915144' target='_blank'>Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Selumetinib (AZD6244)	P124S	EID12:MAP2K1:p.P124	c.370C>T	15_66729162_C_T	ENST00000307102	66729156	66729168
PML	15	A216V	missense_variant	EID1093	PML-RARA A216V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21613260' target='_blank'>Goto et al., 2011, Blood</a>	Acute Promyelocytic Leukemia	Predictive	C: Case study	DOID:0060318	NA	NA	All-trans Retinoic Acid	PML-RARA A216V	EID1093:PML:p.A216	c.647C>T	15_74315213_C_T	ENST00000268058	74315207	74315219
PML	15	L218P	missense_variant	EID1094	PML-RARA L218P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21613260' target='_blank'>Goto et al., 2011, Blood</a>	Acute Promyelocytic Leukemia	Predictive	C: Case study	DOID:0060318	NA	NA	All-trans Retinoic Acid	PML-RARA L218P	EID1094:PML:p.L218	c.653T>C	15_74315219_T_C	ENST00000268058	74315213	74315225
NTRK3	15	G623R	missense_variant	EID1874	ETV6-NTRK3 G623R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26884591' target='_blank'>Drilon et al., 2016, Ann. Oncol.</a>	Breast Cancer	Predictive	C: Case study	DOID:1612	NA	NA	Entrectinib	ETV6-NTRK3 G623R	EID1874:NTRK3:p.G623	c.1867G>A	15_88476265_C_T	ENST00000360948	88476259	88476271
IDH2	15	R172K	missense_variant	EID375	R172K	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21596855' target='_blank'>Green et al., 2011, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	NA	NA	R172K	EID375:IDH2:p.R172	c.515G>A	15_90631838_C_T	ENST00000330062	90631832	90631844
IDH2	15	NA	NA	EID1511	R172	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27276561' target='_blank'>Papaemmanuil et al., 2016, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	172	NA	NA	R172	EID1511:IDH2:p.R172	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID482	R172	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19228619' target='_blank'>Yan et al., 2009, N. Engl. J. Med.</a>	Glioblastoma Multiforme	Prognostic	B: Clinical evidence	DOID:3068	172	NA	NA	R172	EID482:IDH2:p.R172	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID628	R172	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22215888' target='_blank'>Cairns et al., 2012, Blood</a>	Peripheral T-cell Lymphoma	Diagnostic	B: Clinical evidence	DOID:0050749	172	NA	NA	R172	EID628:IDH2:p.R172	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID483	R172	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19228619' target='_blank'>Yan et al., 2009, N. Engl. J. Med.</a>	Astrocytoma	Prognostic	B: Clinical evidence	DOID:3069	172	NA	NA	R172	EID483:IDH2:p.R172	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID627	R172	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26268241' target='_blank'>Wang et al., 2015, Blood</a>	Peripheral T-cell Lymphoma	Prognostic	B: Clinical evidence	DOID:0050749	172	NA	NA	R172	EID627:IDH2:p.R172	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID350	R140	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21596855' target='_blank'>Green et al., 2011, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	140	NA	NA	R140	EID350:IDH2:p.R140	NA	NA	NA	90631933	90631934
TSC2	16	Q1178X	stop_gained	EID1108	Q1178*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25295501' target='_blank'>Wagle et al., 2014, N. Engl. J. Med.</a>	Thyroid Carcinoma	Predictive	C: Case study	DOID:3963	NA	NA	Everolimus	Q1178X	EID1108:TSC2:p.Q1178	c.3532C>T	16_2130300_C_T	ENST00000219476	2130294	2130306
PRKCB	16	D427N	missense_variant	EID6654	D427N	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26437031' target='_blank'>Kataoka et al., 2015, Nat. Genet.</a>	Adult T-cell Leukemia	Diagnostic	D: Preclinical evidence	DOID:0050523	NA	NA	NA	D427N	EID6654:PRKCB:p.D427	c.1279G>A, c.1279_1281delinsAAT	16_24183630_G_A, 16_24183630_GAC_AAT	ENST00000303531	24183624	24183638
TP53	17	R290H	missense_variant	EID4886	R158H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R158H	EID4886:TP53:p.R290	c.869_870delinsAT, c.869G>A	17_7577068_GC_AT, 17_7577069_C_T	ENST00000269305	7577062	7577075
TP53	17	R290L	missense_variant	EID4891	R158L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R158L	EID4891:TP53:p.R290	c.869_870delinsTT, c.869_870delinsTA, c.869_870delinsTG, c.868_870delinsTTA, c.868_870delinsTTG, c.869G>T	17_7577068_GC_AA, 17_7577068_GC_TA, 17_7577068_GC_CA, 17_7577068_GCG_TAA, 17_7577068_GCG_CAA, 17_7577069_C_A	ENST00000269305	7577062	7577076
TP53	17	R282L	missense_variant	EID2818	R282L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	NA	NA	EAP Protocol	R282L	EID2818:TP53:p.R282	c.845G>T	17_7577093_C_A	ENST00000269305	7577087	7577099
TP53	17	R280K	missense_variant	EID4889	R280K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R280K	EID4889:TP53:p.R280	c.839_840delinsAG, c.839G>A	17_7577098_TC_CT, 17_7577099_C_T	ENST00000269305	7577092	7577105
TP53	17	R280T	missense_variant	EID4890	R280T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R280T	EID4890:TP53:p.R280	c.839_840delinsCT, c.839_840delinsCG, c.839_840delinsCC, c.839G>C	17_7577098_TC_AG, 17_7577098_TC_CG, 17_7577098_TC_GG, 17_7577099_C_G	ENST00000269305	7577092	7577105
TP53	17	R273H	missense_variant	EID397	R273H	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	NA	NA	NA	R273H	EID397:TP53:p.R273	c.818G>A	17_7577120_C_T	ENST00000269305	7577114	7577126
TP53	17	R273H	missense_variant	EID398	R273H	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	NA	NA	NA	R273H	EID398:TP53:p.R273	c.818G>A	17_7577120_C_T	ENST00000269305	7577114	7577126
TP53	17	R273H	missense_variant	EID4882	R273H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R273H	EID4882:TP53:p.R273	c.818G>A	17_7577120_C_T	ENST00000269305	7577114	7577126
TP53	17	R273L	missense_variant	EID2286	R273L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11595686' target='_blank'>Reles et al., 2001, Clin. Cancer Res.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Cisplatin, Carboplatin	R273L	EID2286:TP53:p.R273	c.818G>T	17_7577120_C_A	ENST00000269305	7577114	7577126
TP53	17	R273C	missense_variant	EID2292	R273C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	NA	NA	EAP Protocol	R273C	EID2292:TP53:p.R273	c.817C>T	17_7577121_G_A	ENST00000269305	7577115	7577127
TP53	17	R273C	missense_variant	EID395	R273C	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	NA	NA	NA	R273C	EID395:TP53:p.R273	c.817C>T	17_7577121_G_A	ENST00000269305	7577115	7577127
TP53	17	R273C	missense_variant	EID396	R273C	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	NA	NA	NA	R273C	EID396:TP53:p.R273	c.817C>T	17_7577121_G_A	ENST00000269305	7577115	7577127
TP53	17	R273C	missense_variant	EID4881	R273C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R273C	EID4881:TP53:p.R273	c.817C>T	17_7577121_G_A	ENST00000269305	7577115	7577127
TP53	17	R249S	missense_variant	EID4888	R249S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R249S	EID4888:TP53:p.R249	c.747G>T, c.747G>C, c.745_747delinsTCT, c.745_747delinsTCC, c.745_747delinsTCA, c.745_746delinsTC	17_7577534_C_A, 17_7577534_C_G, 17_7577534_CCT_AGA, 17_7577534_CCT_GGA, 17_7577534_CCT_TGA, 17_7577535_CT_GA	ENST00000269305	7577528	7577542
TP53	17	R249T	missense_variant	EID393	R249	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	NA	NA	NA	R249	EID393:TP53:p.R249	c.746G>C	17_7577535_C_G	ENST00000269305	7577529	7577541
TP53	17	R249T	missense_variant	EID399	R249	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	NA	NA	Doxorubicin	R249	EID399:TP53:p.R249	c.746G>C	17_7577535_C_G	ENST00000269305	7577529	7577541
TP53	17	R248Q	missense_variant	EID3042	R248Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R248Q	EID3042:TP53:p.R248	c.743G>A	17_7577538_C_T	ENST00000269305	7577532	7577544
TP53	17	R248Q	missense_variant	EID390	R248Q	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	NA	NA	NA	R248Q	EID390:TP53:p.R248	c.743G>A	17_7577538_C_T	ENST00000269305	7577532	7577544
TP53	17	R248Q	missense_variant	EID391	R248Q	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	NA	NA	NA	R248Q	EID391:TP53:p.R248	c.743G>A	17_7577538_C_T	ENST00000269305	7577532	7577544
TP53	17	R248W	missense_variant	EID392	R248W	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	NA	NA	NA	R248W	EID392:TP53:p.R248	c.742C>T	17_7577539_G_A	ENST00000269305	7577533	7577545
TP53	17	R248W	missense_variant	EID4879	R248W	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R248W	EID4879:TP53:p.R248	c.742C>T	17_7577539_G_A	ENST00000269305	7577533	7577545
TP53	17	G245S	missense_variant	EID4883	G245S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	G245S	EID4883:TP53:p.G245	c.733_735delinsTCA, c.733_735delinsAGT, c.733_735delinsTCT, c.733_735delinsTCG, c.733_734delinsTC, c.733G>A	17_7577546_GCC_TGA, 17_7577546_GCC_ACT, 17_7577546_GCC_AGA, 17_7577546_GCC_CGA, 17_7577547_CC_GA, 17_7577548_C_T	ENST00000269305	7577540	7577554
TP53	17	Y234C	missense_variant	EID2745	Y234C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11595686' target='_blank'>Reles et al., 2001, Clin. Cancer Res.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Cisplatin, Carboplatin	Y234C	EID2745:TP53:p.Y234	c.701A>G	17_7577580_T_C	ENST00000269305	7577574	7577586
TP53	17	Y220C	missense_variant	EID2306	Y220C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	NA	NA	EAP Protocol	Y220C	EID2306:TP53:p.Y220	c.659A>G	17_7578190_T_C	ENST00000269305	7578184	7578196
TP53	17	Y220C	missense_variant	EID4884	Y220C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	Y220C	EID4884:TP53:p.Y220	c.659A>G	17_7578190_T_C	ENST00000269305	7578184	7578196
TP53	17	R213P	missense_variant	EID2819	R213P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	NA	NA	EAP Protocol	R213P	EID2819:TP53:p.R213	c.638G>C	17_7578211_C_G	ENST00000269305	7578205	7578217
TP53	17	R175H	missense_variant	EID2310	R175H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	NA	NA	EAP Protocol	R175H	EID2310:TP53:p.R175	c.524G>A	17_7578406_C_T	ENST00000269305	7578400	7578412
TP53	17	R175H	missense_variant	EID319	R175H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22698404' target='_blank'>Jackson et al., 2012, Cancer Cell</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Doxorubicin	R175H	EID319:TP53:p.R175	c.524G>A	17_7578406_C_T	ENST00000269305	7578400	7578412
TP53	17	R175H	missense_variant	EID389	R175H	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	NA	NA	NA	R175H	EID389:TP53:p.R175	c.524G>A	17_7578406_C_T	ENST00000269305	7578400	7578412
TP53	17	R175H	missense_variant	EID4880	R175H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R175H	EID4880:TP53:p.R175	c.524G>A	17_7578406_C_T	ENST00000269305	7578400	7578412
TP53	17	R158H	missense_variant	EID4886	R158H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R158H	EID4886:TP53:p.R158	c.473_474delinsAT, c.473G>A	17_7578456_GC_AT, 17_7578457_C_T	ENST00000269305	7578450	7578463
TP53	17	R158L	missense_variant	EID4891	R158L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	R158L	EID4891:TP53:p.R158	c.473_474delinsTG, c.473_474delinsTA, c.473_474delinsTT, c.472_474delinsTTA, c.472_474delinsTTG, c.473G>T	17_7578456_GC_CA, 17_7578456_GC_TA, 17_7578456_GC_AA, 17_7578456_GCG_TAA, 17_7578456_GCG_CAA, 17_7578457_C_A	ENST00000269305	7578450	7578464
TP53	17	V157F	missense_variant	EID4887	V157F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	AMGMDS3	V157F	EID4887:TP53:p.V157	c.469G>T	17_7578461_C_A	ENST00000269305	7578455	7578467
ERBB2	17	G309A	missense_variant	EID282	G309A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Neratinib	G309A	EID282:ERBB2:p.G309	c.926G>C	17_37868205_G_C	ENST00000269571	37868199	37868211
ERBB2	17	S310F	missense_variant	EID1179	S310F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	NA	NA	Lapatinib, Neratinib, Trastuzumab	S310F	EID1179:ERBB2:p.S310	c.929C>T, c.929_930delinsTT	17_37868208_C_T, 17_37868208_CC_TT	ENST00000269571	37868202	37868215
ERBB2	17	S310Y	missense_variant	EID1179B	S310Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	NA	NA	Lapatinib, Neratinib, Trastuzumab	S310Y	EID1179B:ERBB2:p.S310	c.929C>A, c.929_930delinsAT	17_37868208_C_A, 17_37868208_CC_AT	ENST00000269571	37868202	37868215
ERBB2	17	R678Q	missense_variant	EID286	R678Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Lapatinib, Neratinib	R678Q	EID286:ERBB2:p.R678	c.2033G>A	17_37879658_G_A	ENST00000269571	37879652	37879664
ERBB2	17	L755S	missense_variant	EID1176	L755S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	NA	NA	Lapatinib, Neratinib, Trastuzumab	L755S	EID1176:ERBB2:p.L755	c.2264T>C	17_37880220_T_C	ENST00000269571	37880214	37880226
ERBB2	17	L755S	missense_variant	EID241	L755S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Lapatinib	L755S	EID241:ERBB2:p.L755	c.2264T>C	17_37880220_T_C	ENST00000269571	37880214	37880226
ERBB2	17	L755S	missense_variant	EID283	L755S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Neratinib	L755S	EID283:ERBB2:p.L755	c.2264T>C	17_37880220_T_C	ENST00000269571	37880214	37880226
ERBB2	17	L755W	missense_variant	EID284	L755W	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Neratinib	L755W	EID284:ERBB2:p.L755	c.2264T>G	17_37880220_T_G	ENST00000269571	37880214	37880226
ERBB2	17	D769H	missense_variant&splice_region_variant	EID279	D769H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Lapatinib, Neratinib	D769H	EID279:ERBB2:p.D769	c.2305G>C	17_37880261_G_C	ENST00000269571	37880255	37880267
ERBB2	17	D769Y	missense_variant&splice_region_variant	EID280	D769Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Neratinib	D769Y	EID280:ERBB2:p.D769	c.2305G>T	17_37880261_G_T	ENST00000269571	37880255	37880267
ERBB2	17	V773A	missense_variant	EID1987	V773A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22046346' target='_blank'>Kancha et al., 2011, PLoS ONE</a>	Head And Neck Squamous Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:5520	NA	NA	Lapatinib	V773A	EID1987:ERBB2:p.V773	c.2318T>C	17_37880989_T_C	ENST00000269571	37880983	37880995
ERBB2	17	M774delinsWLV	protein_altering_variant	EID1894	M774DELINSWLV	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25899785' target='_blank'>Kris et al., 2015, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Dacomitinib	M774DELINSWLV	EID1894:ERBB2:p.M774	c.2320delinsTGGCTGG	17_37880991_A_TGGCTGG	ENST00000269571	37880985	37881003
ERBB2	17	Y772_A775dup	inframe_insertion	EID1045	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26559459' target='_blank'>Li et al., 2015, Lung Cancer</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Afatinib	Y772_A775dup	EID1045:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	37880990	37881014
ERBB2	17	Y772_A775dup	inframe_insertion	EID1047	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19122144' target='_blank'>Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3905	NA	NA	Afatinib	Y772_A775dup	EID1047:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	37880990	37881014
ERBB2	17	Y772_A775dup	inframe_insertion	EID1125	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25789838' target='_blank'>Weiler et al., 2015, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Trastuzumab Emtansine	Y772_A775dup	EID1125:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	37880990	37881014
ERBB2	17	Y772_A775dup	inframe_insertion	EID1888	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22325357' target='_blank'>De Grève et al., 2012, Lung Cancer</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Afatinib	Y772_A775dup	EID1888:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	37880990	37881014
ERBB2	17	Y772_A775dup	inframe_insertion	EID1893	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25899785' target='_blank'>Kris et al., 2015, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Dacomitinib	Y772_A775dup	EID1893:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	37880990	37881014
ERBB2	17	Y772_A775dup	inframe_insertion	EID960	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19122144' target='_blank'>Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Rapamycin (Sirolimus), Afatinib	Y772_A775dup	EID960:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	37880990	37881014
ERBB2	17	G776L	missense_variant	EID1889	G776L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22325357' target='_blank'>De Grève et al., 2012, Lung Cancer</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Afatinib	G776L	EID1889:ERBB2:p.G776	c.2326_2327delinsCT	17_37880997_GG_CT	ENST00000269571	37880991	37881004
ERBB2	17	V777L	missense_variant	EID1177	V777L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	NA	NA	Lapatinib, Neratinib, Trastuzumab	V777L	EID1177:ERBB2:p.V777	c.2329G>T	17_37881000_G_T	ENST00000269571	37880994	37881006
ERBB2	17	V777L	missense_variant	EID288	V777L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Neratinib	V777L	EID288:ERBB2:p.V777	c.2329G>T	17_37881000_G_T	ENST00000269571	37880994	37881006
ERBB2	17	G778_P780dup	inframe_insertion	EID1048	P780INS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25899785' target='_blank'>Kris et al., 2015, Ann. Oncol.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Dacomitinib	P780INS	EID1048:ERBB2:p.G778_P780	c.2332_2340dup	17_37881011_A_AGGCTCCCCA	ENST00000269571	37881005	37881026
ERBB2	17	G778_P780dup	inframe_insertion	EID1890	G778_P780DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22325357' target='_blank'>De Grève et al., 2012, Lung Cancer</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Afatinib	G778_P780dup	EID1890:ERBB2:p.G778_P780	c.2332_2340dup	17_37881011_A_AGGCTCCCCA	ENST00000269571	37881005	37881026
ERBB2	17	G778_P780dup	inframe_insertion	EID1892	G778_P780DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25899785' target='_blank'>Kris et al., 2015, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Dacomitinib	G778_P780dup	EID1892:ERBB2:p.G778_P780	c.2332_2340dup	17_37881011_A_AGGCTCCCCA	ENST00000269571	37881005	37881026
ERBB2	17	G778_P780dup	inframe_insertion	EID285	P780INS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Neratinib	P780INS	EID285:ERBB2:p.G778_P780	c.2332_2340dup	17_37881011_A_AGGCTCCCCA	ENST00000269571	37881005	37881026
ERBB2	17	V842I	missense_variant	EID1174	V842I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	NA	NA	Trastuzumab, Lapatinib, Neratinib	V842I	EID1174:ERBB2:p.V842	c.2524G>A	17_37881332_G_A	ENST00000269571	37881326	37881338
ERBB2	17	V842I	missense_variant	EID289	V842I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Neratinib	V842I	EID289:ERBB2:p.V842	c.2524G>A	17_37881332_G_A	ENST00000269571	37881326	37881338
ERBB2	17	N857S	missense_variant	EID1988	N857S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22046346' target='_blank'>Kancha et al., 2011, PLoS ONE</a>	Ovarian Cancer	Predictive	D: Preclinical evidence	DOID:2394	NA	NA	Lapatinib	N857S	EID1988:ERBB2:p.N857	c.2570A>G	17_37881378_A_G	ENST00000269571	37881372	37881384
ERBB2	17	T862A	missense_variant	EID1986	T862A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22046346' target='_blank'>Kancha et al., 2011, PLoS ONE</a>	Stomach Carcinoma	Predictive	D: Preclinical evidence	DOID:5517	NA	NA	Lapatinib	T862A	EID1986:ERBB2:p.T862	c.2584A>G	17_37881392_A_G	ENST00000269571	37881386	37881398
ERBB2	17	L866M	missense_variant	EID1178	L866M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	NA	NA	Neratinib, Lapatinib, Trastuzumab	L866M	EID1178:ERBB2:p.L866	c.2596C>A	17_37881404_C_A	ENST00000269571	37881398	37881410
ERBB2	17	H878Y	missense_variant	EID1989	H878Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22046346' target='_blank'>Kancha et al., 2011, PLoS ONE</a>	Hepatocellular Carcinoma	Predictive	D: Preclinical evidence	DOID:684	NA	NA	Lapatinib	H878Y	EID1989:ERBB2:p.H878	c.2632C>T	17_37881440_C_T	ENST00000269571	37881434	37881446
ERBB2	17	R896C	missense_variant	EID287	R896C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Neratinib	R896C	EID287:ERBB2:p.R896	c.2686C>T	17_37881616_C_T	ENST00000269571	37881610	37881622
BRCA1	17	W1836X	stop_gained	EID4623	W1815X	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23415752' target='_blank'>Stordal et al., 2013, Mol Oncol</a>	Ovarian Cancer	Predictive	D: Preclinical evidence	DOID:2394	NA	NA	Olaparib	W1815X	EID4623:BRCA1:p.W1836	c.5508G>A	17_41199682_C_T	ENST00000471181	41199676	41199688
BRCA1	17	D1713N	missense_variant&splice_region_variant	EID2876	D1692N	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	D1692N	EID2876:BRCA1:p.D1713	c.5137G>A	17_41219625_C_T	ENST00000471181	41219619	41219631
BRCA1	17	E1580K	missense_variant&splice_region_variant	EID2875	E1559K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	E1559K	EID2875:BRCA1:p.E1580	c.4738G>A	17_41226348_C_T	ENST00000471181	41226342	41226354
BRCA1	17	R1516M	missense_variant&splice_region_variant	EID2874	R1495M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	R1495M	EID2874:BRCA1:p.R1516	c.4547G>T	17_41228505_C_A	ENST00000471181	41228499	41228511
BRCA1	17	Q1488X	stop_gained	EID2878	Q1467*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	Q1467X	EID2878:BRCA1:p.Q1488	c.4462C>T	17_41228590_G_A	ENST00000471181	41228584	41228596
BRCA1	17	R1443X	stop_gained	EID2877	R1443*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	R1443X	EID2877:BRCA1:p.R1443	c.4327C>T	17_41234451_G_A	ENST00000471181	41234445	41234457
BRCA1	17	R71K	missense_variant&splice_region_variant	EID2873	R71K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	R71K	EID2873:BRCA1:p.R71	c.212G>A	17_41258473_C_T	ENST00000471181	41258467	41258479
BRCA1	17	R71G	missense_variant&splice_region_variant	EID2872	R71G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	R71G	EID2872:BRCA1:p.R71	c.211A>G	17_41258474_T_C	ENST00000471181	41258468	41258480
BRCA1	17	C64Y	missense_variant	EID2871	C64Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	C64Y	EID2871:BRCA1:p.C64	c.191G>A	17_41258494_C_T	ENST00000471181	41258488	41258500
BRCA1	17	C61G	missense_variant	EID2870	C61G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	C61G	EID2870:BRCA1:p.C61	c.181T>G	17_41258504_A_C	ENST00000471181	41258498	41258510
BRCA1	17	M1?	start_lost	EID2869	M1I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	M1I	EID2869:BRCA1:p.M1?	c.3G>T	17_41276111_C_A	ENST00000471181	41276105	41276117
BRCA1	17	M1?	start_lost	EID2868	M1V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	M1V	EID2868:BRCA1:p.M1?	c.1A>G	17_41276113_T_C	ENST00000471181	41276107	41276119
SETBP1	18	NA	NA	EID839	EXON 4 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23222956' target='_blank'>Piazza et al., 2013, Nat. Genet.</a>	Chronic Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:8552	NA	4	NA	EXON 4 MUTATION	EID839:SETBP1:exon4	NA	NA	NA	42531876	42531918
SETBP1	18	G870S	missense_variant	EID840	G870S	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23222956' target='_blank'>Piazza et al., 2013, Nat. Genet.</a>	Chronic Myeloid Leukemia	Prognostic	D: Preclinical evidence	DOID:8552	NA	NA	NA	G870S	EID840:SETBP1:p.G870	c.2608G>A	18_42531913_G_A	ENST00000282030	42531907	42531919
STK11	19	NA	NA	EID750	EXON 1-2 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26625312' target='_blank'>Pécuchet et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	1	NA	EXON 1-2 MUTATION	EID750:STK11:exon1	NA	NA	NA	1205739	1218499
STK11	19	NA	NA	EID750	EXON 1-2 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26625312' target='_blank'>Pécuchet et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	2	NA	EXON 1-2 MUTATION	EID750:STK11:exon2	NA	NA	NA	1205739	1218499
GNA11	19	NA	NA	EID1212	Q209	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24938562' target='_blank'>Carvajal et al., 2014, JAMA</a>	Uveal Melanoma	Predictive	B: Clinical evidence	DOID:6039	209	NA	Selumetinib (AZD6244)	Q209	EID1212:GNA11:p.Q209	NA	NA	NA	3118941	3118942
CALR	19	NA	NA	EID1482	EXON 9 FRAMESHIFT	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26486786' target='_blank'>Verger et al., 2015, Blood</a>	Chronic Myeloproliferative Disease	Predictive	B: Clinical evidence	DOID:2226	NA	9	Pegylated IFN-alpha-2a	EXON 9 FRAMESHIFT	EID1482:CALR:exon9	NA	NA	NA	13054526	13054727
CALR	19	NA	NA	EID1649	EXON 9 FRAMESHIFT	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24496303' target='_blank'>Tefferi et al., 2014, Leukemia</a>	Myelofibrosis	Prognostic	B: Clinical evidence	DOID:4971	NA	9	NA	EXON 9 FRAMESHIFT	EID1649:CALR:exon9	NA	NA	NA	13054526	13054727
CALR	19	NA	NA	EID1387	EXON 9 FRAMESHIFT	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25037629' target='_blank'>Tefferi et al., 2014, Blood</a>	Myelofibrosis	Prognostic	A: Validated	DOID:4971	NA	9	NA	EXON 9 FRAMESHIFT	EID1387:CALR:exon9	NA	NA	NA	13054526	13054727
PIK3R2	19	N561D	missense_variant	EID4783	N561D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	N561D	EID4783:PIK3R2:p.N561	c.1681A>G, c.1681_1683delinsGAT	19_18278061_A_G, 19_18278061_AAC_GAT	ENST00000222254	18278055	18278069
POLD1	19	C284Y	missense_variant	EID4776	C284Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25765070' target='_blank'>Rizvi et al., 2015, Science</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Pembrolizumab	C284Y	EID4776:POLD1:p.C284	c.851G>A, c.851_852delinsAT	19_50905879_G_A, 19_50905879_GC_AT	ENST00000440232	50905873	50905886
POLD1	19	E374K	missense_variant	EID4777	E374K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25765070' target='_blank'>Rizvi et al., 2015, Science</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Pembrolizumab	E374K	EID4777:POLD1:p.E374	c.1120G>A, c.1120_1122delinsAAA	19_50906459_G_A, 19_50906459_GAG_AAA	ENST00000440232	50906453	50906467
DNMT3A	2	NA	NA	EID11	R882	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22081665' target='_blank'>LaRochelle et al., 2011, Oncotarget</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	882	NA	Daunorubicin	R882	EID11:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID18	R882	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22081665' target='_blank'>LaRochelle et al., 2011, Oncotarget</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	882	NA	Idarubicin	R882	EID18:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID25	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID25:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID66	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22291079' target='_blank'>Marcucci et al., 2012, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID66:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID31	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24512939' target='_blank'>El Ghannam et al., Blood Cells Mol. Dis.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID31:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID64	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID64:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID186	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22490330' target='_blank'>Ribeiro et al., 2012, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID186:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID189	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22490330' target='_blank'>Ribeiro et al., 2012, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID189:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID112	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID112:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID65	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24512939' target='_blank'>El Ghannam et al., Blood Cells Mol. Dis.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID65:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID113	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID113:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID170	R882	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID170:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID68	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22291079' target='_blank'>Marcucci et al., 2012, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID68:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID110	R882	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID110:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID62	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID62:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID187	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22291079' target='_blank'>Marcucci et al., 2012, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID187:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID114	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID114:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID67	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22490330' target='_blank'>Ribeiro et al., 2012, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID67:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID50	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID50:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID115	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID115:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID4	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22490330' target='_blank'>Ribeiro et al., 2012, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID4:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID3	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22081665' target='_blank'>LaRochelle et al., 2011, Oncotarget</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID3:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID61	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Prognostic	A: Validated	DOID:9119	882	NA	NA	R882	EID61:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID63	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	EID63:DNMT3A:p.R882	NA	NA	NA	25457240	25457243
ALK	2	R1275Q	missense_variant	EID1270	R1275Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23598171' target='_blank'>Mossé et al., 2013, Lancet Oncol.</a>	Neuroblastoma	Predictive	C: Case study	DOID:769	NA	NA	Crizotinib	R1275Q	EID1270:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	29432658	29432670
ALK	2	R1275Q	missense_variant	EID1331	R1275Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26554404' target='_blank'>Infarinato et al., 2016, Cancer Discov</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	Lorlatinib	R1275Q	EID1331:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	29432658	29432670
ALK	2	R1275Q	missense_variant	EID143	R1275Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22072639' target='_blank'>Bresler et al., 2011, Sci Transl Med</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	Crizotinib	R1275Q	EID143:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	29432658	29432670
ALK	2	R1275Q	missense_variant	EID39	R1275Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18923525' target='_blank'>George et al., 2008, Nature</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	TAE684	R1275Q	EID39:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	29432658	29432670
ALK	2	R1275Q	missense_variant	EID48	R1275Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18923525' target='_blank'>George et al., 2008, Nature</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	TAE684	R1275Q	EID48:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	29432658	29432670
ALK	2	G1269A	missense_variant	EID1342	ALK FUSION G1269A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Ceritinib	ALK FUSION G1269A	EID1342:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	29432676	29432688
ALK	2	G1269A	missense_variant	EID1353	ALK FUSION G1269A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Brigatinib	ALK FUSION G1269A	EID1353:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	29432676	29432688
ALK	2	G1269A	missense_variant	EID1354	ALK FUSION G1269A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Alectinib (CH5424802)	ALK FUSION G1269A	EID1354:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	29432676	29432688
ALK	2	G1269A	missense_variant	EID1355	ALK FUSION G1269A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Ceritinib	ALK FUSION G1269A	EID1355:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	29432676	29432688
ALK	2	G1269A	missense_variant	EID764	EML4-ALK G1269A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22235099' target='_blank'>Doebele et al., 2012, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Crizotinib	EML4-ALK G1269A	EID764:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	29432676	29432688
ALK	2	G1269A	missense_variant	EID765	EML4-ALK G1269A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23344087' target='_blank'>Kim et al., 2013, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Crizotinib	EML4-ALK G1269A	EID765:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	29432676	29432688
ALK	2	F1245C	missense_variant	EID1330	F1245C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26554404' target='_blank'>Infarinato et al., 2016, Cancer Discov</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	Lorlatinib	F1245C	EID1330:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	29436853	29436865
ALK	2	F1245C	missense_variant	EID1333	F1245C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23598171' target='_blank'>Mossé et al., 2013, Lancet Oncol.</a>	Neuroblastoma	Predictive	C: Case study	DOID:769	NA	NA	Crizotinib	F1245C	EID1333:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	29436853	29436865
ALK	2	F1245C	missense_variant	EID1337	ALK FUSION F1245C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22034911' target='_blank'>Zhang et al., 2011, Chem Biol Drug Des</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Crizotinib	ALK FUSION F1245C	EID1337:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	29436853	29436865
ALK	2	F1245C	missense_variant	EID1338	ALK FUSION F1245C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26775591' target='_blank'>Kodityal et al., 2016, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Ceritinib	ALK FUSION F1245C	EID1338:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	29436853	29436865
ALK	2	F1245C	missense_variant	EID1339	ALK FUSION F1245C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26775591' target='_blank'>Kodityal et al., 2016, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Crizotinib	ALK FUSION F1245C	EID1339:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	29436853	29436865
ALK	2	S1206Y	missense_variant	EID1343	EML4-ALK S1206Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Ceritinib	EML4-ALK S1206Y	EID1343:ALK:p.S1206	c.3617C>A	2_29443600_G_T	ENST00000389048	29443594	29443606
ALK	2	S1206Y	missense_variant	EID443	EML4-ALK S1206Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	EML4-ALK S1206Y	EID443:ALK:p.S1206	c.3617C>A	2_29443600_G_T	ENST00000389048	29443594	29443606
ALK	2	G1202R	missense_variant	EID1345	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Ceritinib	ALK FUSION G1202R	EID1345:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	29443607	29443619
ALK	2	G1202R	missense_variant	EID1350	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Alectinib (CH5424802)	ALK FUSION G1202R	EID1350:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	29443607	29443619
ALK	2	G1202R	missense_variant	EID1351	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Brigatinib	ALK FUSION G1202R	EID1351:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	29443607	29443619
ALK	2	G1202R	missense_variant	EID1352	ALK FUSION G1202R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	17-AAG	ALK FUSION G1202R	EID1352:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	29443607	29443619
ALK	2	G1202R	missense_variant	EID1357	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Crizotinib	ALK FUSION G1202R	EID1357:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	29443607	29443619
ALK	2	G1202R	missense_variant	EID441	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	ALK FUSION G1202R	EID441:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	29443607	29443619
ALK	2	L1196M	missense_variant	EID1341	EML4-ALK L1196M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Ceritinib	EML4-ALK L1196M	EID1341:ALK:p.L1196	c.3586C>A	2_29443631_G_T	ENST00000389048	29443625	29443637
ALK	2	L1196M	missense_variant	EID141	EML4-ALK L1196M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21575866' target='_blank'>Sakamoto et al., 2011, Cancer Cell</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Alectinib (CH5424802)	EML4-ALK L1196M	EID141:ALK:p.L1196	c.3586C>A	2_29443631_G_T	ENST00000389048	29443625	29443637
ALK	2	L1196M	missense_variant	EID237	EML4-ALK L1196M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20979473' target='_blank'>Choi et al., 2010, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Crizotinib	EML4-ALK L1196M	EID237:ALK:p.L1196	c.3586C>A	2_29443631_G_T	ENST00000389048	29443625	29443637
ALK	2	L1196M	missense_variant	EID442	EML4-ALK L1196M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	EML4-ALK L1196M	EID442:ALK:p.L1196	c.3586C>A	2_29443631_G_T	ENST00000389048	29443625	29443637
ALK	2	V1180L	missense_variant	EID1286	EML4-ALK  V1180L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Alectinib (CH5424802)	EML4-ALK  V1180L	EID1286:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	29443673	29443685
ALK	2	V1180L	missense_variant	EID1288	EML4-ALK  V1180L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	EML4-ALK  V1180L	EID1288:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	29443673	29443685
ALK	2	V1180L	missense_variant	EID1289	EML4-ALK  V1180L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Ceritinib	EML4-ALK  V1180L	EID1289:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	29443673	29443685
ALK	2	V1180L	missense_variant	EID1290	EML4-ALK  V1180L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	TAE684	EML4-ALK  V1180L	EID1290:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	29443673	29443685
ALK	2	V1180L	missense_variant	EID1291	EML4-ALK  V1180L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Brigatinib	EML4-ALK  V1180L	EID1291:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	29443673	29443685
ALK	2	F1174L	missense_variant	EID125	F1174L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22072639' target='_blank'>Bresler et al., 2011, Sci Transl Med</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	Crizotinib	F1174L	EID125:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	29443689	29443701
ALK	2	F1174L	missense_variant	EID1271	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23598171' target='_blank'>Mossé et al., 2013, Lancet Oncol.</a>	Neuroblastoma	Predictive	C: Case study	DOID:769	NA	NA	Crizotinib	F1174L	EID1271:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	29443689	29443701
ALK	2	F1174L	missense_variant	EID1327	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26786851' target='_blank'>Wang et al., 2016, Sci Rep</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	AZD3463	F1174L	EID1327:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	29443689	29443701
ALK	2	F1174L	missense_variant	EID1329	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26554404' target='_blank'>Infarinato et al., 2016, Cancer Discov</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	Lorlatinib	F1174L	EID1329:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	29443689	29443701
ALK	2	F1174L	missense_variant	EID142	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18923525' target='_blank'>George et al., 2008, Nature</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	TAE684	F1174L	EID142:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	29443689	29443701
ALK	2	F1174L	missense_variant	EID32	F1174L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21030459' target='_blank'>Sasaki et al., 2010, Cancer Res.</a>	Inflammatory Myofibroblastic Tumor	Predictive	D: Preclinical evidence	DOID:0050905	NA	NA	Crizotinib	F1174L	EID32:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	29443689	29443701
ALK	2	F1174L	missense_variant	EID33	F1174L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21030459' target='_blank'>Sasaki et al., 2010, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	F1174L	EID33:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	29443689	29443701
ALK	2	F1174L	missense_variant	EID37	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21575866' target='_blank'>Sakamoto et al., 2011, Cancer Cell</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	Alectinib (CH5424802)	F1174L	EID37:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	29443689	29443701
ALK	2	F1174L	missense_variant	EID38	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21948233' target='_blank'>Heuckmann et al., 2011, Clin. Cancer Res.</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	NA	NA	Crizotinib	F1174L	EID38:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	29443689	29443701
ALK	2	I1171N	missense_variant	EID1483	HIP1-ALK I1171N	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25393796' target='_blank'>Ou et al., 2014, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Alectinib (CH5424802), Crizotinib	HIP1-ALK I1171N	EID1483:ALK:p.I1171	c.3512T>A	2_29445213_A_T	ENST00000389048	29445207	29445219
ALK	2	I1171S	missense_variant	EID1484	EML4-ALK I1171S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25393796' target='_blank'>Ou et al., 2014, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Alectinib (CH5424802), Crizotinib	EML4-ALK I1171S	EID1484:ALK:p.I1171	c.3512T>G	2_29445213_A_C	ENST00000389048	29445207	29445219
ALK	2	I1171T	missense_variant	EID1283	ALK FUSION I1171	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Alectinib (CH5424802)	ALK FUSION I1171	EID1283:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	29445207	29445219
ALK	2	I1171T	missense_variant	EID1284	ALK FUSION I1171	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Ceritinib	ALK FUSION I1171	EID1284:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	29445207	29445219
ALK	2	I1171T	missense_variant	EID1285	ALK FUSION I1171	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	TAE684	ALK FUSION I1171	EID1285:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	29445207	29445219
ALK	2	I1171T	missense_variant	EID1287	ALK FUSION I1171	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	ALK FUSION I1171	EID1287:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	29445207	29445219
ALK	2	I1171T	missense_variant	EID1344	ALK FUSION I1171	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Ceritinib	ALK FUSION I1171	EID1344:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	29445207	29445219
ALK	2	I1171T	missense_variant	EID1367	ALK FUSION I1171	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25736571' target='_blank'>Ou et al., 2015, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Alectinib (CH5424802)	ALK FUSION I1171	EID1367:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	29445207	29445219
ALK	2	I1171T	missense_variant	EID1368	ALK FUSION I1171	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25736571' target='_blank'>Ou et al., 2015, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Ceritinib	ALK FUSION I1171	EID1368:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	29445207	29445219
ALK	2	C1156Y	missense_variant	EID1346	EML4-ALK C1156Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	EML4-ALK C1156Y	EID1346:ALK:p.C1156	c.3467G>A	2_29445258_C_T	ENST00000389048	29445252	29445264
ALK	2	C1156Y	missense_variant	EID841	EML4-ALK C1156Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26698910' target='_blank'>Shaw et al., 2016, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	AUY922, Ceritinib, Crizotinib	EML4-ALK C1156Y	EID841:ALK:p.C1156	c.3467G>A	2_29445258_C_T	ENST00000389048	29445252	29445264
ALK	2	C1156Y	missense_variant	EID842	EML4-ALK C1156Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26698910' target='_blank'>Shaw et al., 2016, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Lorlatinib	EML4-ALK C1156Y	EID842:ALK:p.C1156	c.3467G>A	2_29445258_C_T	ENST00000389048	29445252	29445264
ALK	2	L1152R	missense_variant	EID763	EML4-ALK L1152R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21791641' target='_blank'>Sasaki et al., 2011, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Crizotinib	EML4-ALK L1152R	EID763:ALK:p.L1152	c.3455T>G	2_29445270_A_C	ENST00000389048	29445264	29445276
ALK	2	T1151dup	inframe_insertion	EID1347	EML4-ALK T1151INST	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Alectinib (CH5424802)	EML4-ALK T1151INST	EID1347:ALK:p.T1151	c.3451_3453dup	2_29445271_G_GCGT	ENST00000389048	29445265	29445280
ALK	2	T1151dup	inframe_insertion	EID1348	EML4-ALK T1151INST	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	TAE684	EML4-ALK T1151INST	EID1348:ALK:p.T1151	c.3451_3453dup	2_29445271_G_GCGT	ENST00000389048	29445265	29445280
ALK	2	T1151dup	inframe_insertion	EID1349	EML4-ALK T1151INST	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	17-AAG	EML4-ALK T1151INST	EID1349:ALK:p.T1151	c.3451_3453dup	2_29445271_G_GCGT	ENST00000389048	29445265	29445280
ALK	2	T1151dup	inframe_insertion	EID444	EML4-ALK T1151INST	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Crizotinib	EML4-ALK T1151INST	EID444:ALK:p.T1151	c.3451_3453dup	2_29445271_G_GCGT	ENST00000389048	29445265	29445280
ACVR1	2	G328E	missense_variant	EID6091	G328E	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24705252' target='_blank'>Taylor et al., 2014, Nat. Genet.</a>	Diffuse Intrinsic Pontine Glioma	Diagnostic	C: Case study	NA	NA	NA	NA	G328E	EID6091:ACVR1:p.G328	c.983_984delinsAA, c.983G>A	2_158622515_CC_TT, 2_158622516_C_T	ENST00000263640	158622509	158622522
ACVR1	2	G328V	missense_variant	EID4846	G328V	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24705250' target='_blank'>Fontebasso et al., 2014, Nat. Genet.</a>	Diffuse Intrinsic Pontine Glioma	Diagnostic	B: Clinical evidence	NA	NA	NA	NA	G328V	EID4846:ACVR1:p.G328	c.983G>T	2_158622516_C_A	ENST00000263640	158622510	158622522
ACVR1	2	G328V	missense_variant	EID6955	G328V	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24705254' target='_blank'>Buczkowicz et al., 2014, Nat. Genet.</a>	Diffuse Intrinsic Pontine Glioma	Diagnostic	B: Clinical evidence	NA	NA	NA	NA	G328V	EID6955:ACVR1:p.G328	c.983G>T	2_158622516_C_A	ENST00000263640	158622510	158622522
SF3B1	2	K700E	missense_variant	EID1417	K700E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25424858' target='_blank'>Maguire et al., 2015, J. Pathol.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Spliceostatin A	K700E	EID1417:SF3B1:p.K700	c.2098A>G	2_198266834_T_C	ENST00000335508	198266828	198266840
SF3B1	2	K666N	missense_variant	EID1418	K666N	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25424858' target='_blank'>Maguire et al., 2015, J. Pathol.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Spliceostatin A	K666N	EID1418:SF3B1:p.K666	c.1998G>T	2_198267359_C_A	ENST00000335508	198267353	198267365
IDH1	2	R132H	missense_variant	EID5987	R132H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27466707' target='_blank'>Brody et al., 2016, Cancer Biol. Ther.</a>	Pancreatic Ductal Adenocarcinoma	Predictive	C: Case study	DOID:3498	NA	NA	AG-120	R132H	EID5987:IDH1:p.R132	c.395G>A	2_209113112_C_T	ENST00000415913	209113106	209113118
IDH1	2	R132H	missense_variant	EID979	R132H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23558169' target='_blank'>Rohle et al., 2013, Science</a>	Anaplastic Oligodendroglioma	Predictive	D: Preclinical evidence	DOID:3181	NA	NA	AGI-5198	R132H	EID979:IDH1:p.R132	c.395G>A	2_209113112_C_T	ENST00000415913	209113106	209113118
IDH1	2	R132L	missense_variant	EID2020	R132L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22199315' target='_blank'>Lv et al., 2011, Anticancer Res.</a>	Malignant Glioma	Predictive	B: Clinical evidence	DOID:3070	NA	NA	Bevacizumab	R132L	EID2020:IDH1:p.R132	c.395G>T	2_209113112_C_A	ENST00000415913	209113106	209113118
IDH1	2	R132C	missense_variant	EID224	R132C	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20538800' target='_blank'>Abbas et al., 2010, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	NA	NA	R132C	EID224:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	209113107	209113119
IDH1	2	R132C	missense_variant	EID2327	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20975057' target='_blank'>Houillier et al., 2010, Neurology</a>	Brain Glioma	Predictive	B: Clinical evidence	DOID:0060108	NA	NA	Temozolomide	R132C	EID2327:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	209113107	209113119
IDH1	2	R132C	missense_variant	EID2329	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23558169' target='_blank'>Rohle et al., 2013, Science</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	NA	NA	AGI-5198	R132C	EID2329:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	209113107	209113119
IDH1	2	R132C	missense_variant	EID2330	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22199315' target='_blank'>Lv et al., 2011, Anticancer Res.</a>	Malignant Glioma	Predictive	B: Clinical evidence	DOID:3070	NA	NA	Bevacizumab	R132C	EID2330:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	209113107	209113119
IDH1	2	R132C	missense_variant	EID2331	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25583779' target='_blank'>2015, Cancer Discov</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	NA	AG-120	R132C	EID2331:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	209113107	209113119
IDH1	2	R132C	missense_variant	EID2332	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24333121' target='_blank'>Emadi et al., 2014, Exp. Hematol.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	Bis-2-[5-(phenylacetamide)-1,3,4-thiadiazol-2-yl]ethyl Sulfide	R132C	EID2332:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	209113107	209113119
IDH1	2	R132C	missense_variant	EID4032	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22199315' target='_blank'>Lv et al., 2011, Anticancer Res.</a>	Glioblastoma Multiforme	Predictive	B: Clinical evidence	DOID:3068	NA	NA	Cetuximab	R132C	EID4032:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	209113107	209113119
IDH1	2	R132C	missense_variant	EID732	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26436839' target='_blank'>Okoye-Okafor et al., 2015, Nat. Chem. Biol.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	GSK321	R132C	EID732:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	209113107	209113119
IDH1	2	R132S	missense_variant	EID2339	R132S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22199315' target='_blank'>Lv et al., 2011, Anticancer Res.</a>	Malignant Glioma	Predictive	B: Clinical evidence	DOID:3070	NA	NA	Bevacizumab	R132S	EID2339:IDH1:p.R132	c.394C>A	2_209113113_G_T	ENST00000415913	209113107	209113119
IDH1	2	NA	NA	EID374	R132	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20494930' target='_blank'>Thol et al., 2010, Haematologica</a>	Myelodysplastic Syndrome	Prognostic	B: Clinical evidence	DOID:0050908	132	NA	NA	R132	EID374:IDH1:p.R132	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID349	R132	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20127344' target='_blank'>Bleeker et al., 2010, Acta Neuropathol.</a>	Glioblastoma Multiforme	Prognostic	B: Clinical evidence	DOID:3068	132	NA	NA	R132	EID349:IDH1:p.R132	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID348	R132	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19933982' target='_blank'>Dubbink et al., 2009, Neurology</a>	Astrocytoma	Prognostic	B: Clinical evidence	DOID:3069	132	NA	NA	R132	EID348:IDH1:p.R132	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID481	R132	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19228619' target='_blank'>Yan et al., 2009, N. Engl. J. Med.</a>	Astrocytoma	Prognostic	B: Clinical evidence	DOID:3069	132	NA	NA	R132	EID481:IDH1:p.R132	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID223	R132	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20376086' target='_blank'>Ho et al., 2010, Leukemia</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	132	NA	NA	R132	EID223:IDH1:p.R132	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID480	R132	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19228619' target='_blank'>Yan et al., 2009, N. Engl. J. Med.</a>	Glioblastoma Multiforme	Prognostic	B: Clinical evidence	DOID:3068	132	NA	NA	R132	EID480:IDH1:p.R132	NA	NA	NA	209113110	209113113
ASXL1	20	NA	NA	EID1379	EXON 12 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23018865' target='_blank'>Schnittger et al., 2013, Leukemia</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID1379:ASXL1:exon12	NA	NA	NA	31021086	31021720
GNAS	20	R844C	missense_variant	EID1906	R201C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27729313' target='_blank'>Hong et al., 2016, Cancer Discov</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Irinotecan, Cetuximab, Vemurafenib	R201C	EID1906:GNAS:p.R844	c.2530C>T	20_57484420_C_T	ENST00000371100	57484414	57484426
GNAS	20	R844H	missense_variant	EID3045	R201H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26788326' target='_blank'>Lu et al., 2016, Endocrinol Diabetes Metab Case Rep</a>	Follicular Thyroid Carcinoma	Predictive	C: Case study	DOID:3962	NA	NA	Radioactive Iodine	R201H	EID3045:GNAS:p.R844	c.2531G>A, c.2531_2532inv	20_57484421_G_A, 20_57484421_GT_AC	ENST00000371100	57484415	57484428
U2AF1	21	Q157P	missense_variant	EID217	Q157P/R	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23029227' target='_blank'>Qian et al., 2012, PLoS ONE</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	NA	NA	Q157P/R	EID217:U2AF1:p.Q157	c.470A>C	21_44514777_T_G	ENST00000291552	44514771	44514783
U2AF1	21	Q157P	missense_variant	EID400	Q157P/R	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23861105' target='_blank'>Wu et al., 2013, Am. J. Hematol.</a>	Myelodysplastic Syndrome	Prognostic	B: Clinical evidence	DOID:0050908	NA	NA	NA	Q157P/R	EID400:U2AF1:p.Q157	c.470A>C	21_44514777_T_G	ENST00000291552	44514771	44514783
U2AF1	21	S34F	missense_variant	EID218	S34Y/F	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23029227' target='_blank'>Qian et al., 2012, PLoS ONE</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	NA	NA	S34Y/F	EID218:U2AF1:p.S34	c.101C>T	21_44524456_G_A	ENST00000291552	44524450	44524462
U2AF1	21	S34F	missense_variant	EID401	S34Y/F	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23861105' target='_blank'>Wu et al., 2013, Am. J. Hematol.</a>	Myelodysplastic Syndrome	Prognostic	B: Clinical evidence	DOID:0050908	NA	NA	NA	S34Y/F	EID401:U2AF1:p.S34	c.101C>T	21_44524456_G_A	ENST00000291552	44524450	44524462
MAPK1	22	E322K	missense_variant&splice_region_variant	EID791	E322K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26181029' target='_blank'>Van Allen et al., 2015, JAMA Oncol</a>	Head And Neck Squamous Cell Carcinoma	Predictive	C: Case study	DOID:5520	NA	NA	Erlotinib	E322K	EID791:MAPK1:p.E322	c.964G>A	22_22127164_C_T	ENST00000215832	22127158	22127170
NF2	22	NA	NA	EID715	K159FS*16	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25878190' target='_blank'>Moulder et al., 2015, Ann. Oncol.</a>	Breast Cancer	Predictive	C: Case study	DOID:1612	159	NA	Temsirolimus	K159	EID715:NF2:p.K159	NA	NA	NA	30050672	30050675
NF2	22	Y177fs	frameshift_variant	EID649	Y177FS	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25798586' target='_blank'>Sheffield et al., 2015, PLoS ONE</a>	Peritoneal Mesothelioma	Predictive	C: Case study	DOID:1788	NA	NA	Cisplatin, Carboplatin	Y177fs	EID649:NF2:p.Y177	c.527dup	22_30051593_T_TT	ENST00000338641	30051587	30051600
MYD88	3	L273P	missense_variant	EID1489	L265P	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24943832' target='_blank'>Baliakas et al., 2015, Leukemia</a>	Chronic Lymphocytic Leukemia	Prognostic	B: Clinical evidence	DOID:1040	NA	NA	NA	L265P	EID1489:MYD88:p.L273	c.818T>C	3_38182641_T_C	ENST00000417037	38182635	38182647
MYD88	3	L273P	missense_variant	EID1641	L265P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22931316' target='_blank'>Treon et al., 2012, N. Engl. J. Med.</a>	Waldenström's Macroglobulinemia	Predictive	D: Preclinical evidence	DOID:	NA	NA	IMG-2005-5, IRAK-1/4 Inhibitor	L265P	EID1641:MYD88:p.L273	c.818T>C	3_38182641_T_C	ENST00000417037	38182635	38182647
MYD88	3	L273P	missense_variant	EID986	L265P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25853747' target='_blank'>Treon et al., 2015, N. Engl. J. Med.</a>	Waldenström's Macroglobulinemia	Predictive	B: Clinical evidence	DOID:	NA	NA	Ibrutinib	L265P	EID986:MYD88:p.L273	c.818T>C	3_38182641_T_C	ENST00000417037	38182635	38182647
CTNNB1	3	T41A	missense_variant	EID2973	T41A	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	NA	NA	NA	T41A	EID2973:CTNNB1:p.T41	c.121A>G	3_41266124_A_G	ENST00000349496	41266118	41266130
CTNNB1	3	T41A	missense_variant	EID3044	T41A	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Prognostic	B: Clinical evidence	NA	NA	NA	NA	T41A	EID3044:CTNNB1:p.T41	c.121A>G	3_41266124_A_G	ENST00000349496	41266118	41266130
CTNNB1	3	T41A	missense_variant	EID5070	T41A	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22766794' target='_blank'>Le Guellec et al., 2012, Mod. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	NA	NA	NA	T41A	EID5070:CTNNB1:p.T41	c.121A>G	3_41266124_A_G	ENST00000349496	41266118	41266130
CTNNB1	3	S45P	missense_variant	EID2975	S45P	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	NA	NA	NA	S45P	EID2975:CTNNB1:p.S45	c.133T>C	3_41266136_T_C	ENST00000349496	41266130	41266142
CTNNB1	3	S45P	missense_variant	EID3043	S45P	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Prognostic	B: Clinical evidence	NA	NA	NA	NA	S45P	EID3043:CTNNB1:p.S45	c.133T>C	3_41266136_T_C	ENST00000349496	41266130	41266142
CTNNB1	3	S45P	missense_variant	EID5072	S45P	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22766794' target='_blank'>Le Guellec et al., 2012, Mod. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	NA	NA	NA	S45P	EID5072:CTNNB1:p.S45	c.133T>C	3_41266136_T_C	ENST00000349496	41266130	41266142
CTNNB1	3	S45F	missense_variant	EID2974	S45F	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	NA	NA	NA	S45F	EID2974:CTNNB1:p.S45	c.134C>T	3_41266137_C_T	ENST00000349496	41266131	41266143
CTNNB1	3	S45F	missense_variant	EID2976	S45F	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Prognostic	B: Clinical evidence	NA	NA	NA	NA	S45F	EID2976:CTNNB1:p.S45	c.134C>T	3_41266137_C_T	ENST00000349496	41266131	41266143
CTNNB1	3	S45F	missense_variant	EID6049	S45F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24788118' target='_blank'>Hamada et al., 2014, PLoS ONE</a>	Desmoid Fibromatosis	Predictive	C: Case study	NA	NA	NA	Meloxicam	S45F	EID6049:CTNNB1:p.S45	c.134C>T	3_41266137_C_T	ENST00000349496	41266131	41266143
FOXL2	3	C134W	missense_variant	EID479	C134W	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20693978' target='_blank'>Jamieson et al., 2010, Mod. Pathol.</a>	Ovarian Granulosa Cell Tumor	Diagnostic	B: Clinical evidence	DOID:2999	NA	NA	NA	C134W	EID479:FOXL2:p.C134	c.402C>G	3_138665163_G_C	ENST00000330315	138665157	138665169
FOXL2	3	C134W	missense_variant	EID6034	C134W	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26033501' target='_blank'>Goulvent et al., 2016, Histopathology</a>	Ovarian Sex Cord-stromal Tumours	Diagnostic	A: Validated	NA	NA	NA	NA	C134W	EID6034:FOXL2:p.C134	c.402C>G	3_138665163_G_C	ENST00000330315	138665157	138665169
ATR	3	NA	NA	EID690	I774FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19470935' target='_blank'>Zighelboim et al., 2009, J. Clin. Oncol.</a>	Endometrial Cancer	Prognostic	B: Clinical evidence	DOID:1380	774	NA	NA	I774	EID690:ATR:p.I774	NA	NA	NA	142274739	142274740
PIK3CA	3	D350G	missense_variant	EID4784	D350G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	D350G	EID4784:PIK3CA:p.D350	c.1049A>G	3_178921567_A_G	ENST00000263967	178921561	178921573
PIK3CA	3	P471L	missense_variant	EID739	P471L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26466009' target='_blank'>Shiver et al., 2015, N. Engl. J. Med.</a>	Merkel Cell Carcinoma	Predictive	C: Case study	DOID:3965	NA	NA	Idelalisib	P471L	EID739:PIK3CA:p.P471	c.1412C>T	3_178928226_C_T	ENST00000263967	178928220	178928232
PIK3CA	3	E542K	missense_variant	EID1549	E542K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26787751' target='_blank'>Dolly et al., 2016, Clin. Cancer Res.</a>	Head And Neck Squamous Cell Carcinoma	Predictive	C: Case study	DOID:5520	NA	NA	Apitolisib	E542K	EID1549:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	178936076	178936088
PIK3CA	3	E542K	missense_variant	EID1626	E542K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19706758' target='_blank'>Liu et al., 2009, Cancer Res.</a>	Thyroid Cancer	Predictive	D: Preclinical evidence	DOID:1781	NA	NA	Perifosine, Temsirolimus	E542K	EID1626:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	178936076	178936088
PIK3CA	3	E542K	missense_variant	EID256	E542K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab, Panitumumab	E542K	EID256:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	178936076	178936088
PIK3CA	3	E542K	missense_variant	EID310	E542K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21558396' target='_blank'>Tanaka et al., 2011, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	CH5132799	E542K	EID310:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	178936076	178936088
PIK3CA	3	E542K	missense_variant	EID311	E542K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15647370' target='_blank'>Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Rapamycin (Sirolimus)	E542K	EID311:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	178936076	178936088
PIK3CA	3	E542K	missense_variant	EID384	E542K	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22357840' target='_blank'>Liao et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Prognostic	E: Indirect evidence	DOID:9256	NA	NA	NA	E542K	EID384:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	178936076	178936088
PIK3CA	3	E542K	missense_variant	EID385	E542K	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	E542K	EID385:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	178936076	178936088
PIK3CA	3	E545K	missense_variant	EID1171	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16906227' target='_blank'>Engelman et al., 2006, J. Clin. Invest.</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	NA	NA	Gefitinib	E545K	EID1171:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID1453	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18829560' target='_blank'>Serra et al., 2008, Cancer Res.</a>	Her2-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060079	NA	NA	Trastuzumab	E545K	EID1453:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID1550	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26787751' target='_blank'>Dolly et al., 2016, Clin. Cancer Res.</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Apitolisib	E545K	EID1550:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID1670	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27304188' target='_blank'>Belchis et al., 2016, Oncotarget</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	NA	Gefitinib, Erlotinib, Afatinib	E545K	EID1670:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID2034	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20453058' target='_blank'>O'Brien et al., 2010, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Pictilisib	E545K	EID2034:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID2035	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21594665' target='_blank'>Razis et al., 2011, Breast Cancer Res. Treat.</a>	Breast Cancer	Predictive	C: Case study	DOID:1612	NA	NA	Trastuzumab	E545K	EID2035:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID2036	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26920887' target='_blank'>Baselga et al., 2016, Clin. Cancer Res.</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	NA	NA	Ado-trastuzumab Emtansine	E545K	EID2036:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID2037	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab, Cetuximab	E545K	EID2037:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID2038	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23094721' target='_blank'>Liao et al., 2012, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Aspirin	E545K	EID2038:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID2040	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19513541' target='_blank'>Zou et al., 2009, Int. J. Mol. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	PI103	E545K	EID2040:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID3722	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	E545K	EID3722:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID387	E545K	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	E545K	EID387:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545K	missense_variant	EID710	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23888070' target='_blank'>Beaver et al., 2013, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	MK-2206, Pictilisib	E545K	EID710:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	178936085	178936097
PIK3CA	3	E545G	missense_variant	EID3724	E545G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	E545G	EID3724:PIK3CA:p.E545	c.1634A>G	3_178936092_A_G	ENST00000263967	178936086	178936098
PIK3CA	3	NA	NA	EID138	EXON 21 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	21	Cetuximab	EXON 21 MUTATION	EID138:PIK3CA:exon21	NA	NA	NA	178951881	178952495
PIK3CA	3	H1047R	missense_variant	EID1361	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25855885' target='_blank'>Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg</a>	Head And Neck Cancer	Predictive	D: Preclinical evidence	DOID:11934	NA	NA	BEZ235 (NVP-BEZ235, Dactolisib)	H1047R	EID1361:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID1362	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23619167' target='_blank'>Lui et al., 2013, Cancer Discov</a>	Head And Neck Cancer	Predictive	D: Preclinical evidence	DOID:11934	NA	NA	BEZ235 (NVP-BEZ235, Dactolisib)	H1047R	EID1362:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID1363	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23619167' target='_blank'>Lui et al., 2013, Cancer Discov</a>	Head And Neck Cancer	Predictive	D: Preclinical evidence	DOID:11934	NA	NA	Cetuximab, BEZ235 (NVP-BEZ235, Dactolisib)	H1047R	EID1363:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID1401	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25550549' target='_blank'>Keam et al., 2015, Anticancer Res.</a>	Head And Neck Cancer	Predictive	D: Preclinical evidence	DOID:11934	NA	NA	BYL719 (Alpelisib)	H1047R	EID1401:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID1447	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19029981' target='_blank'>Engelman et al., 2008, Nat. Med.</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	NA	NA	BEZ235 (NVP-BEZ235, Dactolisib)	H1047R	EID1447:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID1465	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26589432' target='_blank'>Zumsteg et al., 2016, Clin. Cancer Res.</a>	Head And Neck Squamous Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:5520	NA	NA	Taselisib (GDC-0032)	H1047R	EID1465:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID1505	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22294718' target='_blank'>Davies et al., 2012, Mol. Cancer Ther.</a>	Her2-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060079	NA	NA	AZD5363, Trastuzumab	H1047R	EID1505:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID1506	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22294718' target='_blank'>Davies et al., 2012, Mol. Cancer Ther.</a>	Her2-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060079	NA	NA	AZD5363, Lapatinib	H1047R	EID1506:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID1623	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27445490' target='_blank'>Sun et al., 2016, Onco Targets Ther</a>	Her2-receptor Positive Breast Cancer	Predictive	C: Case study	DOID:0060079	NA	NA	Everolimus, Fulvestrant	H1047R	EID1623:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID1625	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19706758' target='_blank'>Liu et al., 2009, Cancer Res.</a>	Thyroid Cancer	Predictive	D: Preclinical evidence	DOID:1781	NA	NA	Perifosine, Temsirolimus	H1047R	EID1625:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID2098	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21594665' target='_blank'>Razis et al., 2011, Breast Cancer Res. Treat.</a>	Breast Cancer	Predictive	C: Case study	DOID:1612	NA	NA	Trastuzumab	H1047R	EID2098:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID2100	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17202311' target='_blank'>Maruyama et al., 2007, Clin. Cancer Res.</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	NA	NA	Trastuzumab	H1047R	EID2100:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID2102	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20453058' target='_blank'>O'Brien et al., 2010, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Trastuzumab	H1047R	EID2102:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID2103	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26920887' target='_blank'>Baselga et al., 2016, Clin. Cancer Res.</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	NA	NA	Ado-trastuzumab Emtansine	H1047R	EID2103:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID2105	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17590872' target='_blank'>Kato et al., 2007, Int. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Panitumumab	H1047R	EID2105:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID2106	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19903786' target='_blank'>He et al., 2009, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Panitumumab	H1047R	EID2106:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID2110	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19513541' target='_blank'>Zou et al., 2009, Int. J. Mol. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	PI103	H1047R	EID2110:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID258	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab, Panitumumab	H1047R	EID258:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID314	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21558396' target='_blank'>Tanaka et al., 2011, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	CH5132799	H1047R	EID314:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
PIK3CA	3	H1047R	missense_variant	EID388	H1047R	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	H1047R	EID388:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	178952079	178952091
FGFR3	4	S249C	missense_variant	EID1603	S249C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25766722' target='_blank'>Palma et al., 2015, Eur. Urol.</a>	Urothelial Carcinoma	Predictive	C: Case study	DOID:2671	NA	NA	Pazopanib	S249C	EID1603:FGFR3:p.S249	c.746C>G	4_1803568_C_G	ENST00000340107	1803562	1803574
FGFR3	4	Y375C	missense_variant	EID477	Y375C	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20542753' target='_blank'>Bodoor et al., 2010, Cancer Epidemiol</a>	Bladder Carcinoma	Diagnostic	B: Clinical evidence	DOID:4007	NA	NA	NA	Y375C	EID477:FGFR3:p.Y375	c.1124A>G	4_1806099_A_G	ENST00000340107	1806093	1806105
PDGFRA	4	V561A	missense_variant	EID652	V561A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12949711' target='_blank'>Hirota et al., 2003, Gastroenterology</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	NA	NA	Imatinib	V561A	EID652:PDGFRA:p.V561	c.1682T>C	4_55141036_T_C	ENST00000257290	55141030	55141042
PDGFRA	4	P577S	missense_variant	EID1974	P577S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24132921' target='_blank'>Dai et al., 2013, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Imatinib, Crenolanib	P577S	EID1974:PDGFRA:p.P577	c.1729C>T	4_55141083_C_T	ENST00000257290	55141077	55141089
PDGFRA	4	T674I	missense_variant	EID1446	FIP1L1-PDGFRA T674I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12660384' target='_blank'>Cools et al., 2003, N. Engl. J. Med.</a>	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Predictive	C: Case study	DOID:0080164	NA	NA	Imatinib	FIP1L1-PDGFRA T674I	EID1446:PDGFRA:p.T674	c.2021C>T	4_55144547_C_T	ENST00000257290	55144541	55144553
PDGFRA	4	T674I	missense_variant	EID1779	FIP1L1-PDGFRA T674I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24407160' target='_blank'>Sadovnik et al., 2014, Exp. Hematol.</a>	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Predictive	D: Preclinical evidence	DOID:0080164	NA	NA	Ponatinib	FIP1L1-PDGFRA T674I	EID1779:PDGFRA:p.T674	c.2021C>T	4_55144547_C_T	ENST00000257290	55144541	55144553
PDGFRA	4	D842Y	missense_variant	EID45	D842Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22745105' target='_blank'>Heinrich et al., 2012, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	NA	NA	Crenolanib	D842Y	EID45:PDGFRA:p.D842	c.2524G>T	4_55152092_G_T	ENST00000257290	55152086	55152098
PDGFRA	4	D842I	missense_variant	EID43	D842I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22745105' target='_blank'>Heinrich et al., 2012, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	NA	NA	Crenolanib	D842I	EID43:PDGFRA:p.D842	c.2524_2525delinsAT	4_55152092_GA_AT	ENST00000257290	55152086	55152099
PDGFRA	4	D842V	missense_variant	EID15	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15928335' target='_blank'>Corless et al., 2005, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	NA	Imatinib	D842V	EID15:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	55152087	55152099
PDGFRA	4	D842V	missense_variant	EID16	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	NA	Imatinib	D842V	EID16:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	55152087	55152099
PDGFRA	4	D842V	missense_variant	EID2	D842V	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15146165' target='_blank'>Lasota et al., 2004, Lab. Invest.</a>	Gastrointestinal Stromal Tumor	Diagnostic	B: Clinical evidence	DOID:9253	NA	NA	NA	D842V	EID2:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	55152087	55152099
PDGFRA	4	D842V	missense_variant	EID4060	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	NA	NA	Sunitinib	D842V	EID4060:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	55152087	55152099
PDGFRA	4	D842V	missense_variant	EID44	D842V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22745105' target='_blank'>Heinrich et al., 2012, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	NA	NA	Crenolanib	D842V	EID44:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	55152087	55152099
PDGFRA	4	D842V	missense_variant	EID651	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12949711' target='_blank'>Hirota et al., 2003, Gastroenterology</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	NA	NA	Imatinib	D842V	EID651:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	55152087	55152099
PDGFRA	4	D842V	missense_variant	EID738	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26130666' target='_blank'>Yoo et al., 2016, Cancer Res Treat</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	NA	Imatinib	D842V	EID738:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	55152087	55152099
PDGFRA	4	D842_I843delinsVM	missense_variant	EID47	DI842-843VM	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22745105' target='_blank'>Heinrich et al., 2012, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	NA	NA	Crenolanib	DI842-843VM	EID47:PDGFRA:p.D842_I843	c.2525_2529delinsTCATG	4_55152093_ACATC_TCATG	ENST00000257290	55152087	55152103
PDGFRA	4	H845Y	missense_variant	EID1976	H845Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24132921' target='_blank'>Dai et al., 2013, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Imatinib, Crenolanib	H845Y	EID1976:PDGFRA:p.H845	c.2533C>T	4_55152101_C_T	ENST00000257290	55152095	55152107
PDGFRA	4	G853D	missense_variant	EID1977	G853D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24132921' target='_blank'>Dai et al., 2013, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Imatinib, Crenolanib	G853D	EID1977:PDGFRA:p.G853	c.2558G>A	4_55152126_G_A	ENST00000257290	55152120	55152132
KIT	4	NA	NA	EID1424	EXON 9 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Sunitinib	EXON 9 MUTATION	EID1424:KIT:exon9	NA	NA	NA	55592022	55592216
KIT	4	NA	NA	EID1221	EXON 9 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16624552' target='_blank'>Debiec-Rychter et al., 2006, Eur. J. Cancer</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Imatinib	EXON 9 MUTATION	EID1221:KIT:exon9	NA	NA	NA	55592022	55592216
KIT	4	NA	NA	EID1223	EXON 9 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22439647' target='_blank'>Rutkowski et al., 2012, BMC Cancer</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Sunitinib	EXON 9 MUTATION	EID1223:KIT:exon9	NA	NA	NA	55592022	55592216
KIT	4	M541L	missense_variant	EID1423	M541L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25015329' target='_blank'>Iurlo et al., 2014, Oncotarget</a>	Chronic Leukemia	Predictive	C: Case study	DOID:1036	NA	NA	Imatinib	M541L	EID1423:KIT:p.M541	c.1621A>C	4_55593464_A_C	ENST00000288135	55593458	55593470
KIT	4	M541L	missense_variant	EID485	M541L	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16307017' target='_blank'>Krüger et al., 2006, Leukemia</a>	Chronic Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:8552	NA	NA	NA	M541L	EID485:KIT:p.M541	c.1621A>C	4_55593464_A_C	ENST00000288135	55593458	55593470
KIT	4	NA	NA	EID58	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23775962' target='_blank'>Hodi et al., 2013, J. Clin. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	11	Imatinib	EXON 11 MUTATION	EID58:KIT:exon11	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID1224	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22261812' target='_blank'>Minor et al., 2012, Clin. Cancer Res.</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	11	Sunitinib	EXON 11 MUTATION	EID1224:KIT:exon11	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID654	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	11	Imatinib	EXON 11 MUTATION	EID654:KIT:exon11	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID376	EXON 11 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/10485475' target='_blank'>Taniguchi et al., 1999, Cancer Res.</a>	Gastrointestinal Stromal Tumor	Prognostic	B: Clinical evidence	DOID:9253	NA	11	NA	EXON 11 MUTATION	EID376:KIT:exon11	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID225	EXON 11 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/10485475' target='_blank'>Taniguchi et al., 1999, Cancer Res.</a>	Gastrointestinal Stromal Tumor	Diagnostic	B: Clinical evidence	DOID:9253	NA	11	NA	EXON 11 MUTATION	EID225:KIT:exon11	NA	NA	NA	55593581	55593708
KIT	4	V559D	missense_variant	EID3028	V559D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22114577' target='_blank'>Cameron et al., 2011, Case Rep Oncol</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	NA	NA	Imatinib	V559D	EID3028:KIT:p.V559	c.1676T>A	4_55593610_T_A	ENST00000288135	55593604	55593616
KIT	4	V559D	missense_variant	EID3029	V559D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16046538' target='_blank'>Carter et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	SU11248, MLN518, PD-180970, BMS-354825, Imatinib	V559D	EID3029:KIT:p.V559	c.1676T>A	4_55593610_T_A	ENST00000288135	55593604	55593616
KIT	4	L576P	missense_variant	EID303	L576P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17372901' target='_blank'>Antonescu et al., 2007, Int. J. Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Dasatinib, Imatinib, Nilotinib	L576P	EID303:KIT:p.L576	c.1727T>C	4_55593661_T_C	ENST00000288135	55593655	55593667
KIT	4	L576P	missense_variant	EID34	L576P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19671763' target='_blank'>Woodman et al., 2009, Mol. Cancer Ther.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Imatinib, Nilotinib, Sorafenib	L576P	EID34:KIT:p.L576	c.1727T>C	4_55593661_T_C	ENST00000288135	55593655	55593667
KIT	4	L576P	missense_variant	EID42	L576P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19671763' target='_blank'>Woodman et al., 2009, Mol. Cancer Ther.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Dasatinib	L576P	EID42:KIT:p.L576	c.1727T>C	4_55593661_T_C	ENST00000288135	55593655	55593667
KIT	4	K642E	missense_variant	EID2889	K642E	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18510589' target='_blank'>Lutzky et al., 2008, Pigment Cell Melanoma Res</a>	Melanoma	Prognostic	C: Case study	DOID:1909	NA	NA	NA	K642E	EID2889:KIT:p.K642	c.1924A>G	4_55594221_A_G	ENST00000288135	55594215	55594227
KIT	4	V654A	missense_variant	EID249	V654A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	NA	NA	Imatinib	V654A	EID249:KIT:p.V654	c.1961T>C	4_55594258_T_C	ENST00000288135	55594252	55594264
KIT	4	V654A	missense_variant	EID304	V654A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16638875' target='_blank'>Prenen et al., 2006, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	NA	Sunitinib	V654A	EID304:KIT:p.V654	c.1961T>C	4_55594258_T_C	ENST00000288135	55594252	55594264
KIT	4	NA	NA	EID70	EXON 14 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16551858' target='_blank'>Wardelmann et al., 2006, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Prognostic	B: Clinical evidence	DOID:9253	NA	14	NA	EXON 14 MUTATION	EID70:KIT:exon14	NA	NA	NA	55595500	55595651
KIT	4	T670I	missense_variant	EID2924	T670I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	NA	NA	Imatinib	T670I	EID2924:KIT:p.T670	c.2009C>T	4_55595519_C_T	ENST00000288135	55595513	55595525
KIT	4	C809G	missense_variant	EID2920	C809G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	NA	NA	Imatinib	C809G	EID2920:KIT:p.C809	c.2425T>G	4_55599299_T_G	ENST00000288135	55599293	55599305
KIT	4	D816H	missense_variant	EID2923	D816H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	NA	NA	Imatinib	D816H	EID2923:KIT:p.D816	c.2446G>C	4_55599320_G_C	ENST00000288135	55599314	55599326
KIT	4	D816V	missense_variant	EID1725	D816V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27355533' target='_blank'>Gotlib et al., 2016, N. Engl. J. Med.</a>	Systemic Mastocytosis	Predictive	B: Clinical evidence	DOID:349	NA	NA	Midostaurin	D816V	EID1725:KIT:p.D816	c.2447A>T	4_55599321_A_T	ENST00000288135	55599315	55599327
KIT	4	D816V	missense_variant	EID1726	D816V	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26464169' target='_blank'>Jawhar et al., 2016, Leukemia</a>	Systemic Mastocytosis	Prognostic	B: Clinical evidence	DOID:349	NA	NA	NA	D816V	EID1726:KIT:p.D816	c.2447A>T	4_55599321_A_T	ENST00000288135	55599315	55599327
KIT	4	D816V	missense_variant	EID26	D816V	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16384925' target='_blank'>Cairoli et al., 2006, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	NA	NA	D816V	EID26:KIT:p.D816	c.2447A>T	4_55599321_A_T	ENST00000288135	55599315	55599327
KIT	4	D820Y	missense_variant	EID2886	D820Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21642685' target='_blank'>Carvajal et al., 2011, JAMA</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Imatinib	D820Y	EID2886:KIT:p.D820	c.2458G>T	4_55599332_G_T	ENST00000288135	55599326	55599338
KIT	4	D820A	missense_variant	EID2921	D820A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	NA	NA	Imatinib	D820A	EID2921:KIT:p.D820	c.2459A>C	4_55599333_A_C	ENST00000288135	55599327	55599339
KIT	4	D820G	missense_variant	EID2922	D820G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	NA	NA	Imatinib	D820G	EID2922:KIT:p.D820	c.2459A>G	4_55599333_A_G	ENST00000288135	55599327	55599339
KIT	4	N822K	missense_variant	EID2918	N822K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	NA	NA	Imatinib	N822K	EID2918:KIT:p.N822	c.2466T>A	4_55599340_T_A	ENST00000288135	55599334	55599346
KIT	4	Y823D	missense_variant	EID2919	Y823D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	NA	NA	Imatinib	Y823D	EID2919:KIT:p.Y823	c.2467T>G	4_55599341_T_G	ENST00000288135	55599335	55599347
KDR	4	A1065T	missense_variant&splice_region_variant	EID1106	A1065T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19723655' target='_blank'>Antonescu et al., 2009, Cancer Res.</a>	Angiosarcoma	Predictive	D: Preclinical evidence	DOID:0001816	NA	NA	Sorafenib, Sunitinib	A1065T	EID1106:KDR:p.A1065	c.3193G>A	4_55955969_C_T	ENST00000263923	55955963	55955975
KDR	4	R961W	missense_variant	EID1191	R961W	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27004155' target='_blank'>Loaiza-Bonilla et al., 2016, Cureus</a>	Colorectal Adenocarcinoma	Predictive	C: Case study	DOID:0050861	NA	NA	Regorafenib	R961W	EID1191:KDR:p.R961	c.2881C>T	4_55961059_G_A	ENST00000263923	55961053	55961065
KDR	4	D717V	missense_variant	EID1107	D717V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19723655' target='_blank'>Antonescu et al., 2009, Cancer Res.</a>	Angiosarcoma	Predictive	D: Preclinical evidence	DOID:0001816	NA	NA	Sorafenib, Sunitinib	D717V	EID1107:KDR:p.D717	c.2150A>T	4_55968180_T_A	ENST00000263923	55968174	55968186
TERT	5	.	upstream_gene_variant	EID1646	C228T	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25121551' target='_blank'>Liu et al., 2014, Endocr. Relat. Cancer</a>	Thyroid Cancer	Diagnostic	B: Clinical evidence	DOID:1781	NA	NA	NA	C228T	TERT:upstream_gene_variant_C228T	NA	5_1295228_G_A	NA	1295222	1295234
TERT	5	.	upstream_gene_variant	EID655	C228T	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25024077' target='_blank'>Xing et al., 2014, J. Clin. Oncol.</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	NA	NA	NA	C228T	TERT:upstream_gene_variant_C228T	NA	5_1295228_G_A	NA	1295222	1295234
RAD50	5	L1237F	missense_variant	EID5829	L1237F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24934408' target='_blank'>Al-Ahmadie et al., 2014, Cancer Discov</a>	Ureter Small Cell Carcinoma	Predictive	C: Case study	DOID:6886	NA	NA	Irinotecan, AZD7762	L1237F	EID5829:RAD50:p.L1237	c.3709C>T, c.3709_3711delinsTTC	5_131976454_C_T, 5_131976454_CTT_TTC	ENST00000265335	131976448	131976462
NPM1	5	NA	NA	EID147	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22417203' target='_blank'>Patel et al., 2012, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	12	Daunorubicin	EXON 12 MUTATION	EID147:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID148	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24797300' target='_blank'>Tassara et al., 2014, Blood</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	12	Valproic Acid	EXON 12 MUTATION	EID148:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID149	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21719597' target='_blank'>Balusu et al., 2011, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	12	NSC348884, All-trans Retinoic Acid	EXON 12 MUTATION	EID149:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID151	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24927407' target='_blank'>Ehninger et al., 2014, Blood Cancer J</a>	Acute Myeloid Leukemia	Predictive	E: Indirect evidence	DOID:9119	NA	12	Anti-CD33	EXON 12 MUTATION	EID151:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID150	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24927407' target='_blank'>Ehninger et al., 2014, Blood Cancer J</a>	Acute Myeloid Leukemia	Predictive	E: Indirect evidence	DOID:9119	NA	12	Anti-CD33, Anti-CD123	EXON 12 MUTATION	EID150:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID137	EXON 12 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19965647' target='_blank'>Burnett et al., 2010, Blood</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	12	All-trans Retinoic Acid	EXON 12 MUTATION	EID137:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID146	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19059939' target='_blank'>Schlenk et al., 2009, Haematologica</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	12	All-trans Retinoic Acid	EXON 12 MUTATION	EID146:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID120	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19059939' target='_blank'>Schlenk et al., 2009, Haematologica</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID120:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID119	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16455956' target='_blank'>Thiede et al., 2006, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID119:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID1369	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16046528' target='_blank'>Boissel et al., 2005, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID1369:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID196	EXON 12 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19587375' target='_blank'>Schnittger et al., 2009, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID196:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID177	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15659725' target='_blank'>Falini et al., 2005, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID177:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID182	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22430270' target='_blank'>Gaidzik et al., 2012, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID182:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID181	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24855211' target='_blank'>Linch et al., 2014, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID181:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID108	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16455956' target='_blank'>Thiede et al., 2006, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID108:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID1102	EXON 12 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26789727' target='_blank'>Ivey et al., 2016, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID1102:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID184	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20026798' target='_blank'>Becker et al., 2010, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID184:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID179	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22417203' target='_blank'>Patel et al., 2012, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID179:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID175	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16455956' target='_blank'>Thiede et al., 2006, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID175:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID180	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19047294' target='_blank'>Büchner et al., 2009, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID180:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID117	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17957027' target='_blank'>Gale et al., 2008, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID117:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID185	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16051734' target='_blank'>Döhner et al., 2005, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID185:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID116	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19357394' target='_blank'>Vardiman et al., 2009, Blood</a>	Acute Myeloid Leukemia	Diagnostic	A: Validated	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID116:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID174	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19059939' target='_blank'>Schlenk et al., 2009, Haematologica</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID174:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID111	EXON 12 MUTATION	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16076867' target='_blank'>Schnittger et al., 2005, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID111:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID199	EXON 12 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24859829' target='_blank'>Tian et al., 2014, Int. J. Hematol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID199:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID176	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16076867' target='_blank'>Schnittger et al., 2005, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID176:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID173	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17957027' target='_blank'>Gale et al., 2008, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID173:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID183	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18450602' target='_blank'>Schlenk et al., 2008, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID183:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID118	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16076867' target='_blank'>Schnittger et al., 2005, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	EID118:NPM1:exon12	NA	NA	NA	170837530	170837569
NPM1	5	W288fs	frameshift_variant	EID109	W288FS	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	NA	NA	W288fs	EID109:NPM1:p.W288	c.860_863dup	5_170837547_G_GTCTG	ENST00000296930	170837541	170837557
NPM1	5	W288fs	frameshift_variant	EID121	W288FS	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	NA	NA	W288fs	EID121:NPM1:p.W288	c.860_863dup	5_170837547_G_GTCTG	ENST00000296930	170837541	170837557
NPM1	5	W288fs	frameshift_variant	EID152	W288FS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21719597' target='_blank'>Balusu et al., 2011, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	NA	NSC348884	W288fs	EID152:NPM1:p.W288	c.860_863dup	5_170837547_G_GTCTG	ENST00000296930	170837541	170837557
NPM1	5	W288fs	frameshift_variant	EID153	W288FS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15659725' target='_blank'>Falini et al., 2005, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Predictive	E: Indirect evidence	DOID:9119	NA	NA	Induction Therapy	W288fs	EID153:NPM1:p.W288	c.860_863dup	5_170837547_G_GTCTG	ENST00000296930	170837541	170837557
ROS1	6	L2155S	missense_variant	EID1256	CD74-ROS1 L2155S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	TAE684, Foretinib, Crizotinib	CD74-ROS1 L2155S	EID1256:ROS1:p.L2155	c.6464T>C	6_117630062_A_G	ENST00000368508	117630056	117630068
ROS1	6	G2101A	missense_variant	EID1259	CD74-ROS1 G2101A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	CD74-ROS1 G2101A	EID1259:ROS1:p.G2101	c.6302G>C	6_117631376_C_G	ENST00000368508	117631370	117631382
ROS1	6	G2101A	missense_variant	EID1260	CD74-ROS1 G2101A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Foretinib	CD74-ROS1 G2101A	EID1260:ROS1:p.G2101	c.6302G>C	6_117631376_C_G	ENST00000368508	117631370	117631382
ROS1	6	G2032R	missense_variant	EID1100	CD74-ROS1 G2032R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23724914' target='_blank'>Awad et al., 2013, N. Engl. J. Med.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Crizotinib	CD74-ROS1 G2032R	EID1100:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	117638341	117638353
ROS1	6	G2032R	missense_variant	EID1101	CD74-ROS1 G2032R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25351743' target='_blank'>Katayama et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Cabozantinib	CD74-ROS1 G2032R	EID1101:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	117638341	117638353
ROS1	6	G2032R	missense_variant	EID1249	CD74-ROS1 G2032R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26372962' target='_blank'>Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Cabozantinib, Foretinib	CD74-ROS1 G2032R	EID1249:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	117638341	117638353
ROS1	6	G2032R	missense_variant	EID1250	CD74-ROS1 G2032R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26372962' target='_blank'>Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	AZD3463, Ceritinib, Brigatinib, Crizotinib	CD74-ROS1 G2032R	EID1250:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	117638341	117638353
ROS1	6	G2032R	missense_variant	EID1251	CD74-ROS1 G2032R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25733882' target='_blank'>Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Lorlatinib	CD74-ROS1 G2032R	EID1251:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	117638341	117638353
ROS1	6	G2032R	missense_variant	EID1254	CD74-ROS1 G2032R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Crizotinib	CD74-ROS1 G2032R	EID1254:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	117638341	117638353
ROS1	6	G2032R	missense_variant	EID1255	CD74-ROS1 G2032R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Foretinib	CD74-ROS1 G2032R	EID1255:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	117638341	117638353
ROS1	6	G2032R	missense_variant	EID2934	G2032R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23724914' target='_blank'>Awad et al., 2013, N. Engl. J. Med.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Crizotinib	G2032R	EID2934:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	117638341	117638353
ROS1	6	L2026M	missense_variant	EID1252	CD74-ROS1 L2026M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25733882' target='_blank'>Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	CD74-ROS1 L2026M	EID1252:ROS1:p.L2026	c.6076C>A	6_117638365_G_T	ENST00000368508	117638359	117638371
ROS1	6	L2026M	missense_variant	EID1253	CD74-ROS1 L2026M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25733882' target='_blank'>Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Lorlatinib	CD74-ROS1 L2026M	EID1253:ROS1:p.L2026	c.6076C>A	6_117638365_G_T	ENST00000368508	117638359	117638371
ROS1	6	L2026M	missense_variant	EID1257	CD74-ROS1 L2026M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Crizotinib	CD74-ROS1 L2026M	EID1257:ROS1:p.L2026	c.6076C>A	6_117638365_G_T	ENST00000368508	117638359	117638371
ROS1	6	L2026M	missense_variant	EID1258	CD74-ROS1 L2026M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Foretinib	CD74-ROS1 L2026M	EID1258:ROS1:p.L2026	c.6076C>A	6_117638365_G_T	ENST00000368508	117638359	117638371
ESR1	6	S463P	missense_variant	EID1727	S463P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Estrogen-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060075	NA	NA	Aromatase Inhibitor	S463P	EID1727:ESR1:p.S463	c.1387T>C	6_152415537_T_C	ENST00000440973	152415531	152415543
ESR1	6	L536Q	missense_variant	EID242	L536Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Hormone Therapy	L536Q	EID242:ESR1:p.L536	c.1607_1608delinsAG	6_152419920_TC_AG	ENST00000440973	152419914	152419927
ESR1	6	L536Q	missense_variant	EID290	L536Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Fulvestrant, Tamoxifen	L536Q	EID290:ESR1:p.L536	c.1607_1608delinsAG	6_152419920_TC_AG	ENST00000440973	152419914	152419927
ESR1	6	Y537N	missense_variant	EID245	Y537N	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Hormone Therapy	Y537N	EID245:ESR1:p.Y537	c.1609T>A	6_152419922_T_A	ENST00000440973	152419916	152419928
ESR1	6	Y537N	missense_variant	EID293	Y537N	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Fulvestrant, Tamoxifen	Y537N	EID293:ESR1:p.Y537	c.1609T>A	6_152419922_T_A	ENST00000440973	152419916	152419928
ESR1	6	Y537C	missense_variant	EID244	Y537C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Hormone Therapy	Y537C	EID244:ESR1:p.Y537	c.1610A>G	6_152419923_A_G	ENST00000440973	152419917	152419929
ESR1	6	Y537C	missense_variant	EID292	Y537C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Fulvestrant, Tamoxifen	Y537C	EID292:ESR1:p.Y537	c.1610A>G	6_152419923_A_G	ENST00000440973	152419917	152419929
ESR1	6	Y537S	missense_variant	EID246	Y537S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Hormone Therapy	Y537S	EID246:ESR1:p.Y537	c.1610A>C	6_152419923_A_C	ENST00000440973	152419917	152419929
ESR1	6	Y537S	missense_variant	EID294	Y537S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Fulvestrant, Tamoxifen	Y537S	EID294:ESR1:p.Y537	c.1610A>C	6_152419923_A_C	ENST00000440973	152419917	152419929
ESR1	6	D538G	missense_variant	EID243	D538G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Hormone Therapy	D538G	EID243:ESR1:p.D538	c.1613A>G	6_152419926_A_G	ENST00000440973	152419920	152419932
ESR1	6	D538G	missense_variant	EID291	D538G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	NA	NA	Fulvestrant, Tamoxifen	D538G	EID291:ESR1:p.D538	c.1613A>G	6_152419926_A_G	ENST00000440973	152419920	152419932
ESR1	6	D538G	missense_variant	EID4814	D538G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27556863' target='_blank'>Gyanchandani et al., 2016, Oncotarget</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	NA	NA	Letrozole, Palbociclib	D538G	EID4814:ESR1:p.D538	c.1613A>G	6_152419926_A_G	ENST00000440973	152419920	152419932
RAC1	7	P29S	missense_variant	EID873	P29S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25056119' target='_blank'>Watson et al., 2014, Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Dabrafenib, Vemurafenib	P29S	EID873:RAC1:p.P29	c.85C>T	7_6426892_C_T	ENST00000356142	6426886	6426898
EGFR	7	R108K	missense_variant	EID4186	R108K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	NA	NA	Erlotinib	R108K	EID4186:EGFR:p.R108	c.323G>A, c.323_324delinsAG	7_55211080_G_A, 7_55211080_GA_AG	ENST00000275493	55211074	55211087
EGFR	7	NA	NA	EID662	EXON 4 DELETION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23764753' target='_blank'>Zhang et al., 2013, Carcinogenesis</a>	Epithelial Ovarian Cancer	Predictive	D: Preclinical evidence	DOID:2152	NA	4	Cisplatin	EXON 4 DELETION	EID662:EGFR:exon4	NA	NA	NA	55214298	55214433
EGFR	7	T263P	missense_variant	EID4187	T263P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	NA	NA	Erlotinib	T263P	EID4187:EGFR:p.T263	c.787A>C, c.787_789delinsCCA, c.787_789delinsCCG, c.787_789delinsCCT	7_55221743_A_C, 7_55221743_ACC_CCA, 7_55221743_ACC_CCG, 7_55221743_ACC_CCT	ENST00000275493	55221737	55221751
EGFR	7	A289V	missense_variant	EID4188	A289V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	NA	NA	Erlotinib	A289V	EID4188:EGFR:p.A289	c.866C>T	7_55221822_C_T	ENST00000275493	55221816	55221828
EGFR	7	R451C	missense_variant	EID1081	R451C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Sym004, Panitumumab, Cetuximab	R451C	EID1081:EGFR:p.R451	c.1351C>T	7_55227884_C_T	ENST00000275493	55227878	55227890
EGFR	7	G465R	missense_variant	EID1057	G465R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Sym004	G465R	EID1057:EGFR:p.G465	c.1393G>A	7_55227926_G_A	ENST00000275493	55227920	55227932
EGFR	7	G465R	missense_variant	EID1058	G465R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab, Cetuximab	G465R	EID1058:EGFR:p.G465	c.1393G>A	7_55227926_G_A	ENST00000275493	55227920	55227932
EGFR	7	K467T	missense_variant	EID1082	K467T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Sym004, Panitumumab	K467T	EID1082:EGFR:p.K467	c.1400A>C	7_55227933_A_C	ENST00000275493	55227927	55227939
EGFR	7	K467T	missense_variant	EID1083	K467T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	K467T	EID1083:EGFR:p.K467	c.1400A>C	7_55227933_A_C	ENST00000275493	55227927	55227939
EGFR	7	S492R	missense_variant	EID1078	S492R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22270724' target='_blank'>Montagut et al., 2012, Nat. Med.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Panitumumab	S492R	EID1078:EGFR:p.S492	c.1476C>A	7_55228009_C_A	ENST00000275493	55228003	55228015
EGFR	7	S492R	missense_variant	EID1079	S492R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Panitumumab, Sym004	S492R	EID1079:EGFR:p.S492	c.1476C>A	7_55228009_C_A	ENST00000275493	55228003	55228015
EGFR	7	S492R	missense_variant	EID1080	S492R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	S492R	EID1080:EGFR:p.S492	c.1476C>A	7_55228009_C_A	ENST00000275493	55228003	55228015
EGFR	7	S492R	missense_variant	EID717	S492R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22270724' target='_blank'>Montagut et al., 2012, Nat. Med.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Cetuximab	S492R	EID717:EGFR:p.S492	c.1476C>A	7_55228009_C_A	ENST00000275493	55228003	55228015
EGFR	7	R705K	missense_variant	EID6182	R705K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23749122' target='_blank'>Locatelli-Sanchez et al., 2013, Lung</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib, Erlotinib	R705K	EID6182:EGFR:p.R705	c.2114G>A, c.2114_2115delinsAA	7_55241666_G_A, 7_55241666_GG_AA	ENST00000275493	55241660	55241673
EGFR	7	G719S	missense_variant	EID1736	G719S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26124334' target='_blank'>Otsuka et al., 2015, Anticancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Erlotinib, Gefitinib	G719S	EID1736:EGFR:p.G719	c.2155G>A	7_55241707_G_A	ENST00000275493	55241701	55241713
EGFR	7	G719S	missense_variant	EID274	G719S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15118125' target='_blank'>Paez et al., 2004, Science</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Gefitinib	G719S	EID274:EGFR:p.G719	c.2155G>A	7_55241707_G_A	ENST00000275493	55241701	55241713
EGFR	7	G719S	missense_variant	EID4190	G719S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	G719S	EID4190:EGFR:p.G719	c.2155G>A	7_55241707_G_A	ENST00000275493	55241701	55241713
EGFR	7	G719S	missense_variant	EID787	G719S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24894453' target='_blank'>Cho et al., 2014, Mol. Cancer</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	G719S	EID787:EGFR:p.G719	c.2155G>A	7_55241707_G_A	ENST00000275493	55241701	55241713
EGFR	7	G719A	missense_variant	EID2508	G719A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20038723' target='_blank'>Douillard et al., 2010, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	G719A	EID2508:EGFR:p.G719	c.2156G>C	7_55241708_G_C	ENST00000275493	55241702	55241714
EGFR	7	G719A	missense_variant	EID6181	G719A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23749122' target='_blank'>Locatelli-Sanchez et al., 2013, Lung</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib, Erlotinib	G719A	EID6181:EGFR:p.G719	c.2156G>C	7_55241708_G_C	ENST00000275493	55241702	55241714
EGFR	7	G719D	missense_variant	EID4210	G719D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib, Erlotinib	G719D	EID4210:EGFR:p.G719	c.2156G>A, c.2156_2157delinsAT	7_55241708_G_A, 7_55241708_GC_AT	ENST00000275493	55241702	55241715
EGFR	7	NA	NA	EID1780	G719	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	719	NA	Erlotinib	G719	EID1780:EGFR:p.G719	NA	NA	NA	55241706	55241708
EGFR	7	NA	NA	EID4189	G719	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	719	NA	Gefitinib, Erlotinib	G719	EID4189:EGFR:p.G719	NA	NA	NA	55241706	55241708
EGFR	7	NA	NA	EID1782	S720	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	720	NA	Erlotinib	S720	EID1782:EGFR:p.S720	NA	NA	NA	55241709	55241711
EGFR	7	G724S	missense_variant	EID786	G724S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24894453' target='_blank'>Cho et al., 2014, Mol. Cancer</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Cetuximab	G724S	EID786:EGFR:p.G724	c.2170G>A	7_55241722_G_A	ENST00000275493	55241716	55241728
EGFR	7	NA	NA	EID273	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16730237' target='_blank'>Ji et al., 2006, Cancer Cell</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	19	Gefitinib	EXON 19 DELETION	EID273:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID413	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16818686' target='_blank'>Jackman et al., 2006, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	19	Gefitinib, Erlotinib	EXON 19 DELETION	EID413:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID880	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23816960' target='_blank'>Sequist et al., 2013, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Afatinib	EXON 19 DELETION	EID880:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID881	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25862853' target='_blank'>Banno et al., 2015, Anticancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	19	Afatinib	EXON 19 DELETION	EID881:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID882	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22452895' target='_blank'>Yang et al., 2012, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Afatinib	EXON 19 DELETION	EID882:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID884	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22285168' target='_blank'>Rosell et al., 2012, Lancet Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	19	Erlotinib	EXON 19 DELETION	EID884:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID969	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26515464' target='_blank'>Hirano et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	19	Afatinib	EXON 19 DELETION	EID969:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID981	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24439929' target='_blank'>Wu et al., 2014, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Afatinib	EXON 19 DELETION	EID981:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID983	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25589191' target='_blank'>Yang et al., 2015, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Afatinib	EXON 19 DELETION	EID983:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID1666	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18509184' target='_blank'>Yang et al., 2008, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	19	Gefitinib	EXON 19 DELETION	EID1666:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID2519	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22370314' target='_blank'>Han et al., 2012, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Gefitinib	EXON 19 DELETION	EID2519:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID2995	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24868098' target='_blank'>Khozin et al., 2014, Oncologist</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	19	Erlotinib	EXON 19 DELETION	EID2995:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID2996	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23982599' target='_blank'>Dungo et al., 2013, Drugs</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	19	Afatinib	EXON 19 DELETION	EID2996:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID4766	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27566387' target='_blank'>Kanemaru et al., 2016, Respir Investig</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	19	Erlotinib	EXON 19 DELETION	EID4766:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID4859	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26768165' target='_blank'>Ramalingam et al., 2016, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	19	Dacomitinib, Erlotinib	EXON 19 DELETION	EID4859:EGFR:exon19	NA	NA	NA	55242414	55242513
EGFR	7	W731L	missense_variant	EID4655	W731L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	NA	NA	Erlotinib	W731L	EID4655:EGFR:p.W731	c.2191_2192delinsCT, c.2191_2193delinsCTA, c.2191_2193delinsCTC, c.2191_2193delinsCTT, c.2192G>T, c.2192_2193delinsTA	7_55242421_TG_CT, 7_55242421_TGG_CTA, 7_55242421_TGG_CTC, 7_55242421_TGG_CTT, 7_55242422_G_T, 7_55242422_GG_TA	ENST00000275493	55242415	55242429
EGFR	7	E734Q	missense_variant	EID4656	E734Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	NA	NA	Erlotinib	E734Q	EID4656:EGFR:p.E734	c.2200G>C, c.2200_2202delinsCAG	7_55242430_G_C, 7_55242430_GAA_CAG	ENST00000275493	55242424	55242438
EGFR	7	V742A	missense_variant	EID4197	V742A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	V742A	EID4197:EGFR:p.V742	c.2225T>C, c.2225_2226delinsCA, c.2225_2226delinsCG, c.2225_2226delinsCT	7_55242455_T_C, 7_55242455_TC_CA, 7_55242455_TC_CG, 7_55242455_TC_CT	ENST00000275493	55242449	55242462
EGFR	7	E746G	missense_variant	EID1787	E746G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	E746G	EID1787:EGFR:p.E746	c.2237A>G	7_55242467_A_G	ENST00000275493	55242461	55242473
EGFR	7	L747P	missense_variant	EID4220	L747P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib	L747P	EID4220:EGFR:p.L747	c.2239_2240delinsCC, c.2239_2241delinsCCC, c.2239_2241delinsCCG, c.2239_2241delinsCCT	7_55242469_TT_CC, 7_55242469_TTA_CCC, 7_55242469_TTA_CCG, 7_55242469_TTA_CCT	ENST00000275493	55242463	55242477
EGFR	7	P753S	missense_variant	EID1089	P753S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24934779' target='_blank'>Ganesan et al., 2016, J. Clin. Oncol.</a>	Skin Squamous Cell Carcinoma	Predictive	C: Case study	DOID:3151	NA	NA	Rapamycin (Sirolimus), Cetuximab	P753S	EID1089:EGFR:p.P753	c.2257C>T	7_55242487_C_T	ENST00000275493	55242481	55242493
EGFR	7	K757R	missense_variant	EID1786	K757R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	K757R	EID1786:EGFR:p.K757	c.2270A>G	7_55242500_A_G	ENST00000275493	55242494	55242506
EGFR	7	D761Y	missense_variant&splice_region_variant	EID1763	D761Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17085664' target='_blank'>Balak et al., 2006, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib, Gefitinib	D761Y	EID1763:EGFR:p.D761	c.2281G>T	7_55242511_G_T	ENST00000275493	55242505	55242517
EGFR	7	A763_Y764insFQEA	inframe_insertion	EID4497	A763_Y764insFQEA	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	A763_Y764insFQEA	EID4497:EGFR:p.A763_Y764	c.2284-5_2290dup	7_55248992_T_TTCCAGGAAGCCT	ENST00000275493	55248986	55249010
EGFR	7	NA	NA	EID4650	EXON 20 INSERTION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22895145' target='_blank'>Lund-Iversen et al., 2012, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	20	Erlotinib	EXON 20 INSERTION	EID4650:EGFR:exon20	NA	NA	NA	55248990	55249022
EGFR	7	NA	NA	EID1809	EXON 20 INSERTION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26051236' target='_blank'>Yang et al., 2015, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	20	Afatinib	EXON 20 INSERTION	EID1809:EGFR:exon20	NA	NA	NA	55248990	55249022
EGFR	7	A767_V769dup	inframe_insertion	EID4665	A767_V769dupASV	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	A767_V769dupASV	EID4665:EGFR:p.A767_V769	c.2300_2308dup	7_55249000_G_GGCCAGCGTG	ENST00000275493	55248994	55249015
EGFR	7	S768I	missense_variant	EID1394	S768I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25521405' target='_blank'>Hellmann et al., 2014, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	S768I	EID1394:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	55248999	55249011
EGFR	7	S768I	missense_variant	EID1395	S768I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20522446' target='_blank'>Masago et al., 2010, Jpn. J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Gefitinib	S768I	EID1395:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	55248999	55249011
EGFR	7	S768I	missense_variant	EID2906	S768I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27211795' target='_blank'>Leventakos et al., 2016, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib	S768I	EID2906:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	55248999	55249011
EGFR	7	S768I	missense_variant	EID4273	S768I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22895145' target='_blank'>Lund-Iversen et al., 2012, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	S768I	EID4273:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	55248999	55249011
EGFR	7	S768I	missense_variant	EID4274	S768I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	NA	NA	Erlotinib	S768I	EID4274:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	55248999	55249011
EGFR	7	A767_V769dup	inframe_insertion	EID1799	V769_770insASV	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	V769_770insASV	EID1799:EGFR:p.A767_V769	c.2300_2308dup	7_55249009_G_GGCCAGCGTG	ENST00000275493	55249003	55249024
EGFR	7	D770_N771insGL	inframe_insertion	EID4494	D770_N771insGL	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	D770_N771insGL	EID4494:EGFR:p.D770_N771	c.2310_2311insGGGTTA	7_55249012_C_CGGGTTA	ENST00000275493	55249006	55249024
EGFR	7	D770_N771insGT	inframe_insertion	EID4643	D770_N771insGT	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23371856' target='_blank'>Arcila et al., 2013, Mol. Cancer Ther.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	D770_N771insGT	EID4643:EGFR:p.D770_N771	c.2310_2311insGGCACA	7_55249012_C_CGGCACA	ENST00000275493	55249006	55249024
EGFR	7	N771_H773dup	inframe_insertion	EID4493	H773_V774insNPH	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	H773_V774insNPH	EID4493:EGFR:p.N771_H773	c.2311_2319dup	7_55249012_C_CAACCCCCAC	ENST00000275493	55249006	55249027
EGFR	7	S768_D770dup	inframe_insertion	EID4275	D770_N771insSVD	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	D770_N771insSVD	EID4275:EGFR:p.S768_D770	c.2303_2311dup	7_55249013_A_AGCGTGGACA	ENST00000275493	55249007	55249028
EGFR	7	V774M	missense_variant	EID4231	V774M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib	V774M	EID4231:EGFR:p.V774	c.2320G>A	7_55249022_G_A	ENST00000275493	55249016	55249028
EGFR	7	V774A	missense_variant	EID4226	V774A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	V774A	EID4226:EGFR:p.V774	c.2321T>C, c.2321_2322inv, c.2321_2322delinsCC, c.2321_2322delinsCT	7_55249023_T_C, 7_55249023_TG_CA, 7_55249023_TG_CC, 7_55249023_TG_CT	ENST00000275493	55249017	55249030
EGFR	7	R776C	missense_variant	EID4468	R776C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	R776C	EID4468:EGFR:p.R776	c.2326C>T, c.2326_2328delinsTGT	7_55249028_C_T, 7_55249028_CGC_TGT	ENST00000275493	55249022	55249036
EGFR	7	T785A	missense_variant	EID4657	T785A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	NA	NA	Erlotinib	T785A	EID4657:EGFR:p.T785	c.2353A>G, c.2353_2355delinsGCA, c.2353_2355delinsGCG, c.2353_2355delinsGCT	7_55249055_A_G, 7_55249055_ACC_GCA, 7_55249055_ACC_GCG, 7_55249055_ACC_GCT	ENST00000275493	55249049	55249063
EGFR	7	T790M	missense_variant	EID1391	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23470965' target='_blank'>Yu et al., 2013, Clin. Cancer Res.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	NA	Gefitinib, Erlotinib	T790M	EID1391:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID1397	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26181354' target='_blank'>Yu et al., 2015, JAMA Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Osimertinib	T790M	EID1397:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID1592	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26729184' target='_blank'>Greig, 2016, Drugs</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	NA	Osimertinib	T790M	EID1592:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID1667	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27304188' target='_blank'>Belchis et al., 2016, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Gefitinib, Erlotinib, Afatinib	T790M	EID1667:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID1863	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24035188' target='_blank'>Sun et al., 2013, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Afatinib	T790M	EID1863:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID1867	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27959700' target='_blank'>Mok et al., 2016, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	NA	Osimertinib	T790M	EID1867:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID2157	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26269204' target='_blank'>Planchard et al., 2015, Ann. Oncol.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Osimertinib	T790M	EID2157:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID2158	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15737014' target='_blank'>Pao et al., 2005, PLoS Med.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	T790M	EID2158:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID2159	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17020982' target='_blank'>Kosaka et al., 2006, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	T790M	EID2159:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID2160	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Lapatinib	T790M	EID2160:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID2161	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18089823' target='_blank'>Engelman et al., 2007, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	PF 00299804	T790M	EID2161:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID2162	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16818618' target='_blank'>Shimamura et al., 2006, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Neratinib	T790M	EID2162:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID2163	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Afatinib	T790M	EID2163:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID2164	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21732342' target='_blank'>Cha et al., 2012, Int. J. Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Afatinib	T790M	EID2164:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID2165	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Canertinib	T790M	EID2165:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID238	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25668228' target='_blank'>Denis et al., 2015, Clin. Chim. Acta</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	NA	Erlotinib	T790M	EID238:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID239	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15728811' target='_blank'>Kobayashi et al., 2005, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Gefitinib	T790M	EID239:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID240	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21430269' target='_blank'>Sequist et al., 2011, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Dacomitinib	T790M	EID240:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID277	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24636847' target='_blank'>Li et al., 2014, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib, Pemetrexed	T790M	EID277:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID278	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24658966' target='_blank'>Ai et al., 2014, Amino Acids</a>	Non-small Cell Lung Carcinoma	Predictive	E: Indirect evidence	DOID:3908	NA	NA	Staurosporine	T790M	EID278:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID369	T790M	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24623981' target='_blank'>Ding et al., 2014, Onco Targets Ther</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	NA	NA	T790M	EID369:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID370	T790M	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24729716' target='_blank'>Li et al., 2014, Onco Targets Ther</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	NA	NA	T790M	EID370:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID642	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18227510' target='_blank'>Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A.</a>	Lung Cancer	Predictive	D: Preclinical evidence	DOID:1324	NA	NA	Gefitinib, AEE788	T790M	EID642:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID646	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25923550' target='_blank'>Sequist et al., 2015, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Rociletinib	T790M	EID646:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID762	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24065731' target='_blank'>Walter et al., 2013, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Rociletinib	T790M	EID762:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID963	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24893891' target='_blank'>Cross et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Osimertinib	T790M	EID963:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID965	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25923549' target='_blank'>Jänne et al., 2015, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Osimertinib	T790M	EID965:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID966	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26720284' target='_blank'>Sequist et al., 2016, JAMA Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Osimertinib	T790M	EID966:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	T790M	missense_variant	EID967	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26515464' target='_blank'>Hirano et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Osimertinib, Rociletinib	T790M	EID967:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	55249065	55249077
EGFR	7	L792P	missense_variant	EID4220	L747P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib	L747P	EID4220:EGFR:p.L792	c.2375T>C, c.2375_2376delinsCA, c.2375_2376delinsCG, c.2375_2376delinsCT	7_55249077_T_C, 7_55249077_TC_CA, 7_55249077_TC_CG, 7_55249077_TC_CT	ENST00000275493	55249071	55249084
EGFR	7	C797S	missense_variant	EID1396	C797S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26181354' target='_blank'>Yu et al., 2015, JAMA Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Osimertinib	C797S	EID1396:EGFR:p.C797	c.2389T>A	7_55249091_T_A	ENST00000275493	55249085	55249097
EGFR	7	C797S	missense_variant	EID964	C797S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25939061' target='_blank'>Thress et al., 2015, Nat. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Osimertinib	C797S	EID964:EGFR:p.C797	c.2389T>A	7_55249091_T_A	ENST00000275493	55249085	55249097
EGFR	7	C797Y	missense_variant	EID4658	C797Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	NA	NA	Erlotinib	C797Y	EID4658:EGFR:p.C797	c.2390G>A	7_55249092_G_A	ENST00000275493	55249086	55249098
EGFR	7	Y801H	missense_variant	EID4659	Y801H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	NA	NA	Erlotinib	Y801H	EID4659:EGFR:p.Y801	c.2401T>C, c.2401_2403delinsCAC	7_55249103_T_C, 7_55249103_TAT_CAC	ENST00000275493	55249097	55249111
EGFR	7	K806E	missense_variant	EID4239	K806E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	K806E	EID4239:EGFR:p.K806	c.2416A>G	7_55249118_A_G	ENST00000275493	55249112	55249124
EGFR	7	V819M	missense_variant	EID4231	V774M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib	V774M	EID4231:EGFR:p.V819	c.2455G>A	7_55249157_G_A	ENST00000275493	55249151	55249163
EGFR	7	V819A	missense_variant	EID4226	V774A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	V774A	EID4226:EGFR:p.V819	c.2456T>C, c.2456_2457inv, c.2456_2457delinsCT, c.2456_2457delinsCC	7_55249158_T_C, 7_55249158_TG_CA, 7_55249158_TG_CT, 7_55249158_TG_CC	ENST00000275493	55249152	55249165
EGFR	7	N826S	missense_variant	EID4496	N826S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	N826S	EID4496:EGFR:p.N826	c.2476_2477delinsTC, c.2476_2478delinsTCA, c.2476_2478delinsTCG, c.2476_2478delinsTCT, c.2477A>G, c.2477_2478inv	7_55259418_AA_TC, 7_55259418_AAC_TCA, 7_55259418_AAC_TCG, 7_55259418_AAC_TCT, 7_55259419_A_G, 7_55259419_AC_GT	ENST00000275493	55259412	55259426
EGFR	7	N826Y	missense_variant	EID4244	N826Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib	N826Y	EID4244:EGFR:p.N826	c.2476A>T, c.2476_2478delinsTAT	7_55259418_A_T, 7_55259418_AAC_TAT	ENST00000275493	55259412	55259426
EGFR	7	R831H	missense_variant	EID4279	R831H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	NA	NA	Erlotinib	R831H	EID4279:EGFR:p.R831	c.2492G>A	7_55259434_G_A	ENST00000275493	55259428	55259440
EGFR	7	V834I	missense_variant	EID4248	V834I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	V834I	EID4248:EGFR:p.V834	c.2500_2502delinsATA, c.2500_2502delinsATC, c.2500_2502delinsATT	7_55259442_GTG_ATA, 7_55259442_GTG_ATC, 7_55259442_GTG_ATT	ENST00000275493	55259436	55259450
EGFR	7	L838V	missense_variant	EID4280	L838V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	L838V	EID4280:EGFR:p.L838	c.2512C>G, c.2512_2514delinsGTC, c.2512_2514delinsGTA, c.2512_2514delinsGTT	7_55259454_C_G, 7_55259454_CTG_GTC, 7_55259454_CTG_GTA, 7_55259454_CTG_GTT	ENST00000275493	55259448	55259462
EGFR	7	L838P	missense_variant	EID4252	L838P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	L838P	EID4252:EGFR:p.L838	c.2513T>C, c.2513_2514delinsCC, c.2513_2514inv, c.2513_2514delinsCT	7_55259455_T_C, 7_55259455_TG_CC, 7_55259455_TG_CA, 7_55259455_TG_CT	ENST00000275493	55259449	55259462
EGFR	7	N842S	missense_variant	EID4256	N842S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	N842S	EID4256:EGFR:p.N842	c.2524_2525delinsTC, c.2524_2526delinsTCG, c.2524_2526delinsTCT, c.2524_2526delinsTCA, c.2525A>G, c.2525_2526inv	7_55259466_AA_TC, 7_55259466_AAC_TCG, 7_55259466_AAC_TCT, 7_55259466_AAC_TCA, 7_55259467_A_G, 7_55259467_AC_GT	ENST00000275493	55259460	55259474
EGFR	7	T847I	missense_variant	EID4260	T847I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	T847I	EID4260:EGFR:p.T847	c.2540C>T, c.2540_2541delinsTT, c.2540_2541delinsTC	7_55259482_C_T, 7_55259482_CA_TT, 7_55259482_CA_TC	ENST00000275493	55259476	55259489
EGFR	7	V851I	missense_variant	EID4264	V851I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib	V851I	EID4264:EGFR:p.V851	c.2551G>A, c.2551_2553delinsATA, c.2551_2553delinsATT	7_55259493_G_A, 7_55259493_GTC_ATA, 7_55259493_GTC_ATT	ENST00000275493	55259487	55259501
EGFR	7	L858R	missense_variant	EID1665	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18509184' target='_blank'>Yang et al., 2008, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Gefitinib	L858R	EID1665:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID229	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24736073' target='_blank'>Lim et al., 2014, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Gefitinib, Erlotinib	L858R	EID229:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2621	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20038723' target='_blank'>Douillard et al., 2010, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Gefitinib	L858R	EID2621:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2624	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15329413' target='_blank'>Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Gefitinib	L858R	EID2624:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2625	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24893891' target='_blank'>Cross et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Gefitinib	L858R	EID2625:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2626	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Lapatinib	L858R	EID2626:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2627	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18089823' target='_blank'>Engelman et al., 2007, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	PF 00299804	L858R	EID2627:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2628	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16818618' target='_blank'>Shimamura et al., 2006, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Neratinib	L858R	EID2628:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2629	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Afatinib	L858R	EID2629:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2631	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Canertinib	L858R	EID2631:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2632	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15329413' target='_blank'>Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib	L858R	EID2632:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2634	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22370314' target='_blank'>Han et al., 2012, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	NA	Gefitinib	L858R	EID2634:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID275	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24457318' target='_blank'>Fukihara et al., 2014, Oncology</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Gefitinib, Erlotinib	L858R	EID275:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID276	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15118125' target='_blank'>Paez et al., 2004, Science</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Gefitinib	L858R	EID276:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2994	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24868098' target='_blank'>Khozin et al., 2014, Oncologist</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	NA	Erlotinib	L858R	EID2994:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID2997	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23982599' target='_blank'>Dungo et al., 2013, Drugs</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	NA	Afatinib	L858R	EID2997:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID347	L858R	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24662454' target='_blank'>Douillard et al., 2014, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	NA	NA	L858R	EID347:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID3811	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Gefitinib, Erlotinib, AEE788	L858R	EID3811:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4265	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17877814' target='_blank'>de Gunst et al., 2007, Mol. Cancer</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Erlotinib	L858R	EID4265:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4284	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	L858R	EID4284:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4285	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21132006' target='_blank'>Harada et al., 2011, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	L858R	EID4285:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4286	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	L858R	EID4286:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4287	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27612423' target='_blank'>Ray et al., 2016, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	L858R	EID4287:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4288	L858R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22235099' target='_blank'>Doebele et al., 2012, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Crizotinib	L858R	EID4288:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4290	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27032107' target='_blank'>De Grève et al., 2016, PLoS ONE</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	NA	Erlotinib	L858R	EID4290:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4291	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27102076' target='_blank'>Konduri et al., 2016, Cancer Discov</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	NA	NA	Erlotinib	L858R	EID4291:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4292	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27102076' target='_blank'>Konduri et al., 2016, Cancer Discov</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	NA	NA	Cetuximab	L858R	EID4292:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4295	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	NA	NA	Erlotinib	L858R	EID4295:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID4860	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26768165' target='_blank'>Ramalingam et al., 2016, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Dacomitinib	L858R	EID4860:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID6183	L858R	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27022112' target='_blank'>Urata et al., 2016, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	NA	Gefitinib	L858R	EID6183:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID879	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23816960' target='_blank'>Sequist et al., 2013, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	NA	Afatinib	L858R	EID879:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID883	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22452895' target='_blank'>Yang et al., 2012, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	NA	Afatinib	L858R	EID883:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID885	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22285168' target='_blank'>Rosell et al., 2012, Lancet Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Erlotinib	L858R	EID885:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID968	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26515464' target='_blank'>Hirano et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Afatinib	L858R	EID968:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L858R	missense_variant	EID982	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24439929' target='_blank'>Wu et al., 2014, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	NA	Afatinib	L858R	EID982:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	55259509	55259521
EGFR	7	L861R	missense_variant	EID4669	L861R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	L861R	EID4669:EGFR:p.L861	c.2581_2582inv, c.2581_2583delinsAGA, c.2582T>G, c.2582_2583delinsGA, c.2582_2583delinsGT, c.2582_2583delinsGC	7_55259523_CT_AG, 7_55259523_CTG_AGA, 7_55259524_T_G, 7_55259524_TG_GA, 7_55259524_TG_GT, 7_55259524_TG_GC	ENST00000275493	55259517	55259531
EGFR	7	L861Q	missense_variant	EID3802	L861Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	L861Q	EID3802:EGFR:p.L861	c.2582T>A, c.2582_2583delinsAA	7_55259524_T_A, 7_55259524_TG_AA	ENST00000275493	55259518	55259531
EGFR	7	L861Q	missense_variant	EID4299	L861Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	NA	NA	Erlotinib	L861Q	EID4299:EGFR:p.L861	c.2582T>A, c.2582_2583delinsAA	7_55259524_T_A, 7_55259524_TG_AA	ENST00000275493	55259518	55259531
EGFR	7	A864T	missense_variant	EID4495	A864T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	A864T	EID4495:EGFR:p.A864	c.2590G>A	7_55259532_G_A	ENST00000275493	55259526	55259538
EGFR	7	E868G	missense_variant	EID4301	E868G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	NA	NA	Erlotinib	E868G	EID4301:EGFR:p.E868	c.2603A>G, c.2603_2604delinsGT, c.2603_2604delinsGG, c.2603_2604delinsGC	7_55259545_A_G, 7_55259545_AA_GT, 7_55259545_AA_GG, 7_55259545_AA_GC	ENST00000275493	55259539	55259552
EGFR	7	L883P	missense_variant	EID4252	L838P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	L838P	EID4252:EGFR:p.L883	c.2647_2648delinsCC, c.2647_2649delinsCCT, c.2647_2649delinsCCA, c.2647_2649delinsCCC	7_55260480_TT_CC, 7_55260480_TTG_CCT, 7_55260480_TTG_CCA, 7_55260480_TTG_CCC	ENST00000275493	55260474	55260488
EGFR	7	L883V	missense_variant	EID4280	L838V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Erlotinib	L838V	EID4280:EGFR:p.L883	c.2647T>G, c.2647_2649delinsGTT, c.2647_2649delinsGTA, c.2647_2649delinsGTC	7_55260480_T_G, 7_55260480_TTG_GTT, 7_55260480_TTG_GTA, 7_55260480_TTG_GTC	ENST00000275493	55260474	55260488
EGFR	7	T892I	missense_variant	EID4260	T847I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Gefitinib	T847I	EID4260:EGFR:p.T892	c.2675C>T, c.2675_2676delinsTA, c.2675_2676delinsTT	7_55260508_C_T, 7_55260508_CC_TA, 7_55260508_CC_TT	ENST00000275493	55260502	55260515
EGFR	7	V904I	missense_variant	EID4264	V851I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Erlotinib	V851I	EID4264:EGFR:p.V904	c.2710G>A, c.2710_2712delinsATA, c.2710_2712delinsATC	7_55266418_G_A, 7_55266418_GTT_ATA, 7_55266418_GTT_ATC	ENST00000275493	55266412	55266426
MET	7	D1246N	missense_variant	EID1652	D1228N	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27343442' target='_blank'>Heist et al., 2016, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Crizotinib	D1228N	EID1652:MET:p.D1246	c.3736G>A	7_116423407_G_A	ENST00000318493	116423401	116423413
MET	7	D1246V	missense_variant	EID1864	D1228V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27694386' target='_blank'>Bahcall et al., 2016, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Cabozantinib	D1228V	EID1864:MET:p.D1246	c.3737A>T	7_116423408_A_T	ENST00000318493	116423402	116423414
MET	7	D1246V	missense_variant	EID1865	D1228V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27694386' target='_blank'>Bahcall et al., 2016, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Savolitinib	D1228V	EID1865:MET:p.D1246	c.3737A>T	7_116423408_A_T	ENST00000318493	116423402	116423414
SMO	7	L412F	missense_variant	EID4653	L412F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25759020' target='_blank'>Atwood et al., 2015, Cancer Cell</a>	Basal Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:2513	NA	NA	Vismodegib	L412F	EID4653:SMO:p.L412	c.1234C>T	7_128846398_C_T	ENST00000249373	128846392	128846404
SMO	7	L412F	missense_variant	EID4654	L412F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26822128' target='_blank'>Khamaysi et al., 2016, Br. J. Dermatol.</a>	Basal Cell Carcinoma	Predictive	C: Case study	DOID:2513	NA	NA	Vismodegib	L412F	EID4654:SMO:p.L412	c.1234C>T	7_128846398_C_T	ENST00000249373	128846392	128846404
SMO	7	D473H	missense_variant	EID1099	D473H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22550175' target='_blank'>Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A.</a>	Brain Medulloblastoma	Predictive	D: Preclinical evidence	DOID:0060105	NA	NA	Saridegib	D473H	EID1099:SMO:p.D473	c.1417G>C	7_128849189_G_C	ENST00000249373	128849183	128849195
SMO	7	D473H	missense_variant	EID745	D473H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19726788' target='_blank'>Yauch et al., 2009, Science</a>	Brain Medulloblastoma	Predictive	C: Case study	DOID:0060105	NA	NA	Vismodegib	D473H	EID745:SMO:p.D473	c.1417G>C	7_128849189_G_C	ENST00000249373	128849183	128849195
SMO	7	D473H	missense_variant	EID755	D473H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25759020' target='_blank'>Atwood et al., 2015, Cancer Cell</a>	Basal Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:2513	NA	NA	Vismodegib	D473H	EID755:SMO:p.D473	c.1417G>C	7_128849189_G_C	ENST00000249373	128849183	128849195
BRAF	7	P731T	missense_variant	EID5972	P731T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Vemurafenib	P731T	EID5972:BRAF:p.P731	c.2191C>A	7_140434507_G_T	ENST00000288602	140434501	140434513
BRAF	7	G606E	missense_variant	EID5970	G606E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Vemurafenib	G606E	EID5970:BRAF:p.G606	c.1817G>A	7_140453118_C_T	ENST00000288602	140453112	140453124
BRAF	7	K601E	missense_variant	EID1462	K601E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	Trametinib, Vemurafenib	K601E	EID1462:BRAF:p.K601	c.1801A>G	7_140453134_T_C	ENST00000288602	140453128	140453140
BRAF	7	V600D	missense_variant	EID4488	V600D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18287029' target='_blank'>Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	V600D	EID4488:BRAF:p.V600	c.1799_1800delinsAT	7_140453135_CA_AT	ENST00000288602	140453129	140453142
BRAF	7	V600D	missense_variant	EID4489	V600D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20551065' target='_blank'>Yang et al., 2010, Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	V600D	EID4489:BRAF:p.V600	c.1799_1800delinsAT	7_140453135_CA_AT	ENST00000288602	140453129	140453142
BRAF	7	V600D	missense_variant	EID94	V600D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23463675' target='_blank'>Ponti et al., 2013, J. Clin. Pathol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Dabrafenib	V600D	EID94:BRAF:p.V600	c.1799_1800delinsAT	7_140453135_CA_AT	ENST00000288602	140453129	140453142
BRAF	7	V600E	missense_variant	EID6262	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Dabrafenib, Vemurafenib	V600E	EID6262:BRAF:p.V600	c.1799_1800delinsAA, c.1799T>A	7_140453135_CA_TT, 7_140453136_A_T	ENST00000288602	140453129	140453142
BRAF	7	V600E	missense_variant	EID1005	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26678033' target='_blank'>Penna et al., 2016, Oncotarget</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Selumetinib (AZD6244), BEZ235 (NVP-BEZ235, Dactolisib)	V600E	EID1005:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID102	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24354346' target='_blank'>Walczyk et al., 2014, Clin. Endocrinol. (Oxf)</a>	Thyroid Cancer	Prognostic	B: Clinical evidence	DOID:1781	NA	NA	NA	V600E	EID102:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID103	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24594804' target='_blank'>Chen et al., 2014, PLoS ONE</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	V600E	EID103:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID104	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24388723' target='_blank'>Nagore et al., 2014, J. Am. Acad. Dermatol.</a>	Melanoma	Prognostic	B: Clinical evidence	DOID:1909	NA	NA	NA	V600E	EID104:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID105	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21594703' target='_blank'>Howell et al., 2011, Ann. Surg. Oncol.</a>	Thyroid Cancer	Prognostic	B: Clinical evidence	DOID:1781	NA	NA	NA	V600E	EID105:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID106	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24396464' target='_blank'>He et al., 2014, Oncol Lett</a>	Thyroid Cancer	Prognostic	B: Clinical evidence	DOID:1781	NA	NA	NA	V600E	EID106:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID107	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21594703' target='_blank'>Howell et al., 2011, Ann. Surg. Oncol.</a>	Thyroid Cancer	Prognostic	B: Clinical evidence	DOID:1781	NA	NA	NA	V600E	EID107:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1127	V600E	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21663470' target='_blank'>Tiacci et al., 2011, N. Engl. J. Med.</a>	Hairy Cell Leukemia	Diagnostic	B: Clinical evidence	DOID:285	NA	NA	NA	V600E	EID1127:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1141	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23934108' target='_blank'>Hatzivassiliou et al., 2013, Nature</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	NA	NA	Cobimetinib	V600E	EID1141:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID126	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab	V600E	EID126:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1398	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24508103' target='_blank'>McArthur et al., 2014, Lancet Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib	V600E	EID1398:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1405	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26460303' target='_blank'>Kopetz et al., 2015, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Vemurafenib	V600E	EID1405:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1406	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22608338' target='_blank'>Falchook et al., 2012, Lancet</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Dabrafenib	V600E	EID1406:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1408	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22281684' target='_blank'>Prahallad et al., 2012, Nature</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Vemurafenib, Gefitinib, Cetuximab	V600E	EID1408:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1409	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21639808' target='_blank'>Chapman et al., 2011, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	A: Validated	DOID:8923	NA	NA	Vemurafenib	V600E	EID1409:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1410	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22356324' target='_blank'>Sosman et al., 2012, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	B: Clinical evidence	DOID:8923	NA	NA	Vemurafenib	V600E	EID1410:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1411	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25399551' target='_blank'>Robert et al., 2015, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	A: Validated	DOID:8923	NA	NA	Trametinib, Dabrafenib	V600E	EID1411:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1413	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25589621' target='_blank'>Yaeger et al., 2015, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Vemurafenib, Panitumumab	V600E	EID1413:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1414	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24987354' target='_blank'>Ali et al., 2014, Case Rep Oncol</a>	Papillary Thyroid Carcinoma	Predictive	C: Case study	DOID:3969	NA	NA	Vemurafenib	V600E	EID1414:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1421	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25265494' target='_blank'>Larkin et al., 2014, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib, Cobimetinib	V600E	EID1421:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1428	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23549875' target='_blank'>Coffee et al., 2013, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	BEZ235 (NVP-BEZ235, Dactolisib), GDC-0879	V600E	EID1428:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1430	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27048246' target='_blank'>Klempner et al., 2016, Cancer Discov</a>	Gastrointestinal Neuroendocrine Tumor	Predictive	C: Case study	DOID:0050626	NA	NA	Dabrafenib, Trametinib, Vemurafenib	V600E	EID1430:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1552	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27404270' target='_blank'>Amaki-Takao et al., 2016, Oncology</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	V600E	EID1552:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1579	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26352686' target='_blank'>Tiacci et al., 2015, N. Engl. J. Med.</a>	Hairy Cell Leukemia	Predictive	B: Clinical evidence	DOID:285	NA	NA	Vemurafenib	V600E	EID1579:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1589	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27325282' target='_blank'>Pietrantonio et al., 2016, Cancer Discov</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Vemurafenib, Panitumumab	V600E	EID1589:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1591	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27460442' target='_blank'>Brose et al., 2016, Lancet Oncol.</a>	Papillary Thyroid Carcinoma	Predictive	B: Clinical evidence	DOID:3969	NA	NA	Vemurafenib	V600E	EID1591:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1698	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24997557' target='_blank'>Sharman et al., 2014, Clin Lymphoma Myeloma Leuk</a>	Multiple Myeloma	Predictive	C: Case study	DOID:9538	NA	NA	Vemurafenib	V600E	EID1698:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1699	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24997557' target='_blank'>Sharman et al., 2014, Clin Lymphoma Myeloma Leuk</a>	Multiple Myeloma	Predictive	C: Case study	DOID:9538	NA	NA	Vemurafenib	V600E	EID1699:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1749	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20818844' target='_blank'>Flaherty et al., 2010, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib	V600E	EID1749:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1902	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27729313' target='_blank'>Hong et al., 2016, Cancer Discov</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Vemurafenib, Cetuximab, Irinotecan	V600E	EID1902:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID1940	V600E	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27302369' target='_blank'>Schell et al., 2016, Nat Commun</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	V600E	EID1940:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID2115	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19001320' target='_blank'>Di Nicolantonio et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Panitumumab, Cetuximab	V600E	EID2115:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID2117	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Oxaliplatin	V600E	EID2117:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID2118	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Irinotecan	V600E	EID2118:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID2121	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19571295' target='_blank'>Tol et al., 2009, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Bevacizumab	V600E	EID2121:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID2135	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22663011' target='_blank'>Flaherty et al., 2012, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Trametinib	V600E	EID2135:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID2503	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21882184' target='_blank'>Kim et al., 2012, Cancer</a>	Thyroid Cancer	Predictive	B: Clinical evidence	DOID:1781	NA	NA	Sorafenib	V600E	EID2503:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID3017	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27283860' target='_blank'>Planchard et al., 2016, Lancet Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	NA	Dabrafenib, Trametinib	V600E	EID3017:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID3739	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25666295' target='_blank'>Kaczirek et al., 2015, Clin Colorectal Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab	V600E	EID3739:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID3750	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23569304' target='_blank'>Trunzer et al., 2013, J. Clin. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib	V600E	EID3750:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID3755	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26557775' target='_blank'>Rutkowski et al., 2015, Contemp Oncol (Pozn)</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib	V600E	EID3755:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID3757	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25524477' target='_blank'>Ugurel et al., 2015, Ann. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib	V600E	EID3757:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID3758	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25399551' target='_blank'>Robert et al., 2015, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	B: Clinical evidence	DOID:8923	NA	NA	Dabrafenib, Trametinib	V600E	EID3758:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID3777	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25524464' target='_blank'>del Bufalo et al., 2014, J Transl Med</a>	Ganglioglioma	Predictive	C: Case study	DOID:5078	NA	NA	Vemurafenib	V600E	EID3777:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID3787	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26490654' target='_blank'>Combe et al., 2015, Invest New Drugs</a>	Ovarian Cystadenocarcinoma	Predictive	C: Case study	DOID:3605	NA	NA	Vemurafenib	V600E	EID3787:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID463	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23612012' target='_blank'>Andrulis et al., 2013, Cancer Discov</a>	Myeloma	Prognostic	B: Clinical evidence	DOID:0070004	NA	NA	NA	V600E	EID463:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID5902	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28480077' target='_blank'>Kocsis et al., 2017, J Gastrointest Oncol</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	NA	NA	Dabrafenib, Trametinib DMSO	V600E	EID5902:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID5903	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28078132' target='_blank'>Lavingia et al., 2016, J Gastrointest Oncol</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	NA	NA	Dabrafenib, Trametinib DMSO	V600E	EID5903:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID5904	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25435907' target='_blank'>Loaiza-Bonilla et al., 2014, Ecancermedicalscience</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	NA	NA	Dabrafenib, Trametinib DMSO	V600E	EID5904:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID5906	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26687137' target='_blank'>Silkin et al., 2016, J Gastrointest Cancer</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	NA	NA	Vemurafenib, Panitumumab, Irinotecan	V600E	EID5906:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID5958	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	NA	Vemurafenib	V600E	EID5958:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID5959	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Ovarian Cancer	Predictive	B: Clinical evidence	DOID:2394	NA	NA	Vemurafenib	V600E	EID5959:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID5960	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Vemurafenib	V600E	EID5960:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID5962	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Laryngeal Squamous Cell Carcinoma	Predictive	C: Case study	DOID:2876	NA	NA	Vemurafenib	V600E	EID5962:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID6045	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Anaplastic Thyroid Cancer	Predictive	B: Clinical evidence	NA	NA	NA	Vemurafenib	V600E	EID6045:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID6123	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29431699' target='_blank'>Corcoran et al., 2018, Cancer Discov</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Dabrafenib, Panitumumab, Trametinib	V600E	EID6123:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID6124	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29431699' target='_blank'>Corcoran et al., 2018, Cancer Discov</a>	Colorectal Adenocarcinoma	Predictive	B: Clinical evidence	DOID:0050861	NA	NA	Trametinib, Panitumumab	V600E	EID6124:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID6178	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28891408' target='_blank'>Long et al., 2017, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Dabrafenib, Trametinib	V600E	EID6178:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID656	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25024077' target='_blank'>Xing et al., 2014, J. Clin. Oncol.</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	NA	NA	NA	V600E	EID656:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID757	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25370471' target='_blank'>Sarker et al., 2015, Clin. Cancer Res.</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Pictilisib	V600E	EID757:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID79	V600E	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21594703' target='_blank'>Howell et al., 2011, Ann. Surg. Oncol.</a>	Thyroid Cancer	Diagnostic	B: Clinical evidence	DOID:1781	NA	NA	NA	V600E	EID79:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID80	V600E	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24570209' target='_blank'>Crescenzi et al., 2014, Horm. Metab. Res.</a>	Thyroid Cancer	Diagnostic	B: Clinical evidence	DOID:1781	NA	NA	NA	V600E	EID80:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID816	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25989278' target='_blank'>Rowland et al., 2015, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Cetuximab, Panitumumab	V600E	EID816:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID86	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24576830' target='_blank'>Nissan et al., 2014, Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Trametinib, PD0325901	V600E	EID86:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID89	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19001320' target='_blank'>Di Nicolantonio et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Sorafenib, Panitumumab	V600E	EID89:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID90	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24576830' target='_blank'>Nissan et al., 2014, Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	V600E	EID90:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID91	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23524406' target='_blank'>Rudin et al., 2013, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Dabrafenib	V600E	EID91:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID95	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24583796' target='_blank'>Menzies et al., 2014, Clin. Cancer Res.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Dabrafenib, Trametinib	V600E	EID95:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID96	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23845441' target='_blank'>Rad et al., 2013, Cancer Cell</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	PLX4720, GDC0941	V600E	EID96:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID97	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23812671' target='_blank'>Ji et al., 2013, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	PLX4720, Nutlin-3	V600E	EID97:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID98	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22180495' target='_blank'>Yang et al., 2012, Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Capecitabine, Vemurafenib, Bevacizumab	V600E	EID98:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600E	missense_variant	EID99	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22180495' target='_blank'>Yang et al., 2012, Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	NA	NA	Vemurafenib	V600E	EID99:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	140453130	140453142
BRAF	7	V600K	missense_variant	EID1399	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24508103' target='_blank'>McArthur et al., 2014, Lancet Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib	V600K	EID1399:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	140453130	140453143
BRAF	7	V600K	missense_variant	EID1400	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26989536' target='_blank'>Sahadudheen et al., 2016, Case Rep Oncol Med</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Vemurafenib	V600K	EID1400:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	140453130	140453143
BRAF	7	V600K	missense_variant	EID1422	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25265494' target='_blank'>Larkin et al., 2014, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib, Cobimetinib	V600K	EID1422:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	140453130	140453143
BRAF	7	V600K	missense_variant	EID2505	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21343559' target='_blank'>Long et al., 2011, J. Clin. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Dabrafenib	V600K	EID2505:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	140453130	140453143
BRAF	7	V600K	missense_variant	EID2506	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22663011' target='_blank'>Flaherty et al., 2012, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Trametinib	V600K	EID2506:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	140453130	140453143
BRAF	7	V600K	missense_variant	EID4180	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25524477' target='_blank'>Ugurel et al., 2015, Ann. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib	V600K	EID4180:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	140453130	140453143
BRAF	7	V600K	missense_variant	EID4181	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25399551' target='_blank'>Robert et al., 2015, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	B: Clinical evidence	DOID:8923	NA	NA	Trametinib, Dabrafenib	V600K	EID4181:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	140453130	140453143
BRAF	7	V600K	missense_variant	EID6179	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28891408' target='_blank'>Long et al., 2017, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Dabrafenib, Trametinib	V600K	EID6179:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	140453130	140453143
BRAF	7	NA	NA	EID88	V600	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23325582' target='_blank'>Peeters et al., 2013, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Panitumumab	V600	EID88:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID93	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23020132' target='_blank'>Flaherty et al., 2012, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib, Trametinib	V600	EID93:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID994	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24947927' target='_blank'>Zimmer et al., 2014, Clin. Cancer Res.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	RO4987655	V600	EID994:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1407	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22608338' target='_blank'>Falchook et al., 2012, Lancet</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib	V600	EID1407:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1415	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26392102' target='_blank'>Corcoran et al., 2015, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Dabrafenib, Trametinib	V600	EID1415:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1000	V600	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23434733' target='_blank'>Weekes et al., 2013, Clin. Cancer Res.</a>	Melanoma	Predictive	C: Case study	DOID:1909	600	NA	BAY 86-9766	V600	EID1000:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1574	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	600	NA	Vemurafenib	V600	EID1574:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1575	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Langerhans-Cell Histiocytosis	Predictive	B: Clinical evidence	DOID:2571	600	NA	Vemurafenib	V600	EID1575:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1576	V600	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Vemurafenib	V600	EID1576:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1598	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Cetuximab, Vemurafenib	V600	EID1598:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1750	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22663011' target='_blank'>Flaherty et al., 2012, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib	V600	EID1750:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID5905	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Cholangiocarcinoma	Predictive	B: Clinical evidence	DOID:4947	600	NA	Vemurafenib	V600	EID5905:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6044	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27480103' target='_blank'>Ascierto et al., 2016, Lancet Oncol.</a>	Melanoma	Predictive	A: Validated	DOID:1909	600	NA	Cobimetinib, Vemurafenib	V600	EID6044:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6046	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28363909' target='_blank'>van Geel et al., 2017, Cancer Discov</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Encorafenib, Cetuximab	V600	EID6046:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6047	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28363909' target='_blank'>van Geel et al., 2017, Cancer Discov</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Encorafenib, Cetuximab, Alpelisib	V600	EID6047:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6180	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28891408' target='_blank'>Long et al., 2017, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib, Dabrafenib	V600	EID6180:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID30	V600	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21166657' target='_blank'>Lee et al., 2011, Br. J. Dermatol.</a>	Melanoma	Diagnostic	B: Clinical evidence	DOID:1909	600	NA	NA	V600	EID30:BRAF:p.V600	NA	NA	NA	140453135	140453137
BRAF	7	L597Q	missense_variant	EID1461	L597Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	Trametinib, Vemurafenib	L597Q	EID1461:BRAF:p.L597	c.1790T>A	7_140453145_A_T	ENST00000288602	140453139	140453151
BRAF	7	L597Q	missense_variant	EID4905	L597Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24933606' target='_blank'>Bowyer et al., 2014, Melanoma Res.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	NA	NA	Trametinib	L597Q	EID4905:BRAF:p.L597	c.1790T>A	7_140453145_A_T	ENST00000288602	140453139	140453151
BRAF	7	L597Q	missense_variant	EID5971	L597Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Vemurafenib	L597Q	EID5971:BRAF:p.L597	c.1790T>A	7_140453145_A_T	ENST00000288602	140453139	140453151
BRAF	7	L597R	missense_variant	EID1458	L597R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	Trametinib, Vemurafenib	L597R	EID1458:BRAF:p.L597	c.1790T>G	7_140453145_A_C	ENST00000288602	140453139	140453151
BRAF	7	L597R	missense_variant	EID728	L597R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23715574' target='_blank'>Bahadoran et al., 2013, J. Clin. Oncol.</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Vemurafenib	L597R	EID728:BRAF:p.L597	c.1790T>G	7_140453145_A_C	ENST00000288602	140453139	140453151
BRAF	7	L597S	missense_variant	EID1459	L597S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	Trametinib, Vemurafenib	L597S	EID1459:BRAF:p.L597	c.1789_1790delinsTC	7_140453145_AG_GA	ENST00000288602	140453139	140453152
BRAF	7	L597S	missense_variant	EID1460	L597S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	NA	NA	TAK-733	L597S	EID1460:BRAF:p.L597	c.1789_1790delinsTC	7_140453145_AG_GA	ENST00000288602	140453139	140453152
BRAF	7	L597V	missense_variant	EID1463	L597V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22805292' target='_blank'>Falchook et al., 2012, Lancet Oncol.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	NA	NA	Trametinib	L597V	EID1463:BRAF:p.L597	c.1789C>G	7_140453146_G_C	ENST00000288602	140453140	140453152
BRAF	7	G596C	missense_variant	EID1738	G596C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27577079' target='_blank'>Noeparast et al., 2016, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Trametinib, Dabrafenib	G596C	EID1738:BRAF:p.G596	c.1786G>T	7_140453149_C_A	ENST00000288602	140453143	140453155
BRAF	7	G596R	missense_variant	EID5969	G596R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Vemurafenib	G596R	EID5969:BRAF:p.G596	c.1786G>C	7_140453149_C_G	ENST00000288602	140453143	140453155
BRAF	7	D594K	missense_variant	EID6402	D594K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Irinotecan	D594K	EID6402:BRAF:p.D594	c.1780_1782delinsAAG, c.1780_1782delinsAAA	7_140453153_ATC_CTT, 7_140453153_ATC_TTT	ENST00000288602	140453147	140453161
BRAF	7	D594K	missense_variant	EID6403	D594K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	NA	Oxaliplatin	D594K	EID6403:BRAF:p.D594	c.1780_1782delinsAAG, c.1780_1782delinsAAA	7_140453153_ATC_CTT, 7_140453153_ATC_TTT	ENST00000288602	140453147	140453161
BRAF	7	D594A	missense_variant	EID1454	D594A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20141835' target='_blank'>Heidorn et al., 2010, Cell</a>	Skin Melanoma	Predictive	E: Indirect evidence	DOID:8923	NA	NA	MEK Inhibitor, Sorafenib	D594A	EID1454:BRAF:p.D594	c.1781A>C	7_140453154_T_G	ENST00000288602	140453148	140453160
BRAF	7	D594G	missense_variant	EID1551	D594G	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27404270' target='_blank'>Amaki-Takao et al., 2016, Oncology</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	D594G	EID1551:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	140453148	140453160
BRAF	7	D594G	missense_variant	EID1553	D594G	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27404270' target='_blank'>Amaki-Takao et al., 2016, Oncology</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	NA	NA	NA	D594G	EID1553:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	140453148	140453160
BRAF	7	D594G	missense_variant	EID1554	D594G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27404270' target='_blank'>Amaki-Takao et al., 2016, Oncology</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Cetuximab, Panitumumab	D594G	EID1554:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	140453148	140453160
BRAF	7	D594G	missense_variant	EID4472	D594G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26989027' target='_blank'>Hsu et al., 2016, Oncotarget</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Cetuximab	D594G	EID4472:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	140453148	140453160
BRAF	7	D594G	missense_variant	EID6001	D594G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18794803' target='_blank'>Smalley et al., 2009, Oncogene</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	Sorafenib	D594G	EID6001:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	140453148	140453160
BRAF	7	D594V	missense_variant	EID1456	D594V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20141835' target='_blank'>Heidorn et al., 2010, Cell</a>	Skin Melanoma	Predictive	E: Indirect evidence	DOID:8923	NA	NA	Trametinib, Sorafenib	D594V	EID1456:BRAF:p.D594	c.1781A>T	7_140453154_T_A	ENST00000288602	140453148	140453160
BRAF	7	N581S	missense_variant&splice_region_variant	EID5967	N581S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Vemurafenib	N581S	EID5967:BRAF:p.N581	c.1742A>G	7_140453193_T_C	ENST00000288602	140453187	140453199
BRAF	7	L505H	missense_variant	EID1668	L505H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24112705' target='_blank'>Wagenaar et al., 2014, Pigment Cell Melanoma Res</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	NA	NA	Vemurafenib	L505H	EID1668:BRAF:p.L505	c.1514T>A	7_140477794_A_T	ENST00000288602	140477788	140477800
BRAF	7	L505H	missense_variant	EID1669	L505H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25515853' target='_blank'>Hoogstraat et al., 2015, Pigment Cell Melanoma Res</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	NA	Vemurafenib	L505H	EID1669:BRAF:p.L505	c.1514T>A	7_140477794_A_T	ENST00000288602	140477788	140477800
BRAF	7	K483M	missense_variant	EID1457	K483M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20141835' target='_blank'>Heidorn et al., 2010, Cell</a>	Skin Melanoma	Predictive	E: Indirect evidence	DOID:8923	NA	NA	MEK Inhibitor, Sorafenib	K483M	EID1457:BRAF:p.K483	c.1448_1449delinsTG	7_140477859_TT_CA	ENST00000288602	140477853	140477866
BRAF	7	G469A	missense_variant	EID5965	G469A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Vemurafenib	G469A	EID5965:BRAF:p.G469	c.1406G>C	7_140481402_C_G	ENST00000288602	140481396	140481408
BRAF	7	G469E	missense_variant	EID6003	G469E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18794803' target='_blank'>Smalley et al., 2009, Oncogene</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	Sorafenib	G469E	EID6003:BRAF:p.G469	c.1406G>A	7_140481402_C_T	ENST00000288602	140481396	140481408
BRAF	7	G466V	missense_variant	EID5968	G466V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Vemurafenib	G466V	EID5968:BRAF:p.G466	c.1397G>T	7_140481411_C_A	ENST00000288602	140481405	140481417
BRAF	7	G464V	missense_variant	EID5964	G464V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	NA	NA	Vemurafenib	G464V	EID5964:BRAF:p.G464	c.1391G>T	7_140481417_C_A	ENST00000288602	140481411	140481423
EZH2	7	NA	NA	EID1494	Y646	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26304929' target='_blank'>Tiffen et al., 2015, Oncotarget</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	646	NA	GSK126	Y646	EID1494:EZH2:p.Y646	NA	NA	NA	148508725	148508728
EZH2	7	NA	NA	EID433	Y646	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20081860' target='_blank'>Morin et al., 2010, Nat. Genet.</a>	Follicular Lymphoma	Diagnostic	B: Clinical evidence	DOID:0050873	646	NA	NA	Y646	EID433:EZH2:p.Y646	NA	NA	NA	148508725	148508728
EZH2	7	NA	NA	EID432	Y646	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20081860' target='_blank'>Morin et al., 2010, Nat. Genet.</a>	Diffuse Large B-cell Lymphoma	Diagnostic	B: Clinical evidence	DOID:0050745	646	NA	NA	Y646	EID432:EZH2:p.Y646	NA	NA	NA	148508725	148508728
FGFR1	8	N577K	missense_variant	EID1246	N546K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26179511' target='_blank'>Agelopoulos et al., 2015, Clin. Cancer Res.</a>	Bone Ewing's Sarcoma	Predictive	E: Indirect evidence	DOID:3368	NA	NA	Ponatinib	N546K	EID1246:FGFR1:p.N577	c.1731C>A	8_38274849_G_T	ENST00000425967	38274843	38274855
PREX2	8	R172I	missense_variant	EID6268	R172I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Vemurafenib	R172I	EID6268:PREX2:p.R172	c.515G>T, c.515_516delinsTT, c.515_516inv	8_68939530_G_T, 8_68939530_GA_TT, 8_68939530_GA_TC	ENST00000288368	68939524	68939537
JAK2	9	.	splice_donor_variant	EID1568	Exon 12 splice site insertion	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27433843' target='_blank'>Zaretsky et al., 2016, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	NA	NA	Pembrolizumab	Exon 12 splice site insertion	EID1568:JAK2:c.1641+1dup	c.1641+1dup	9_5070053_G_GG	ENST00000381652	5070047	5070060
JAK2	9	.	splice_donor_variant	EID4825	F547 SPLICE SITE MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27433843' target='_blank'>Zaretsky et al., 2016, N. Engl. J. Med.</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Pembrolizumab	F547 SPLICE SITE MUTATION	EID4825:JAK2:c.1641+2T>G	c.1641+2T>G	9_5070054_T_G	ENST00000381652	5070048	5070060
JAK2	9	V617F	missense_variant	EID1	V617F	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16081687' target='_blank'>Levine et al., 2005, Blood</a>	Lymphoid Leukemia	Diagnostic	B: Clinical evidence	DOID:10747	NA	NA	NA	V617F	EID1:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	5073764	5073776
JAK2	9	V617F	missense_variant	EID19	V617F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16709929' target='_blank'>Kiladjian et al., 2006, Blood</a>	Polycythemia Vera	Predictive	B: Clinical evidence	DOID:8997	NA	NA	Pegylated IFN-alpha-2a	V617F	EID19:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	5073764	5073776
JAK2	9	V617F	missense_variant	EID20	V617F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18394554' target='_blank'>Wernig et al., 2008, Cancer Cell</a>	Polycythemia Vera	Predictive	D: Preclinical evidence	DOID:8997	NA	NA	TG101348	V617F	EID20:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	5073764	5073776
JAK2	9	V617F	missense_variant	EID5	V617F	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16081687' target='_blank'>Levine et al., 2005, Blood</a>	Chronic Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:8552	NA	NA	NA	V617F	EID5:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	5073764	5073776
JAK2	9	V617F	missense_variant	EID7	V617F	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19287384' target='_blank'>Kilpivaara et al., 2009, Nat. Genet.</a>	Bone Marrow Cancer	Diagnostic	B: Clinical evidence	DOID:4960	NA	NA	NA	V617F	EID7:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	5073764	5073776
CDKN2A	9	.	upstream_gene_variant	EID1635	RS3814960	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27414035' target='_blank'>Li et al., 2016, PLoS ONE</a>	Esophagus Squamous Cell Carcinoma	Prognostic	B: Clinical evidence	DOID:3748	NA	NA	NA	RS3814960	CDKN2A:upstream_gene_variant_CA12951936	NA	9_21975017_C_T	NA	21975011	21975023
GNAQ	9	Q209P	missense_variant	EID1533	Q209P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24504448' target='_blank'>Turajlic et al., 2014, Ann. Oncol.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	NA	NA	Vemurafenib	Q209P	EID1533:GNAQ:p.Q209	c.626A>C	9_80409488_T_G	ENST00000286548	80409482	80409494
GNAQ	9	Q209P	missense_variant	EID1537	Q209P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24504448' target='_blank'>Turajlic et al., 2014, Ann. Oncol.</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	NA	NA	PLX4720	Q209P	EID1537:GNAQ:p.Q209	c.626A>C	9_80409488_T_G	ENST00000286548	80409482	80409494
GNAQ	9	NA	NA	EID1213	Q209	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24938562' target='_blank'>Carvajal et al., 2014, JAMA</a>	Uveal Melanoma	Predictive	B: Clinical evidence	DOID:6039	209	NA	Selumetinib (AZD6244)	Q209	EID1213:GNAQ:p.Q209	NA	NA	NA	80409486	80409489
GNAQ	9	NA	NA	EID1233	Q209	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23434733' target='_blank'>Weekes et al., 2013, Clin. Cancer Res.</a>	Uveal Melanoma	Predictive	C: Case study	DOID:6039	209	NA	BAY 86-9766	Q209	EID1233:GNAQ:p.Q209	NA	NA	NA	80409486	80409489
ABL1	9	M244V	missense_variant	EID2638	BCR-ABL M244V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib	BCR-ABL M244V	EID2638:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	133738324	133738336
ABL1	9	M244V	missense_variant	EID4302	BCR-ABL M244V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL M244V	EID4302:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	133738324	133738336
ABL1	9	M244V	missense_variant	EID4307	BCR-ABL M244V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL M244V	EID4307:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	133738324	133738336
ABL1	9	M244V	missense_variant	EID6242	BCR-ABL M244V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	BCR-ABL M244V	EID6242:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	133738324	133738336
ABL1	9	L248V	missense_variant	EID2641	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL L248V	EID2641:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	133738336	133738348
ABL1	9	L248V	missense_variant	EID2644	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate, Dasatinib, Nilotinib	BCR-ABL L248V	EID2644:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	133738336	133738348
ABL1	9	L248V	missense_variant	EID4310	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL L248V	EID4310:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	133738336	133738348
ABL1	9	L248V	missense_variant	EID6236	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate, Nilotinib	BCR-ABL L248V	EID6236:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	133738336	133738348
ABL1	9	L248V	missense_variant	EID6308	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL L248V	EID6308:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	133738336	133738348
ABL1	9	G250E	missense_variant	EID2645	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL G250E	EID2645:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	133738343	133738355
ABL1	9	G250E	missense_variant	EID2647	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib	BCR-ABL G250E	EID2647:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	133738343	133738355
ABL1	9	G250E	missense_variant	EID2648	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL G250E	EID2648:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	133738343	133738355
ABL1	9	G250E	missense_variant	EID4313	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL G250E	EID4313:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	133738343	133738355
ABL1	9	G250E	missense_variant	EID4316	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL G250E	EID4316:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	133738343	133738355
ABL1	9	G250E	missense_variant	EID6244	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	BCR-ABL G250E	EID6244:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	133738343	133738355
ABL1	9	G250E	missense_variant	EID6267	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL G250E	EID6267:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	133738343	133738355
ABL1	9	Q252H	missense_variant	EID2650	Q252H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	Q252H	EID2650:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	133738350	133738362
ABL1	9	Q252H	missense_variant	EID4327	Q252H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Dasatinib	Q252H	EID4327:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	133738350	133738362
ABL1	9	Q252H	missense_variant	EID6219	Q252H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	Q252H	EID6219:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	133738350	133738362
ABL1	9	Q252H	missense_variant	EID6245	Q252H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	Q252H	EID6245:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	133738350	133738362
ABL1	9	Q252H	missense_variant	EID6274	Q252H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	Q252H	EID6274:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	133738350	133738362
ABL1	9	Y253H	missense_variant	EID2654	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib, Imatinib Mesylate	BCR-ABL Y253H	EID2654:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	133738351	133738363
ABL1	9	Y253H	missense_variant	EID4331	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL Y253H	EID4331:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	133738351	133738363
ABL1	9	Y253H	missense_variant	EID4335	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL Y253H	EID4335:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	133738351	133738363
ABL1	9	Y253H	missense_variant	EID6237	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate, Nilotinib	BCR-ABL Y253H	EID6237:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	133738351	133738363
ABL1	9	Y253F	missense_variant	EID2655	Y253F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	Y253F	EID2655:ABL1:p.Y253	c.758A>T	9_133738358_A_T	ENST00000318560	133738352	133738364
ABL1	9	Y253F	missense_variant	EID2657	Y253F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib	Y253F	EID2657:ABL1:p.Y253	c.758A>T	9_133738358_A_T	ENST00000318560	133738352	133738364
ABL1	9	Y253F	missense_variant	EID4340	Y253F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	Y253F	EID4340:ABL1:p.Y253	c.758A>T	9_133738358_A_T	ENST00000318560	133738352	133738364
ABL1	9	E255K	missense_variant	EID233	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15194504' target='_blank'>Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL E255K	EID233:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255K	missense_variant	EID2659	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL E255K	EID2659:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255K	missense_variant	EID2661	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL E255K	EID2661:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255K	missense_variant	EID2662	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL E255K	EID2662:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255K	missense_variant	EID4348	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL E255K	EID4348:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255K	missense_variant	EID4350	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL E255K	EID4350:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255K	missense_variant	EID6193	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate, Dasatinib	BCR-ABL E255K	EID6193:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255K	missense_variant	EID6194	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL E255K	EID6194:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255K	missense_variant	EID6214	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib, Imatinib Mesylate	BCR-ABL E255K	EID6214:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255K	missense_variant	EID6282	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	BCR-ABL E255K	EID6282:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	133738357	133738369
ABL1	9	E255V	missense_variant	EID2850	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL E255V	EID2850:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	133738358	133738370
ABL1	9	E255V	missense_variant	EID2851	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib, Imatinib Mesylate	BCR-ABL E255V	EID2851:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	133738358	133738370
ABL1	9	E255V	missense_variant	EID4443	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL E255V	EID4443:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	133738358	133738370
ABL1	9	E255V	missense_variant	EID4447	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL E255V	EID4447:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	133738358	133738370
ABL1	9	D276G	missense_variant	EID2663	BCR-ABL D276G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL D276G	EID2663:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	133747514	133747526
ABL1	9	D276G	missense_variant	EID2666	BCR-ABL D276G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL D276G	EID2666:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	133747514	133747526
ABL1	9	D276G	missense_variant	EID4357	BCR-ABL D276G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL D276G	EID4357:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	133747514	133747526
ABL1	9	D276G	missense_variant	EID4359	BCR-ABL D276G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Dasatinib	BCR-ABL D276G	EID4359:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	133747514	133747526
ABL1	9	D276G	missense_variant	EID6246	BCR-ABL D276G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	BCR-ABL D276G	EID6246:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	133747514	133747526
ABL1	9	E279K	missense_variant	EID4543	E279K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Dasatinib	E279K	EID4543:ABL1:p.E279	c.835G>A	9_133747528_G_A	ENST00000318560	133747522	133747534
ABL1	9	E292V	missense_variant	EID2853	E292V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	E292V	EID2853:ABL1:p.E292	c.875A>T	9_133747568_A_T	ENST00000318560	133747562	133747574
ABL1	9	L298V	missense_variant	EID4475	L298V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	L298V	EID4475:ABL1:p.L298	c.892C>G	9_133747585_C_G	ENST00000318560	133747579	133747591
ABL1	9	V299L	missense_variant	EID2862	BCR-ABL V299L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL V299L	EID2862:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	133747582	133747594
ABL1	9	V299L	missense_variant	EID4540	BCR-ABL V299L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Dasatinib	BCR-ABL V299L	EID4540:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	133747582	133747594
ABL1	9	V299L	missense_variant	EID6216	BCR-ABL V299L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL V299L	EID6216:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	133747582	133747594
ABL1	9	V299L	missense_variant	EID6241	BCR-ABL V299L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib, Imatinib Mesylate	BCR-ABL V299L	EID6241:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	133747582	133747594
ABL1	9	V299L	missense_variant	EID6247	BCR-ABL V299L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL V299L	EID6247:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	133747582	133747594
ABL1	9	F311I	missense_variant	EID4478	BCR-ABL F311I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL F311I	EID4478:ABL1:p.F311	c.931T>A	9_133748270_T_A	ENST00000318560	133748264	133748276
ABL1	9	F311L	missense_variant	EID4546	BCR-ABL F311L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL F311L	EID4546:ABL1:p.F311	c.931T>C	9_133748270_T_C	ENST00000318560	133748264	133748276
ABL1	9	F311L	missense_variant	EID6238	BCR-ABL F311L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib, Imatinib Mesylate	BCR-ABL F311L	EID6238:ABL1:p.F311	c.931T>C	9_133748270_T_C	ENST00000318560	133748264	133748276
ABL1	9	T315I	missense_variant	EID1390	BCR-ABL T315I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23190221' target='_blank'>Cortes et al., 2012, N. Engl. J. Med.</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Ponatinib	BCR-ABL T315I	EID1390:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID234	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20537386' target='_blank'>An et al., 2010, Leuk. Res.</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL T315I	EID234:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID235	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15194504' target='_blank'>Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL T315I	EID235:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID2667	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL T315I	EID2667:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID2669	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib	BCR-ABL T315I	EID2669:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID2670	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL T315I	EID2670:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID4364	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL T315I	EID4364:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID4365	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL T315I	EID4365:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID6192	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib, Imatinib Mesylate	BCR-ABL T315I	EID6192:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID6196	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate, Nilotinib	BCR-ABL T315I	EID6196:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID6234	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate, Dasatinib	BCR-ABL T315I	EID6234:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID6235	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib, Dasatinib	BCR-ABL T315I	EID6235:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	T315I	missense_variant	EID6285	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate, Nilotinib, Dasatinib	BCR-ABL T315I	EID6285:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	133748277	133748289
ABL1	9	F317I	missense_variant	EID6217	BCR-ABL F317I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F317I	EID6217:ABL1:p.F317	c.949T>A	9_133748288_T_A	ENST00000318560	133748282	133748294
ABL1	9	F317I	missense_variant	EID6251	BCR-ABL F317I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F317I	EID6251:ABL1:p.F317	c.949T>A	9_133748288_T_A	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID2674	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL F317L	EID2674:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID2676	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib	BCR-ABL F317L	EID2676:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID2680	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib	BCR-ABL F317L	EID2680:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID4381	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL F317L	EID4381:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID6215	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F317L	EID6215:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID6252	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	BCR-ABL F317L	EID6252:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID6270	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F317L	EID6270:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID6309	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F317L	EID6309:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID637	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18818391' target='_blank'>Jabbour et al., 2008, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F317L	EID637:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID638	BCR-ABL F317L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24236021' target='_blank'>Tanneeru et al., 2013, PLoS ONE</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Ponatinib	BCR-ABL F317L	EID638:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317L	missense_variant	EID639	BCR-ABL F317L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25349473' target='_blank'>Miller et al., 2014, Biologics</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Ponatinib	BCR-ABL F317L	EID639:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	133748282	133748294
ABL1	9	F317V	missense_variant	EID6208	BCR-ABL F317V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F317V	EID6208:ABL1:p.F317	c.949T>G	9_133748288_T_G	ENST00000318560	133748282	133748294
ABL1	9	F317V	missense_variant	EID6253	BCR-ABL F317V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F317V	EID6253:ABL1:p.F317	c.949T>G	9_133748288_T_G	ENST00000318560	133748282	133748294
ABL1	9	G321L	missense_variant	EID4788	G340L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26758680' target='_blank'>Testoni et al., 2016, EMBO Mol Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Imatinib Mesylate, Dasatinib	G340L	EID4788:ABL1:p.G321	c.961_962delinsCT	9_133748300_GG_CT	ENST00000318560	133748294	133748307
ABL1	9	N331S	missense_variant	EID4549	BCR-ABL N331S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL N331S	EID4549:ABL1:p.N331	c.992A>G	9_133748331_A_G	ENST00000318560	133748325	133748337
ABL1	9	M351T	missense_variant	EID2682	M351T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	M351T	EID2682:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	133748385	133748397
ABL1	9	M351T	missense_variant	EID2684	M351T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib	M351T	EID2684:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	133748385	133748397
ABL1	9	M351T	missense_variant	EID2685	M351T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	M351T	EID2685:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	133748385	133748397
ABL1	9	M351T	missense_variant	EID4396	M351T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	M351T	EID4396:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	133748385	133748397
ABL1	9	M351T	missense_variant	EID6254	M351T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	M351T	EID6254:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	133748385	133748397
ABL1	9	E355G	missense_variant	EID4400	BCR-ABL E355G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL E355G	EID4400:ABL1:p.E355	c.1064A>G	9_133748403_A_G	ENST00000318560	133748397	133748409
ABL1	9	E355G	missense_variant	EID4403	BCR-ABL E355G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL E355G	EID4403:ABL1:p.E355	c.1064A>G	9_133748403_A_G	ENST00000318560	133748397	133748409
ABL1	9	E355G	missense_variant	EID6255	BCR-ABL E355G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	BCR-ABL E355G	EID6255:ABL1:p.E355	c.1064A>G	9_133748403_A_G	ENST00000318560	133748397	133748409
ABL1	9	F359I	missense_variant	EID4530	BCR-ABL F359I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL F359I	EID4530:ABL1:p.F359	c.1075T>A	9_133748414_T_A	ENST00000318560	133748408	133748420
ABL1	9	F359I	missense_variant	EID4532	BCR-ABL F359I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F359I	EID4532:ABL1:p.F359	c.1075T>A	9_133748414_T_A	ENST00000318560	133748408	133748420
ABL1	9	F359V	missense_variant	EID2167	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL F359V	EID2167:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	133748408	133748420
ABL1	9	F359V	missense_variant	EID2169	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib	BCR-ABL F359V	EID2169:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	133748408	133748420
ABL1	9	F359V	missense_variant	EID2170	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL F359V	EID2170:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	133748408	133748420
ABL1	9	F359V	missense_variant	EID3815	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL F359V	EID3815:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	133748408	133748420
ABL1	9	F359V	missense_variant	EID3819	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F359V	EID3819:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	133748408	133748420
ABL1	9	F359V	missense_variant	EID6256	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	BCR-ABL F359V	EID6256:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	133748408	133748420
ABL1	9	F359C	missense_variant	EID2854	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate, Nilotinib	BCR-ABL F359C	EID2854:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	133748409	133748421
ABL1	9	F359C	missense_variant	EID4482	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Dasatinib	BCR-ABL F359C	EID4482:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	133748409	133748421
ABL1	9	F359C	missense_variant	EID6239	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib, Imatinib Mesylate	BCR-ABL F359C	EID6239:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	133748409	133748421
ABL1	9	L364P	missense_variant	EID4551	BCR-ABL L364P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL L364P	EID4551:ABL1:p.L364	c.1091T>C	9_133750260_T_C	ENST00000318560	133750254	133750266
ABL1	9	V379I	missense_variant	EID6257	BCR-ABL V379I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	BCR-ABL V379I	EID6257:ABL1:p.V379	c.1135G>A	9_133750304_G_A	ENST00000318560	133750298	133750310
ABL1	9	L384M	missense_variant	EID2861	L384M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate, Nilotinib	L384M	EID2861:ABL1:p.L384	c.1150C>A	9_133750319_C_A	ENST00000318560	133750313	133750325
ABL1	9	L384M	missense_variant	EID4527	L384M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Dasatinib	L384M	EID4527:ABL1:p.L384	c.1150C>A	9_133750319_C_A	ENST00000318560	133750313	133750325
ABL1	9	L387M	missense_variant	EID4406	BCR-ABL L387M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Dasatinib	BCR-ABL L387M	EID4406:ABL1:p.L387	c.1159T>A	9_133750328_T_A	ENST00000318560	133750322	133750334
ABL1	9	L387F	missense_variant	EID2863	L387F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	L387F	EID2863:ABL1:p.L387	c.1161G>C	9_133750330_G_C	ENST00000318560	133750324	133750336
ABL1	9	H396P	missense_variant	EID4554	BCR-ABL H396P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL H396P	EID4554:ABL1:p.H396	c.1187A>C	9_133750356_A_C	ENST00000318560	133750350	133750362
ABL1	9	H396P	missense_variant	EID6240	BCR-ABL H396P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib, Imatinib Mesylate	BCR-ABL H396P	EID6240:ABL1:p.H396	c.1187A>C	9_133750356_A_C	ENST00000318560	133750350	133750362
ABL1	9	H396R	missense_variant	EID2687	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib	BCR-ABL H396R	EID2687:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	133750350	133750362
ABL1	9	H396R	missense_variant	EID2689	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib	BCR-ABL H396R	EID2689:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	133750350	133750362
ABL1	9	H396R	missense_variant	EID4411	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL H396R	EID4411:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	133750350	133750362
ABL1	9	H396R	missense_variant	EID4413	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL H396R	EID4413:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	133750350	133750362
ABL1	9	H396R	missense_variant	EID6258	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Imatinib Mesylate	BCR-ABL H396R	EID6258:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	133750350	133750362
ABL1	9	G398R	missense_variant	EID2864	BCR-ABL G398R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL G398R	EID2864:ABL1:p.G398	c.1192G>C	9_133750361_G_C	ENST00000318560	133750355	133750367
ABL1	9	G398R	missense_variant	EID4561	BCR-ABL G398R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL G398R	EID4561:ABL1:p.G398	c.1192G>C	9_133750361_G_C	ENST00000318560	133750355	133750367
ABL1	9	D421G	missense_variant	EID4559	D421G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	D421G	EID4559:ABL1:p.D421	c.1262A>G	9_133750431_A_G	ENST00000318560	133750425	133750437
ABL1	9	E450V	missense_variant	EID4563	BCR-ABL E450V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL E450V	EID4563:ABL1:p.E450	c.1349A>T	9_133753880_A_T	ENST00000318560	133753874	133753886
ABL1	9	E453K	missense_variant	EID4565	BCR-ABL E453K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL E453K	EID4565:ABL1:p.E453	c.1357G>A	9_133753888_G_A	ENST00000318560	133753882	133753894
ABL1	9	E453Q	missense_variant	EID4486	BCR-ABL E453Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL E453Q	EID4486:ABL1:p.E453	c.1357G>C	9_133753888_G_C	ENST00000318560	133753882	133753894
ABL1	9	E459K	missense_variant	EID6310	BCR-ABL E459K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL E459K	EID6310:ABL1:p.E459	c.1375G>A	9_133753906_G_A	ENST00000318560	133753900	133753912
ABL1	9	P480A	missense_variant	EID4568	BCR-ABL P480A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	BCR-ABL P480A	EID4568:ABL1:p.P480	c.1438C>G	9_133755469_C_G	ENST00000318560	133755463	133755475
ABL1	9	F486S	missense_variant	EID2829	BCR-ABL F486S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	NA	NA	Nilotinib	BCR-ABL F486S	EID2829:ABL1:p.F486	c.1457T>C	9_133755488_T_C	ENST00000318560	133755482	133755494
ABL1	9	F486S	missense_variant	EID4571	BCR-ABL F486S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	NA	NA	Dasatinib	BCR-ABL F486S	EID4571:ABL1:p.F486	c.1457T>C	9_133755488_T_C	ENST00000318560	133755482	133755494
NOTCH1	9	NA	NA	EID1014	P2514FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22077063' target='_blank'>Rossi et al., 2012, Blood</a>	Chronic Lymphocytic Leukemia	Prognostic	B: Clinical evidence	DOID:1040	2514	NA	NA	P2514	EID1014:NOTCH1:p.P2514	NA	NA	NA	139390648	139390650
NOTCH1	9	NA	NA	EID495	P2514FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21670202' target='_blank'>Fabbri et al., 2011, J. Exp. Med.</a>	Chronic Lymphocytic Leukemia	Prognostic	B: Clinical evidence	DOID:1040	2514	NA	NA	P2514	EID495:NOTCH1:p.P2514	NA	NA	NA	139390648	139390650
NOTCH1	9	Q2444fs	frameshift_variant	EID383	V2444FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20007775' target='_blank'>Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	NA	NA	V2444fs	EID383:NOTCH1:p.Q2444	c.7330delinsACA	9_139390861_G_TGT	ENST00000277541	139390855	139390869
NOTCH1	9	R2327W	missense_variant	EID381	R2327W	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20007775' target='_blank'>Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	NA	NA	R2327W	EID381:NOTCH1:p.R2327	c.6979C>T	9_139391212_G_A	ENST00000277541	139391206	139391218
NOTCH1	9	H2275fs	frameshift_variant	EID382	S2275FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20007775' target='_blank'>Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	NA	NA	S2275fs	EID382:NOTCH1:p.H2275	c.6821_6822insT	9_139391369_G_GA	ENST00000277541	139391363	139391376
NOTCH1	9	D1642H	missense_variant	EID380	D1642H	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20007775' target='_blank'>Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	NA	NA	D1642H	EID380:NOTCH1:p.D1642	c.4924G>C	9_139399219_C_G	ENST00000277541	139399213	139399225
ARAF	X	S214C	missense_variant	EID17	S214C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24569458' target='_blank'>Imielinski et al., 2014, J. Clin. Invest.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	NA	NA	Sorafenib	S214C	EID17:ARAF:p.S214	c.641C>G	X_47426121_C_G	ENST00000377045	47426115	47426127
ARAF	X	S214C	missense_variant	EID40	S214C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24569458' target='_blank'>Imielinski et al., 2014, J. Clin. Invest.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Sorafenib	S214C	EID40:ARAF:p.S214	c.641C>G	X_47426121_C_G	ENST00000377045	47426115	47426127
ARAF	X	S214C	missense_variant	EID41	S214C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24569458' target='_blank'>Imielinski et al., 2014, J. Clin. Invest.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	NA	Trametinib	S214C	EID41:ARAF:p.S214	c.641C>G	X_47426121_C_G	ENST00000377045	47426115	47426127
ARAF	X	S490T	missense_variant	EID1905	S490T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27729313' target='_blank'>Hong et al., 2016, Cancer Discov</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	NA	NA	Irinotecan, Cetuximab, Vemurafenib	S490T	EID1905:ARAF:p.S490	c.1468T>A	X_47429340_T_A	ENST00000377045	47429334	47429346
AR	X	NA	NA	EID448	W742	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12517791' target='_blank'>Hara et al., 2003, Cancer Res.</a>	Prostate Carcinoma	Predictive	D: Preclinical evidence	DOID:10286	742	NA	Bicalutamide	W742	EID448:AR:p.W742	NA	NA	NA	66937369	66937372
AR	X	F877L	missense_variant	EID447	F877L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23779130' target='_blank'>Joseph et al., 2013, Cancer Discov</a>	Prostate Cancer	Predictive	D: Preclinical evidence	DOID:10283	NA	NA	ARN-509, Enzalutamide	F877L	EID447:AR:p.F877	c.2629T>C	X_66943549_T_C	ENST00000374690	66943543	66943555
BTK	X	C481S	missense_variant	EID1770	C481S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26182309' target='_blank'>Maddocks et al., 2015, JAMA Oncol</a>	Chronic Lymphocytic Leukemia	Predictive	B: Clinical evidence	DOID:1040	NA	NA	Ibrutinib	C481S	EID1770:BTK:p.C481	c.1441T>A	X_100611165_A_T	ENST00000308731	100611159	100611171
BTK	X	C481S	missense_variant	EID436	C481S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24869598' target='_blank'>Woyach et al., 2014, N. Engl. J. Med.</a>	Chronic Lymphocytic Leukemia	Predictive	B: Clinical evidence	DOID:1040	NA	NA	Ibrutinib	C481S	EID436:BTK:p.C481	c.1441T>A	X_100611165_A_T	ENST00000308731	100611159	100611171
BTK	X	T316A	missense_variant	EID1985	T316A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27626698' target='_blank'>Sharma et al., 2016, Oncotarget</a>	Chronic Lymphocytic Leukemia	Predictive	C: Case study	DOID:1040	NA	NA	Ibrutinib	T316A	EID1985:BTK:p.T316	c.946A>G	X_100613633_T_C	ENST00000308731	100613627	100613639
